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Varicella-Zoster Virus (VZV) is the causative agent of chickenpox during primary infection and 
herpes-zoster or shingles following reactivation from neuronal latency. The VZV ORF66 protein 
kinase is a serine/threonine kinase and one of two VZV protein kinases.  Its homologue in the 
alphaherpesviruses are termed the US3 kinases, and through phosphorylation of targets affect 
many events in infection, influencing processes such as survival of the infected cell to apoptosis, 
the state of permissivity to gene expression, avoidance of immunity, modulating cellular 
pathways affecting host actin dynamics, and influencing the nuclear structure and nuclear 
membrane to enable assembly of virus components. ORF66 is not essential in most cell culture 
but important for viral replication in T cells.  In this work, we have found the ORF66 is critical 
for viral growth in primary corneal fibroblasts and thus established a model for further 
investigatation of cell-type dependent functions for ORF66.  This finding may have important 
applications for viral pathogenesis as VZV reactivates and causes infection of the eye in herpes 
zoster ophthalmicus disease.  Here we also describe a novel ORF66 cellular target, the nuclear 
matrix protein, matrin 3.  Specific matrin 3 phosphorylation is conserved for herpes simplex 
virus - type 1 and pseudorabies virus US3 kinases.  Thus, this finding may have important 
implications for the role of ORF66/US3 function in common alphaherpesvirus strategies to 
utilize host cell machinery in establishing a host cell environment conducive to viral replication.  
ORF66/US3-induced phosphorylation of matrin 3 was needed for matrin nuclear retainment late 
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in viral infection, suggesting that ORF66/US3 may have a role in modulating matrin 3 nuclear 
functions needed for viral replication. The ORF66 kinase is clearly important for VZV growth in 
certain cell types relevant to human disease and our studies underscore the diverse roles of this 
protein in VZV infection.  
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1.0  INTRODUCTION 
1.1 VARICELLA-ZOSTER VIRUS DISEASE 
1.1.1 Clinical Presentation & Complications 
Varicella-Zoster Virus (VZV) is the causative agent of chickenpox during primary infection and 
herpes-zoster or shingles following reactivation.  VZV is a highly communicable agent, spread 
through respiratory aerosols or direct contact with vesicular lesions (140).  In healthy children, 
the virus typically is a benign disease, affecting those between 1-9 years of age. VZV in adults is 
often a more severe disease including complications such as insterstitial pneumonia (140). 
Following an incubation period of 14-15 days, symptoms first appear as fever, headache, and 
general malaise concurrent with an itchy rash that progresses from a macular rash to a vesicular 
lesion that eventually crusts over 1-2 weeks later (67, 140).  In immunocompromised patients 
(e.g. bone marrow, liver, or renal transplant patients) varicella infection is more likely to cause 
severe disseminated disease (67).  The virus then undergoes latency within neurons of the cranial 
nerve ganglia & dorsal root ganglia - potentially along any level of the neuraxis (140).  
Complications associated with chickenpox are serious bacterial infections (40) as well as central 
nervous system complications such as cerebellar ataxia, meningitis, and meningoencephalitis.  
Importantly, VZV can also lead to vasculopathies which can present as a stroke.  Furthermore, 
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untreated vasculopathies which result from productive VZV replication in small and/or large 
cerebral arteries can lead to mortality in 25% of untreated patients (140).   
 VZV then enters sensory nerve fibers innervating the skin and travels retrogradely up the 
nerve to sensory ganglia to undergo neuronal latency usually for decades in its host, and 
reactivates in the form of herpes zoster (“shingles”).  During reactivation, the virus travels in an 
anteretrograde direction from the sensory ganglia to the nerves of the skin leading to a localized 
dermatomal rash. Zoster symptoms are characterized by unilateral radicular pain, itching, 
numbness, or hypersensitivity to touch (allodynia).  Days later a vesicular rash develops in the 
area (usually 1-3 dermatomes) and persists for 7-10 days, followed crusting of lesions which 
usually heal within 4 weeks of rash onset (140, 153).  Zoster is also infectious till the point where 
the lesion is crusted over. Systematic dissemination can occur in immunocompromised patients 
(e.g. hematologic malignancy or iatrogenic immunosuppression), leading to multidermatomal 
involvement (140).   
Zoster has the potential to be a serious, morbid, debilitating disease.  Zoster incidence & 
severity increases with advancing age and/or immunosuppression. A serious neurological 
complication of herpes zoster (HZ) is postherpetic neuralgia (PHN) which affects 10-30 % of 
zoster patients (214) and can range from mild to excruciating pain. PHN is characterized by 
constant severe stabbing or burning pain, as well as allodynia in a majority of affected patients 
(153) that persists for 3 months and potentially years after resolution of rash.  Thoracic zoster is 
the most common form followed by ophthalmicus zoster which follows VZV reactivation from 
the trigeminal ganglia.  Other rare complications have been reported including VZV myelitis 
which can be fatal in immunocompromised patients such as AIDS patients, VZV vasculopathy, 
and zoster sin herpete (reactivation without rash) (63, 140). 
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Herpes zoster ophthalmicus (HZO) occurs when reactivation occurs from the ophthalmic (V-1) 
division of the trigeminal nerve, which is affected approximately 20 times more often than other 
divisions of the TG (156).  Keratitis most often occurs in HZO patients, potentially leading to 
blindness if untreated.  An indicator of involvement of the eye during reactivation is 
Hutchinson’s sign, where rash develops on the tip of the nose. Other ophthalmic complications 
include VZV acute retinal necrosis and progressive outer retinal necrosis, which is the second 
most common opportunistic retinal infection in AIDS patients in North America (140). 
1.1.2 Prevention & Treatment Strategies:  Impact on VZV Epidemiology 
Treatment for varicella infection depends on stage of infection, patients’ age and immune status.  
Chickenpox is usually a mild disease in children and there is usually no specific therapy 
required. Antiviral agents used for the treatment of VZV infections are nucleoside analogues that 
require phosphorylation by a viral thymidine kinase (TK) that act as viral DNA synthesis 
inhibitors, such as acyclovir (ACV) and related drugs exhibiting higher bioavailability.  In cases 
where varicella symptoms are more serious, ACV is suggested 24h following appearance of skin 
lesions, while intravenous ACV is effective in immunosuppressed patients even 72 hrs after 
appearance of lesions.  Foscarnet, also a viral DNA synthesis inhibitor, acts independently of TK 
and can be used in cases of ACV-resistant VZV (145).   
 The aim of treatment for shingles is to reduce the acute symptoms of pain and limit 
spread and duration of lesions, as well as prevent complications like PHN and HZO.  In shingles 
patients over the age of 50 or immunosuppressed patients, antiviral therapy (ACV, valacyclovir, 
famciclovir) must be quickly started within 72 hrs after onset of skin lesions.  Treatments for 
PHN are varied and rarely lead to complete pain relief.  Recommendations depend on harshness 
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of pain, patient mental status and preference. Treatments include topical analgesics, 
anticonvulsants (e.g. gabapentin), tricyclic antidepressants (e.g. amitriptyline), opioids, and other 
treatments (e.g.N-methyl-D aspartate receptor antagonists, intrathecal coricosteriod injection, 
spinal stimulation and surgical removal of the painful skin area) whose efficacy are questionable 
(145). 
 Fortunately, a varicella vaccine and zoster vaccine are available & aimed to prevent 
disease and/or severity of disease.  Before introduction of the VZV vaccine, virtually every child 
in the US was afflicted with chickenpox usually between the 1 and 9 years of age.  Varicella 
infection was responsible for on average, 10,632 hospitalizations and 105 deaths per year (125).  
In 1995, a live attenuated Oka/Merck VZV vaccine (Varivax, Merck) was approved in the US as 
part of universal childhood varicella vaccination program (117).  The vaccine is safe, effective, 
and has high acceptance rates, reported to prevent varicella of any severity by 80-85%, 
hospitalizations by 75-88%, and deaths by 74% (125). Approximately 2-3% of children and 30-
40% of adults experienced breakthrough varicella - infection after exposure to wild type VZV in 
a vaccinee.  Consequently, in 2006 a two-dose vaccine regimen was adopted (117).  
 The lifetime risk for having HZ is 30%, or approximately one million cases per year in 
the US (117).  In 2006, a new live attenuated VZV zoster vaccine ( Zostavax, Merck & Co 
became available as a result of the US Shingles Prevention Study (154).  The aim of the vaccine 
was to boost VZV cell-mediated immunity (CMI) which according to the Hope-Simpson model, 
maintains protection from HZ.  The vaccine was found to reduced the burden of illness from HZ 
by 61.1% and reduce incidence of HZ and PHN by 51.3% and 66.5% respectively (117, 154).  
Currently it is recommended for people over the age of 60, including those who already have had 
an episode of zoster or have chronic medical conditions.  It is not yet recommended for 
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immunosuppressed patients, children, & pregnant women (117) as safety & effectiveness are 
unknown. Furthermore, risk-benefit ratio is unknown for moderately immunosuppressed 
patients. Hence, there are still concerns with the effects of VZV vaccinations.  Duration of 
protection by the varicella vaccine is also unknown.  Additionally, because the VZV vaccine is 
so effective, it is hypothesized that the general population is not receiving VZV CMI “boosters” 
stemming from exposure to WT VZV.  This may result in an increase of HZ in those under 50 
yrs of age (117). 
 
1.2 VZV VIROLOGY 
1.2.1 Classification 
VZV is a member of the family Herpesviridae which divides into three subfamilies, the alpha-, 
beta-, and gamma- herpesviruses.  VZV is an alphaherpesvirus and one of eight human 
herpesviruses which span all three subfamilies (Table 1). While some herpesviruses have a broad 
host range, most display a high degree of host specificity which has aided in their ability to 
coevolve with their host.  It is thought that herpesviruses infected an ancient host progenitor and 
subsequent viruses underwent cospeciation within their host.  Estimates indicate that the three 
subfamilies diverged 180 to 220 million years ago, yet still there are 43 genes common to the 
subfamilies.  A fundamental biological feature of herpesviruses is their ability to establish 
inapparent lifelong latent infection which can reactivate once or multiple times to cause and 
transmit disease (43, 57).  Characteristics of most herpesviruses also include viral replication and 
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capsid assembly occuring in the nucleus, and expression of a large number of proteins involved 
in nucleic acid metabolism (e.g. thymidine kinase), DNA replication (e.g.DNA polymerase, 
helicase/primase), and protein modification (e.g. kinases).   
The αherperviruses are characterized as neurotrophic during their latency stage, & exhibit 
a short replication cycle (~18hrs), efficient cell destruction & variable host range in vitro and in 
vivo (135). In contrast to HSV-1, VZV is highly host-restricted in cell culture yet displays broad 
tissue tropism in humans for reasons unknown (135). Mammalian  αherpesviruses are further 
subdivided into the genera Simplexvirus (α1-herpesviruses) & Varicellovirus (α2-herpesviruses) 
(Table 2) (135). The simplexviruses have primates as their natural hosts, yet the varicelloviruses 
infect a variety of mammals.  Members of two other lineages in the αherpesviruses are Marek’s 
disease virus (MDV) and infectious laryngotracheitis virus, both avian viruses (43). 
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Table 1.  Human Herpesviruses 
Human 
Herpesvirus 
Synonym Subfamily Latency Disease 
HHV-1 Herpes simplex virus type 1 α Neuron facial & labial lesions, HSK 
HHV-2 Herpes simplex virus type 2 α Neuron genital lesions 
HHV-3 Varicella-Zoster Virus α Neuron chickenpox & shingles 
HHV-5 Human cytomegalovirus β 
Monocytes, 
lymphocytes 
& others 
birth defects, retinitis, pneumonia 
HHV-6 HHV-6 β 
T 
lymphocytes 
& others 
childhood roseola 
HHV-7 HHV-7 β 
T 
lymphocytes 
& others 
childhood roseola 
HHV-4 Esptein-Barr virus γ B lymphocytes 
Burkitt’s lymphoma, 
nasal pharyngeal carcinoma, 
infectious mononucleosis 
HHV-8 
Kaposi’s Sarcoma- 
Associated herpesvirus 
γ Unknown 
Kaposi’s Sarcoma, 
primary effusion lymphoma, 
multicentric Castleman disease 
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Table 2.  Examples of mammalian alphaherpesviruses 
Lineage Virus Natural Host Disease in natural host 
α1 HSV-1 
HSV-2 
B virus 
SA8 
 
Humans 
Humans 
Macaques 
Baboons 
Generally asymptomatic 
Generally asymptomatic 
Generally asymptomatic 
Generally asymptomatic 
α2 VZV 
SVV 
EHV-1 
EHV-4 
BHV-1 
BHV-5 
PRV 
Humans 
Old world monkeys 
Horses 
Horses 
Cattle 
Cattle 
Pigs 
Varicella/Herpes zoster 
Varicella-like disease 
Abortion 
Rhinopneumonitis 
Rhinotracheitis/vulvovaginitis 
Meningoencephalitis 
Aujeszky’s disease  
 
 
1.2.2 Physical & Molecular Properties 
Morphologically, the VZV virion is indistinguishable from HSV (prototypic αherpesvirus).  The 
virion is 150-200-nm in diameter and is pleiomorphic. VZV is a linear double-stranded DNA 
virus that is encapsidated by an icosohedral nucleocapsid which consists of 162 capsomeres.  
Capsids, in turn, are surrounded by a proteinaceous tegument layer and cell-derived lipid 
envelope. The VZV genome is approximately 125 kbp nucleotides in length (44), and is closely 
homologous to HSV-1, with an overall genome structure that is similar to other alphaherpesvirus 
(αherpesvirus) members.  Specifically, the VZV genome consists of a covalently linked unique 
long (UL) and unique short (US) regions bounded by inverted repeat sequences IRL/TRL and 
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IRS/TRS.  The UL is 104,836bp long and flanked by 88bp inverted repeats, while the US is 
5232bp long flanked by 7320 bp inverted repeats (Figure 1-1).  
 
 
 
 
Figure 1-1.  VZV genome 
The VZV genome consists of 125 kbp double-stranded DNA, made up of a UL and US region 
(shown as black bars), bounded by internal and terminal repeats (TRL and IRL – red, IRS and TRS 
– yellow).  ORF62 location is depicted within the IRS and TRS regions.  ORF66 location within 
the unique short region (US) is indicated by the black arrow.   
 
 
 
 The VZV genome contains two origins of replication, Oris sites, in the IRS/TRS region.  
Concatameric DNA contains one cleavage site as typical of some α2 viruses - as opposed to two 
sites in the α1 (HSV), thus leading to one cleavage site per VZV genome length.  The US region 
is directed in one of two directions 50% of the time, and the UL region exists in one direction 
95% of the time and 5% in the opposite direction, therefore two VZV genomic isomers 
predominate (177).  The genome encodes 71 predicted open reading frames (ORF), and at least 
68 unique VZV genes.  Five of these genes (ORFs 1, 2, 13, 32, 57) have no HSV homolog, yet 
some are found in EHV-1.  ORFs 62, 63, and 64 are found within the IRS region, and are 
duplicated as ORFs 71, 70, and 69, respectively, in the opposite direction within the TRS region.  
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ORF42 and ORF45 are the only two known splicing products from the same 5.7kbp primary 
transcript. 
The tegument layer connects the nucleocaspsid and lipid envelope and holds a cargo of several 
VZV proteins, including ORFs 4, 9, 10, 47, 62, and 63 (54, 97, 100, 200).  There is also evidence 
for cellular proteins CDK1 & cyclin B1 in the VZV tegument (112), which is not unprecedented 
as cellular proteins in the tegument have been reported for other herpesviruses (6, 47).  Mostly 
through studies in HSV & PRV, functions attributed to the tegument include targeting the virion 
to and from the nucleus during entry and egress, recruiting of molecular motors utilized in virion 
transport, regulation of cell & viral gene and protein expression, and directing virion assembly 
during egress (91).   
 Lastly like other fusogenic viruses, herpesviruses encode for an array of glycoproteins 
involved in the fusion process.  VZV encodes for eight envelope proteins that are glycosylated: 
gB, gC, gE, gH, gI, gK, gL, and gM (96, 224).  It is unknown if gN is glycosylated.  All of these 
are conserved in HSV-1 in the UL region, yet VZV lacks many glycoproteins found in the HSV-1 
US region.  Notably, VZV does not encode a gD homolog which is essential for HSV-1 
replication (135).  Five glycoproteins are conserved amongst all herpesviruses gB, gH, gL, gM, 
and gN suggesting that they provide critical functions for their respective viruses.  Consequently, 
in transient expression systems, a minimum combination of VZV gH and gL or gB and gE are 
required for cell-cell fusion (39).  Additionally, gE is conserved in all αherpesviruses, yet is only 
essential for VZV replication and important for cell-cell spread and fusion (39, 122, 124).  VZV 
is highly cell-associated in vitro, and unlike HSV and PRV, VZV does not spontaneously release 
infectious virions from cultured cells (215).  Differences in use of glycoproteins during viral 
fusion, the fact that VZV causes synctia within vesicles of infected skin, and its cell-associated 
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nature in vitro suggests that the VZV envelope machinery is more geared to accommodate cell-
cell fusion than HSV. 
 
1.2.3 VZV Life cycle 
Entry.  The mechanism for VZV entry is not well understood but advances in our understanding 
of VZV receptors have been made in recent years. In HSV, four cellular proteins - Herpesvirus 
entry mediator A, nectin-1, nectin-2, and 3-O-sulfated heparan sulfate, are established receptors 
involved in entry.  This does not directly translate to VZV as these receptors all have been found 
to interact with HSV gD, of which there is no VZV homologue (29, 134). However, similarly to 
other herpesviruses, heparan sulfate proteoglycan is involved in the initial attachment of VZV 
virions (232).  Thus far, two host cell receptors have been implicated in mediating VZV entry.  
Cation-independent mannose 6-phoshate receptors (MPRci) receptors have been implicated in 
cell-free but not cell-associated VZV entry spread, since MPRci – deficient cells do not restrict 
entry of cell-associated VZV. Four viral glycoproteins (gB, gE, gH, and gI) contain N-linked 
oligosaccharides with mannose 6-phosphate groups (25).  MPRci receptors are acquired during 
virion trafficking on the convex face of the trans-Golgi network (TGN) that become transport 
vesicles directed to late endosomes.  In late endosomes, acidification leads to degradation of 
VZV particles. This process is held responsible for the lack of efficient release of infectious 
particles in cell culture and cell-to-cell VZV dissemination in the body. Interestingly, this 
process is thought to occur in all VZV-infected cells excepted for cells of the suprabasal 
epidermis (corneocytes) which downregulate expression of MPRci  (61).  It is at the outer 
epidermis where infectious cell free VZV is secreted in lesions.  The second receptor, Insulin 
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Degrading Enzyme (IDE), mediates cell-to-cell spread in VZV.  IDE is a zinc metalloproteinase 
that bind various ligands such as glucagon and insulin-like growth factor II, without activation of 
its hydrolyzing activity.  Moreover, IDE has a wide tissue distribution, and is present in the 
cytoplasm as well as plasma membranes, including the surface of differentiated neurons (115). 
Studies do indicate that other receptors may be involved in VZV entry since blocking of IDE did 
not completely block VZV infection (115). 
VZV DNA Replication & Regulatory Proteins. Investigating the kinetics of VZV 
transcription has been difficult because low amounts of cell-free VZV prevent high multiplicity 
synchronized infections. Nevertheless, VZV transcription likely follows the temporally-
controlled transcription cascade found in other herpesviruses (78), where genes are designated as 
immediate early (IE), early (E), or late (L). It is thought that upon entry, tegument proteins - of 
which three are IE proteins - are released and enter the nucleus with the nucleocapsid to activate 
viral genes.  IE gene transcription occurs first without the need for prior de novo protein 
synthesis.  These are transcribed in the nucleus, then translated in the cytoplasm and transported 
back to the nucleus. This cycle repeats with E and L genes.  VZV E gene transcription requires 
IE proteins, and function in facilitating DNA replication and metabolism.  Once DNA replication 
ensues, VZV late proteins are made and locate to the nucleus for capsid assembly. Nucleocapsids 
will then commence nuclear egress.  VZV encodes homologues of the seven viral proteins 
required for origin-dependent DNA synthesis in HSV.  These include a viral DNA polymerase 
catalytic subunit (ORF28) and accessory factor (ORF16), major DNA binding protein (ORF29), 
a putative heterotrimeric helicase/priamse complex encoded by ORFs 6, 52, and 55, as well as an 
origin binding protein ORF 51.  Most αherpesvirus genes are expressed from their own 
promoters.  The model for VZV DNA replication posits that linear DNA from an infecting virion 
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circularizes in the nucleus prior to the intiation of replication.  In the case of closed circular DNA 
this would have happened just prior or post-packaging of DNA (177).  DNA replication then 
begins at one of the two OriS, where unwinding of the origin is likely facilitated by ORF29 
enabling the recruitment of proteins involved in VZV DNA synthesis and a nick is introduced in 
the replicating DNA and shifts to a rolling circle mechanism resulting in head to tail concatemers 
that are cleaved at the novel L-S joint created during circularization (177).  VZV encodes 
homologues to four of five HSV IE genes, ORFs 4, 61, 62, and 63, yet only ORFs 4 (46), 62 
(58), and 63 (150) have found to be expressed under IE conditions.  ORF 61 is potentially an IE 
protein as it is expressed very early in infection (1 hr PI) (174). Only ORF62 contains an 
upstream TAATGARAT-like sequence, which in HSV is important for responsiveness to the 
transcriptional activator VP16.  Analysis of single human fibroblasts has demonstrated that a 
productive cycle of VZV infection occurs between 9 and 12 hours, with viral DNA and 
formation of replication compartments visible by 4 hours (174).   
VZV transcription depends on host cell RNA polymerase and transcription factors, in 
addition to several VZV proteins that have transactivating functions, many of which are 
tegument proteins.  Regulatory proteins include ORFs 4, 10, 61, 62/71, 63/70 (100).  VZV also 
encodes for two kinases ORFs 47 and 66, and as well as functional thymidine kinase. ORF 4 is a 
a transcriptional activator of all gene classes as well as a co-activator of IE62-mediated 
transactivation in transient expression (4, 96).  VZV ORF 10 is the homologue of the essential 
HSV VP16 protein, and shares some of its properties such as it tegument incorporation, 
transactivating property, and binding to TAATGARAT motifs and cell proteins HCF-1 and Oct-
1.  Unlike VP16, VZV ORF10 is a non-essential protein in cultured cells (32) and it 
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transactivates IE62 and not other IE genes (136).  However, ORF10 is important for VZV 
replication in skin xenografts  in vivo (24).    
ORF61 is the homologue of the multifunctional protein HSV-1 ICP0.  In transient 
expression assays the protein transactivated several viral and cell promoters, and repressed or 
enhanced the promoters of ORF4 and IE62 (136, 146, 158).  The transcription factor, specificity 
protein 1 (Sp1), binds to the ORF61promoter, and these sites have been found to be important for 
ORF61 contributions to VZV virulence in severe combined immunodeficiency ( SCID-hu skin) 
xenografts.  Additionally, ORF61 may be involved in inhibiting the chromatin silencing effects 
of histone deacetylases, an important function of ICP0 (28, 211).   
IE62 is a major tegument protein and is the key transcriptional activator of all VZV genes 
and some cellular promoters.  It is divided into 5 regions (I to V) based on alignments with other 
αherpesvirus homologs.  IE62 interacts with several cell transcription factors including Sp1, 
upstream stimulatory factor (USF), TATA binding protein (TBP), TFIIB, human mediator 
complex and upstream cis-activating elements in VZV promoters (157, 178, 225, 227). IE62 can 
also directly bind DNA in region II through the DNA binding domain.  This region is highly 
conserved and responsible for IE62 homodimerization and repressor activities (218).  Region III 
contains the nuclear localization phosphorylation, and also sites for phosphorylation by VZV 
kinases (99, 102).  Region IV functions are unknown and Region V is the site of many mutations 
in VZV vaccine strains (65).   
ORF63 is a tegument protein that is the most abundantly found VZV transcript expressed 
in latently infected human ganglia (34, 38). The protein has been reported to bind IE62 (119).   
Additionally, ORF63 has been reported to act as a transcriptional repressor for VZV and cell 
promoters (18, 50) and involved in inhibiting innate immune responses (2).   
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ORF 47 is a serine/threonine kinase that is conserved amongst all three herpesvirus 
subfamilies & displays homology to HSV-1 UL 13 kinase and casein kinase II (152, 198).  This 
tegument protein is dispensable for VZV replication in fibroblasts and melanoma cells but is 
important for replication in human T cells and skin xenografts in the SCID-hu mouse model cells 
(73, 133, 199).  ORF 47 autophosphorylates and phosphorylates gE, gI, ORF 62, 63, and 32 (73, 
95, 148, 173, 184).  Although the function of ORF47 kinase activity on IE62 is not well 
delineated, ORF47 N-terminal binding to IE62 contribute to VZV replication in skin xenografts 
(15). 
VZV Egress.  For all α-herpesviruses, nucleocapsids are assembled in the nucleus and 
during egress an envelope is acquired as capsids pass through the inner nuclear envelope and into 
the perinuclear space which is continuous with the lumen of the rough endoplasmic reticulum 
(RER).  VZV is thought to then undergo the de-envelopment – re-envelopement process where 
nucleocapsids acquire a primary envelope at the the inner nuclear membrane, enter the 
perinuclear space/RER lumen, and  lose the envelope  as it crosses the RER membrane - as 
opposed to acquiring its final envelope at the inner nuclear membrane.  Most VZV glycoproteins 
tested sort to the TGN, supporting this model (212).  In the TGN, tegument proteins interact with 
the cytoplasmic domains of glycoproteins.  During invagination of the nucleocapsid with the 
TGN, the nucleocapsid then undergoes final envelopement, acquiring tegument and 
glycoproteins. In cell culture, newly synthesized VZV are diverted to the MPR-mediated 
endosomal pathway and eventually the transport vesicles become late endosomes, which then 
through exocytosis release degraded noninfectious virions (70).  Infectious virions are thought to 
be the result of vesicles that have escaped this pathway, with most infection depending on cell to 
cell fusion. 
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VZV Latency.  VZV establishes a latent infection in neurons of sensory ganglia (93), 
where it assumes a circular or concatameric state (27).  Here VZV is present as 2-9 copies in 1 to 
7% of individual neurons, therefore viral burden is predicted to be 30 to 3500 VZV DNA copies 
per 100 ng of total ganglionic DNA (37-38, 93, 159), likely depending on the severity of primary 
infection.  Several transcripts corresponding to ORF 4, 21, 29, 62, 63, 66 have been found in 
latently infected human ganglia, with the most predominant being ORF63 (36, 38, 92) as well 
proteins encoded by these genes (36, 92, 118, 120).  These proteins exhibit a cytoplasmic 
localization in neurons, as compared to nuclear localization for most of these proteins during 
lytic infection – this is thought be a mechanism to regulate nuclear transcriptional activator 
activites and thus maintain latency.  ORF66 functions may be critical in maintenance of latency, 
as during VZV infection it functions in regulating IE62 localization and causes a dramatic IE62 
nuclear exclusion late in infection (35, 52, 54).   In contrast, HSV gene expression is tightly 
regulated with silencing of most lytic expression concomitant with expression of latency 
associated transcript (LAT) gene which encodes a 8.3 kb primary transcript and two stable 
introns (2.0 kb and 1.5 kb) (94), whereas apparently VZV does not encode a LAT homologue.  
While the molecular mechanisms of VZV reactivation are largely unknown, immune responses 
also seem to play a more critical role in control of VZV reactivation compared to HSV (135).  
According to the Hope-Simpson model reported in 1965, Hope-Simpson postulated that 
following chickenpox infection, VZV elicits an immune response that impedes future VZV 
reactivations from progressing to zoster.  This level of immunity over time declines but is 
boosted through subclinical infections stemming from exogenous exposures to VZV in the 
environment (chickenpox or zoster patients) (79, 153).  These boost help slow the age-related 
 16 
decline in immune responses to VZV, yet eventually the patients’ immune response declines to a 
critical level where previously “contained reversions” now advanced to cause herpes-zoster. 
 
1.3 VZV TROPISM & PATHOGENESIS 
VZV has a highly restricted host range and host-cell range in experimental settings, yet exhibits 
broad tissue tropism in humans, its only natural reservoir.   Primary VZV infection begins with 
inoculation of the respiratory mucosal epithelium, and subsequent events have been based on a 
mousepox model.  This Fenner-Grose model dictates that during the first replication or primary 
phase, VZV infects mononuclear cells in regional lymph nodes bringing the virus to 
reticuloendothelial organs, e.g. liver.  Here a second replication occurs leading to a second 
viremia that brings the virus to the skin (68, 106).  However, work by the Arvin group using the 
SCID-hu mouse support a model where infected T cells mediate the transfer to the skin during 
primary viremia, and the VZV incubation period reflects the time it takes to overcome innate 
immune system barriers, e.g. IFNα, at the skin before a chickenpox lesion presents.  VZV infects 
the upper respiratory tract and regional lymph node where the virus targets peripheral blood 
mononuclear cells (PBMC) (121, 219), particularly lymphocytes (105) although all 
subpopulations have been found to be susceptible to infection (82).  Dendritic cells are also 
suspectible to infection and can mediate the transfer to T lymphocytes (1).  Using the SCID-hu 
mouse model VZV possessed a tropism for CD4 and CD8 T cells within thymus/liver 
xenografts.  Specifically tonsil CD4 T cells with activated memory subpopulations are highly 
permissive for VZV infection in vitro (107), as well as those with skin homing markers 
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cutaneous leukocyte antigen (CLA) and chemokine receptor 4 (CCR4).  Interestingly, more than 
20% of mononuclear cells in the tonsils are CD3 T cells, and although B cells are also present, 
VZV infection of B cells induces their apoptosis (105-106).  Hence, this model holds that VZV 
preferentially targets this cell type that is programmed for immune surveillance as a means of 
VZV transmission to the skin.  Interestingly, VZV infection of T cells did not trigger their fusion 
in contrast to the cell-to-cell spread and polykaryocyte formation that is seen in skin cells, 
suggesting T cells depend on infectious cell-free VZV during transfer to the skin (132).  Through 
studies in skin-xenografts, it was found that once VZV reaches the skin there is a progressive 
lesion that eventually extends up to surface keratinocytes.   
 Further studies in the SCID-hu mouse model using dorsal root ganglia xenografts (230) 
have contributed to the understanding of herpes zoster neuropathogenesis (230). VZV 
reactivation is characterized by a lesion involving the dermatome innervated by the successfully 
reactivating sensory ganglia.  This is in contrast to HSV, where reactivation usually presents as a 
more focal region of the affected skin innervated by the reactivating neuron. In the SCID DRG 
xenografts, VZV genomic DNA, proteins, and virions were found both in neurons and satellite 
cells of the DRG.  Furthermore, VZV infection induced cell-cell fusion and polykaryon 
formation between these two cell types . It is postulated that VZV reactivation may begin with 
replication in one neuron which spreads through cell-to-cell fusion to neighboring satellite cells.  
Subsequently, satellite cells would spread VZV to adjacent satellite cells surrounding a separate 
neuron within the ganglion, and thus increase the likelihood for VZV to gain access to more 
neurons within the ganglion and thus affect a large region within the dermatome.  Past studies 
have supported VZV infection within the ganglia prior to involvement in the skin, as patients 
often present with neuralgia several days before the zoster rash appears. 
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 1.4 VZV ORF66 KINASE 
 
1.4.1 Introduction  
The ORF66 protein kinase is one of two VZV protein kinases initially identified based on 
genomic position and homology to herpes simplex virus (HSV) kinases and the presence of 
classical structural motifs found common to all ser/thr kinases.  Homologs of ORF66 are often 
termed the US3 kinases, since they are found in the unique short region of the genome of all 
sequenced neurotrophic αherpesviruses (and probably all αherpesviruses), but are absent in 
members of beta and gamma herpesviruses.  By influencing phosphorylation states, the key 
means of reversible protein functional modulation, the US3 kinase family affect many events in 
infection, such as resistance of the infected cell to apoptosis, the state of permissivity to gene 
expression, avoidance of immunity, modulating cellular pathways affecting host actin dynamics, 
and influencing the nuclear structure and nuclear membrane to enable assembly of virus 
components. The ORF66 kinase is clearly important for VZV growth in certain cell types 
relevant to human disease. Thus, interest in the ORF66 kinase and the search for its targets 
continues.    
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1.4.2 Genetics 
VZV ORF66 lies in the unique short region of the VZV genome (nucleotides 113,037 to 114218  
in VZV Dumas, 113142 – 114323 in POka).  Its genetic disruption in VZV, first reported by 
Heineman et al 1995, established it as not required for growth in cell cultures used for VZV 
propagation. In this regard, ORF66 mirrors similar US3 mutants of HSV, pseudorabiesvirus 
(PRV) and marek’s disease virus (MDV).  In the vaccine Oka background, ORF66 disruption 
had no effect on viral growth rates, but in the parent Oka VZV background, disruption causes 3-
20 fold drop in peak growth levels compared to parental virus, depending on host cell type. As 
the gI gene lies immediately downstream of ORF66, the complete ORF66 gene cannot be deleted 
entirely without affecting gI expression, as ORF66 contains control elements in the gI promoter.   
  VZV mutants lacking ORF66 kinase activity do show more impaired growth in 
certain cell types or in organ culture models, suggesting that the host cell dictates the importance 
of the kinase to infection.  VZV lacking ORF66 grow poorly in cultured T cells (199) and in 
human thymus/liver xenografts in SCID-hu mice (133, 185-186). This has relevance to human 
disease, since current models of VZV infection propose that tonsillar T cells transport VZV from 
the tonsillar respiratory epithelium to the skin (106).  In T cells, VZV lacking ORF66 kinase 
show greater sensitivity to IFN-γ treatment, and increased levels of apoptosis. Electron 
microscopic examination of such cells reveals an apparent defect in the formation of 
nucleocapsids, but do not show the accumulation of abundant nucleocapsids at invaginations of 
the inner nuclear membrane, as seen for US3 kinase-deficient HSV-1 and PRV (see section 
1.4.6.3). Although we have noted accumulation of major capsid protein at the nuclear membrane 
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in VZV-infected cells expressing kinase dead ORF66 kinase (Eisfeld, A. unpublished results).  
The molecular basis for the VZV phenotypes is not yet understood.   
 VZV without functional ORF66 also replicate poorly in primary corneal 
fibroblasts obtained from human corneal stroma donor rims (54).  This is significant to human 
disease, as the cornea is often infected during zoster reactivating from the fifth cranial nerve. 
Corneal fibroblasts were initially evaluated to investigate possible roles of the ORF66 kinase on 
actin dynamics, as they develop prominent stress fibers when cultured on plastic support.  Using 
recombinant VZV in which GFP was tagged N-terminally to ORF66 kinase, a truncated form or 
a kinase-inactive form, it was found that VZV without kinase were blocked for replication at a 
stage following the initial round of replication following infection with  infected human MRC-5 
cells.  VZV lacking ORF66 formed microfoci of GFP positive cells that subsequently fail to 
expand over time. The basis for growth impairment is not yet known, but data suggested it was 
not a result of differential regulation of apoptosis or regulation of cellular localization of IE62 
(54).   
1.4.3 ORF66 Structure & Characteristics 
The ORF66 protein kinase, at 393 residues, has a predicted molecular weight of 44 kDa.  It is a 
phosphoprotein (202) that migrates at 55kDa as two forms which appear to be differentially 
phosphorylated. There is no evidence to suggest alternative forms initiating at alternative ATG 
residues, as seen for US3 kinases of HSV and PRV (164, 209).  ORF66 has a conserved 286 
residue kinase (catalytic) domain spanning amino acids 93 to 378 that has homology to all 
Ser/Thr kinases, which consists of 12 subdomains that fold into a characteristic 3-dimensional 
active core structure to transfer a γ-phosphate from ATP to the hydroxyl group of a specific S/T 
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residue within its protein substrate. These subdomains are remarkably invariant within the 
eukaryotic protein kinase superfamily (71). A constraint-based multiple alignment tool illustrates 
the putative 12 kinase subdomains in ORF66 using known subdomains (71) in cellular 
eukaryotic kinases in (Figure 1-2).  As shown in figure 1-3, these subdomains account for most 
of the homology between αherpesviruses and as expected, kinase invariant residues are preserved 
for those viruses listed. Conservative mutations (D206E and/or K208R) in the central catalytic 
domain spans residues 203-211 disrupt kinase activity (99). Comparing ORF66 to the cellular 
Ser/Thr kinases predicts the ATP binding residue is likely K122: a K122A mutation also 
abrogates kinase activity (99).  Using the entire gene in blast searches, the closest cellular 
homologs are human serine/threonine kinase 9 (also known as cyclin dependent kinase –like 5) 
and the yeast the cell cycle regulator cdc28 (127, 186).  However, the amino terminal region of 
the protein has a high ratio of acidic residues, as found in all US3 kinases and also in the p21-
activated kinases upstream of Cdc42/Rac pathways. The precise role of the acidic domain is not 
clear.     
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     EASVALCA--------EARVGINKA---GFVILKTFTPGAE KA GFAFACMDSKTCEHVVI
     KAKEDFLKKWESPAQNTAHLD-------QFERIKTLGTGSFGRVMLVKHKETGNHYAMKI 
     -------------------ME-------NFQKVEKIGEGTYGVVYKARNKLTGEVVALKK 
     KAKRSLAPRFDLPDMKETKYTVDKRFGMDFKEIELIGSGGFGQVFKAKHRIDGKTYVIKR 
                                  *        *  *                *  
     GQRQGTAT--------- TVLRALTHPSVVQLKGTFT---------------------- EA
     LDKQKVVKLKQIEHTLNEKRILQAVNFPFLVKLEFSFK---------------------- 
     IRLDTETE-GVPSTAIREISLLKELNHPNIVKLLDVIH---------------------- 
     VKYNNEKA-------EREVKALAKLDHVNIVHYNGCWDGFDYDPETSDDSLESSDYDPEN 
                      *   *        *                              
     -------YNKMTCLILPRY-RTDLYCYL--AAKRNLPICDILAIQRSVLRALQYLHNNSI 
     -------DNSNLYMVMEYVPGGEMFSHL--RRIGRFSEPHARFYAAQIVLTFEYLHSLDL 
     -------TENKLYLVFEFL-HQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRV 
     SKNSSRSKTKCLFIQMEFCDKGTLEQWIEKRRGEKLDKVLALELFEQITKGVDYIHSKKL 
                                                            *     
     IHR KSE FINHPGDVCVG AACFPVDINANRYYGWAGTIATNSP A-RDPYGP DI NI DFG ELL
     IYRDLKPENLLIDQQGYIQVTDFGFAK-RVKG--RTWT-LCGTPEYLAPEIIL-SKGYNK 
     LHRDLKPQNLLINTEGAIKLADFGLAR-AFGVPVRTYTHEVVTLWYRAPEILLGSKYYST 
     IHRDLKPSNIFLVDTKQVKIGDFGLVT--SLKNDGKRTRSKGTLRYMSPEQIS-SQDYGK 
       ** *  *            ***                  *     **       *   
     AV SAGIVLFEMATGQNSLFERDGLDGNCDSERQIKLIIRRSGTHPNEFPINPTSNLR DIW
     AVDWWALGVLIYEMAAG-------------------YPPFFADQPIQIYEKIVS------ 
     AVDIWSLGCIFAEMVTR-------------------RALFPGDSEIDQLFRIFRTLGTPD 
     EVDLYALGLILAELLHV-------------CDTAFETSKFFTDLRDGIISDIFD------ 
      **    *    *                                                
     RQ-YIGLAKRSSRKPGSRPLWTNLYE-----LPIDLEYLICKMLSFDARH -----SAE RP
     -----GKVRFPSH------------------FSSDLKDLLRNLLQVDLTKRFGNLKNGVN 
     EVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRI-----SAK 
     ---------------------------------KKEKTLLQKLLSKKPEDRP-----NTS 
                                           *    *      *          
     VLLNHSVFQTLPDPYPNPMEVGD------------------------------------- 
     DIKNHKWFATTDWIAIYQRKVEAPFIPKFKGPGDTSNFDDYEEEEIRVSINEKCGKEFSE 
     AALAHPFF----------QDVTKP-VPHLRL----------------------------- 
     EILRTLTVWK-----------KSP-----------------EKNE-----RHTC------ 
VZV 66
PKA‐c α
CDK2
PKR
VZV 66
PKA‐c α
CDK2
PKR
VZV 66
PKA‐c α
CDK2
PKR
VZV 66
PKA‐c α
CDK2
PKR
VZV 66
PKA‐c α
CDK2
PKR
VZV 66
PKA‐c α
CDK2
PKR
VZV 66
PKA‐c α
CDK2
PKR
I II
III IV
V VIA
VIB VII VIII
IX X
XI
 
Figure 1-2.  VZV ORF66 kinase putative catalytic subdomains 
A constraint based multiple alignment tool (COBALT) was used to perform an alignment of 
VZV ORF66 kinase with Protein Kinase A catalytic subunit alpha (PKA-c α), cyclic-dependent 
kinase 2 (CDK2), and Protein Kinase R (PKR – Eukaryotic translation initiation factor 2-α 
kinase).  Known catalytic subdomains for these cellular kinases (filled yellow/gray boxes), 
domain boundaries were extended to a best fit for ORF66 kinase (grey/yellow-outlined boxes).  
Stars denote shared residues. Invariant catalytic subdomain residues are shown in red.  
Subdomains regions are denoted by roman numerals above alignments.   
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Figure 1-3.  Alphaherpesvirus ORF66/US3 putative catalytic subdomains 
Illustration of kinase catalytic subdomains in the HSV and PRV US3 kinases (colored boxes – 
denoted above by roman numerals) based on the putative ORF66 kinase catalytic subdomains 
outlined in figure 1-2. The red vertical boxes highlight invariant residues conserved in all 
kinases.  The horizontal black box in region VIB is the catalytic loop region of the kinase. The 
vertical box in region XI is the likely consensus motif (his-x-Aromatic-hydrophobic) that is 
found 9-13 residues downstream from the invariant arginine of this subdomain.   
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A significant fraction of ORF66 kinase is insoluble in most buffers designed to solubilize 
the protein without disturbing its kinase activity.  ORF66 solubility is increased in higher pH 
buffers, as found for HSV-1 US3 kinase, and our optimal buffer used to solubilize GST-tagged 
ORF66 from baculovirus-infected cells contains 20mM Tris-HCl pH 8.5, 50mM KCL, 1mM 
EDTA, 1mM DTT, 1%NP40, and 0.5% DOC.  Kinase activity in vitro is optimal in 20mM 
Hepes pH 7.5, 50mM Mn2+, and 50mM KCl.  ORF66 is not inhibited by 10μg/ml heparin (which 
effectively block casein kinase II activity), so this is included in assays. 10mM Mg2+ can also be 
used as the cation in the ORF66 in vitro kinase assay (52).   
The cellular localization of ORF66 protein has an unusual distribution.  While initial 
studies using ORF66 specific antibodies first indicated ORF66 as a cytoplasmic protein (202), 
studies from our lab using epitope tagged or functional GFP-ORF66 fusions indicate both 
nuclear and cytoplasmic distribution in VZV-infected cells and in cells expressing the kinase 
autonomously, with nuclear forms predominating (53, 99, 185).   Nuclear ORF66 shows a 
discrete and distinct punctate nuclear accumulation, forming rings of puncta surrounding the 
infected cell nucleolus (53, 99).  Characterization of these ORF66 speckles is in progress, and 
these appear dynamic (Eisfeld, A., and P.R. Kinchington manuscript in preparation).  Functional 
ORF66 also associates with replication compartments early in infection in MRC-5 cells, whereas 
kinase dead (kd) forms (D206E, K208R) accumulate in both nuclear replication compartments 
and nuclear rim of late stage VZV-infected cells, colocalizing with major capsid protein (MCP) ( 
Eisfeld, A. and P.R. Kinchington manuscript in preparation).  This suggests that ORF66 kinase 
activity influences its own cellular distribution, and may be associated with capsid assembly 
and/or egress.   
 25 
1.4.4 ORF66 targets 
Only one target of ORF66 has been extensively characterized – IE62.  The two sites targeted 
strongly suggest ORF66 is a basophilic kinase that phosphorylates ser/thr residues preceded by 
multiple arginine or lysine residues, particularly at -2 and -3 positions. This is consistent with 
target motifs of PRV and HSV US3 kinases determined by in vitro peptide substrates, and are 
optimal at (R)n-X-(S/T)-Y-Y, where n is >2, S/T is the target site where either serine or threonine 
is phosphorylated, X can be absent or any amino acid but preferably Arg, Ala, Val, Pro, or Ser, 
and Y is similar to X except that it cannot be an absent amino acid, proline, or an acidic residue. 
The optimal consensus sequence is similar except that X is not absent and n is ≥3 (9).  However, 
studies on the US3 kinase suggest the optimal motif is overly restrictive, and sites of 
phosphorylation with much lower matches to the consensus have been reported on lamin C 
(138). Of particular note is that both VZV ORF66 and HSV-1 US3 kinase target motifs overlap 
that targeted by Protein kinase A (PKA).  Using antibodies to the phosphorylated 
serine/threonine in the PKA target motif, we will show that novel substrates are detected in 
extracts of VZV-infected cells that are not found in VZV kinase-deficient infected cells, 
suggesting the kinase targets multiple cellular proteins or induces activation of cellular kinases 
that target phospho-PKA motifs. Interestingly, by western blot the antibody identifies radically 
different protein profiles in the same cell type infected with VZV, HSV and PRV (Section 3.0).    
 
1.4.4.1 Autophosphorylation 
Protein kinase autophosphorylation is frequently employed to uphold the specificity of kinase 
functions, thus it is not surprising that ORF66 autophosphorylates.  Disruption of the kinase 
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catalytic domain or the ATP binding residue result in a poor 32P- incorporation into the protein 
within VZV-infected cells and in in vitro reactions with purified kinase.  The sites of 
phosphorylation remains to be determined. Assuming kinase targeting of serines preceded by 
basophilic residues, likely candidate sites are located at KRS331SRK and RHRPS368.  However, 
mutagenesis studies indicate that the S331 residue is not required for kinase activity (186). VZV 
ORF66 has no obvious equivalent to the S147 autophosphorylation residue found to be the site 
of HSV-1 US3 autophosphorylation (87), and it is not yet known if ORF66 is phosphorylated by 
ORF47. The US3 kinase is phosphorylated by the UL13 kinase (89) in HSV-1 infected cells. 
1.4.4.2 IE62 
ORF66 kinase targets IE62, the major regulatory protein of VZV.  IE62 is a nuclear 
transcriptional regulatory protein that drives VZV transcription by interacting with 
transcriptional activators, components of the mediator complex and members of the general 
factors involved in recruitment of RNA pol II complex (178).  While the underlying mechanisms 
by which IE62 acts are not resolved, its ability to partly substitute for HSV ICP4 infers that both 
IE62 and ICP4 act in a similar manner.  The targeting of IE62 by the VZV ORF66 kinase was 
serendipitously discovered in studies to examine the influence of ORF47 kinase on IE62 
functions, which had previously been shown (148).  Cells transfected to express IE62 with or 
without the ORF47 kinase showed IE62 as a predominantly nuclear protein.  The IE62 nuclear 
localization signal (NLS) is a classical SV40-like signal high in arg/lys rich residues mapping to 
residues 677-85 (102). However, IE62 coexpressed with the ORF66 kinase showed accumulation 
of abundant cytoplasmic forms of IE62, mirroring that seen in late stage VZV-infected cells.  
While IE62 is nuclear early in VZV infection before ORF66 is expressed, IE62 levels build in 
the cytoplasmic compartment as ORF66 accumulates, until some infected cell nuclei appear 
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devoid of IE62.  Cytoplasmic IE62 does not form in cells infected with VZV lacking functional 
ORF66 kinase, establishing that kinase activity was required. The sites of phosphorylation on 
IE62, mapped using plasmids expressing IE62 peptides in ORF66 transfected and VZV-infected 
cells, are predominantly restricted to IE62 residues S686 and S722 (52). ORF66 directly 
phosphorylated IE62 in vitro, and bacterially expressed IE62 peptides with both or one serine 
intact remained a target for purified VZV ORF66 kinase in vitro, whereas loss of both serines 
abrogated the ability of IE62 to be an ORF66 target.  
The ORF66 kinase–mediated regulation of IE62 has not been reported for the 
corresponding proteins of other alphaherpesviruses, but it reflects the regulated nuclear import of 
many cellular proteins through phosphorylation (72, 85).  As phosphorylation is reversible, it can 
enable multifunctional proteins to be controlled by their relocation to different cellular 
compartments.  The nuclear exclusion of IE62 in VZV infection enables the packaging of 
abundant levels of IE62 into VZV virions, at about 50% of the level of the major capsid protein. 
Virions obtained from VZV-infected cells lacking kinase show virtually no structural forms of 
IE62 (98).  It was concluded that nuclear exclusion of IE62 allows it to relocate to the trans-
Golgi network, where VZV tegument is added to the egressing nucleocapsid.  Virion packaging 
of IE62 may allow the introduction of preformed IE62 into the newly infected cell to promote the 
first events of infection, although this remains to be formally shown.  We will show the 
importance of the targeting of S686 in the ORF66 driven relocation of IE62 using a VZV 
recombinant containing S686A changes in both copies of IE62 in the VZV genome (Section 2.0). 
Such virus expressed IE62 protein which did not relocate to cytoplasm or become packaged 
during infection, despite the presence of a functional ORF66 kinase (54).  
We postulate that this interaction may come to play during VZV latency. VZV infects 
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sensory nerve endings during varicella and establishes latency in neural nuclei in dorsal root 
ganglia (DRG).  In contrast to HSV-1, where there is predominant silencing of protein 
expression and expression of non-coding latency associated RNA transcripts (LATs), VZV 
latency is characterized by expression of several lytic mRNAs and some regulatory proteins 
which show nuclear exclusion. Transcripts and proteins of ORF62 and the ORF66 kinase have 
been reported in human latently infected tissue (34-35), and IE62 shows predominantly 
cytoplasmic distribution (35, 118).  It has been proposed that VZV latency is maintained by 
preventing nuclear functions of the regulatory proteins through nuclear exclusion.  Our discovery 
may mechanistically explain IE62 nuclear exclusion during latency. 
 Interestingly S686 in IE62, which immediately follows the nuclear import signal, is 
highly conserved in virtually all the alphaherpesvirus ICP4/IE62 homologs. This suggests that 
their cellular localization may also be regulated by phosphorylation.  Indeed, cotransfection 
studies suggest US3 kinases reduce nuclear import of the corresponding IE62/ ICP4 homolog 
(Yee and Kinchington, in preparation).  However, HSV-1 ICP4 shows cytoplasmic forms as 
infection progresses, but these are more reliant upon the functionality of the HSV ICP27 protein 
(191).  
1.4.4.3 HDACS 
Transcription is strongly influenced by the chromatin state of the template DNA that, in turn, is 
under an elaborate control system that modulates histone binding and condensation. A key 
component is the reversible post translational modification of histones through the addition and 
subtraction of acetyl groups to their lysine tails.  In general, permissive gene expression is 
promoted by histone acetyl transferases which acetylate histones to lessen DNA binding and 
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condensation. Silencing of expression is partly driven by their deacetylation, mediated by histone 
deacetylases (HDACS).  HDACs are an ancient family of enzymes that have a major role in 
numerous biological processes. Eleven different HDAC isoforms have been identified in 
mammalian genomes and these are classified into four different families: class I (HDAC1, 2, 3 
and 8), class II, (HDAC4, 5, 6, 7, 9 and 10), sirtuin class III and class IV (HDAC11) (69, 190). 
Because HDACs lack intrinsic DNA-binding activity, they are recruited to target genes through 
direct association with transcription regulatory proteins. HDAC activity is controlled by 
phosphorylation by numerous cellular kinases (160).  This blocks their deacetylase functions and 
promotes a cellular permissive state of transcription.  The herpesviral infected cell is favored by 
a pro-active transcriptional state in which deacetylation is inhibited.  In HSV-1 infected cells, 
multiple mechanisms are involved in the inactivation of HDAC activity, for example HSV-1 
ICP0 dislodges the LSD1/CoREST/REST complex from HDAC1 and HDAC2, disrupting the 
silencing effects of this repressor complex on viral promoters. More recently, it was reported that 
HDAC-1 and 2 showed novel forms which were induced by the US3 kinase, and that cells 
expressing the US3 kinase showed a more activated transcriptonal state (162-163).    
We have been  part of the recent work suggesting that HDAC-1 and 2 are also modulated 
in VZV-infected cells in an ORF66-dependent manner (213).  HDAC-1 and 2 show novel slower 
mobility forms in SDS-PAGE gels of VZV-infected cell extracts that are not apparent if the 
ORF66 kinase is deleted. The slower form is differentially phosphorylated and is also seen in 
cells expressing the ORF66 protein kinase autonomously by transfection or by transduction with 
ORF66 expressing adenoviruses.  Mapping of the sites of HDAC phosphorylation identified a 
specific phosphorylated residue in the C terminal domain of both proteins which are preceded by 
basic residues at -2 and -3 positions, consistent with PKA target motifs.   
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Functional consequences of ORF66 activity affecting HDACs has been suggested from 
studies using the HDAC inhibitors sodium butyrate. At 1mM, this inhibitor relieves some of the 
attenuation of the ORF66 negative VZV as compared to parental virus. Thus it seems that a 
prime function of the kinase is to regulate cell permissivity at the transcriptional level through 
interactions with HDAC-1 and 2 and possibly other HDACs.   
1.4.5 Additional cellular activities modulated by the ORF66 protein kinase 
1.4.5.1 MHC-1 surface presentation 
The ORF66 protein kinase appears to mediate VZV-encoded immune evasion strategies. In the 
host, viral and cellular antigenic peptides are presented on the cell surface for CD8+ T cell 
recognition in conjunction with the major histocompatibility complex type I or MHC-I.  Most 
herpesviruses have mechanisms to reduce surface presentation of MHC-I coupled viral antigens, 
presumably to allow prolonged survival of the cell in the presence of a developed immune 
system.  In MHC biogenesis, antigenic peptides generated by the host 26S proteasome are 
actively transported to the ER lumen by the Transporter of Antigen Presentation (TAP), 
composed of a heterodimer of TAP-1 and TAP-2. TAP is inhibited by many viruses, because its 
inhibition affects MHC-I A and B, the main antigen presenters, but not MHC-I types that are 
needed to signal to natural killer (NK) cells.  TAP is blocked in HSV-1 infected cells by the 
immediate early protein ICP47 (76), of which there is no homolog in VZV.  Varicelloviruses are 
reported to have a second gene that blocks TAP, of which the bovine herpesvirus UL49.5 is the 
most well characterized (104).  However, we and others have not seen evidence that VZV ORF 
9.5 has similar activities (53).  In the ER lumen, MHC-I heavy chain (Hc) bound to beta 2- 
microglobulin is stabilized by several chaperones (tapasin, ERp57 and calreticulin) until it 
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couples with TAP and the antigenic peptide.  The peptide loading complex can be disrupted or 
actively inhibited by some viral MHC-I modulators (e.g. human Cytomagalovirus US2) (62).  
Once loaded, the antigenic peptide is processed to high affinity forms, which mature through the 
secretory pathway via the Golgi to the cell surface.  Cis- to medial- Golgi transport is concurrent 
with conversion of high mannose glycan side chains to complex endoglycosidase-H (endo H) 
resistant forms. 
   It is not surprising that VZV downmodulates surface antigen presentation, as first 
reported by Abendroth et al (1). VZV has lymphotropic parameter in its human pathogenesis, 
and can sustain infection in multiple cell types over a prolonged period, including professional 
antigen presenting cells and chronic antigen-expressing neurons during latency.  The lack of an 
ICP47 homolog suggests VZV uses novel mechanisms to mediate this block.  Following an 
initial report by Abendroth et al in which reduced MHC-I expression in ORF66 expressing cells, 
we reported that surface MHC-I was reduced in ORF66 expressing cells mediated by 
transfection, adenovirus mediated transduction or in recombinant viruses expressing GFP tagged 
forms of ORF66, but were not downregulated to the same extent in the corresponding conditions 
when the expressed kinase was disrupted or abrogated (53).  In both adenovirus transduced and 
in VZV-infected cells, the ORF66 kinase delays Golgi-processing of MHC-I and induces the 
accumulation of endoglycosidase H sensitive MHC-1 forms, suggesting that it blocks either at 
the assembly stage or the Golgi maturation step prior to cis to medial Golgi processing.  In VZV 
infections without ORF66 kinase, MHC-1 processing is still partly blocked as compared to 
control cells, suggesting that additional mechanisms exist for VZV to block surface MHC-I .  In 
this respect, VZV is like many herpesviruses, and employs overlapping mechanisms.  This is 
currently under further study.  
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1.4.5.2 IFN Signaling 
Schaap et al demonstrated that expression of ORF66 correlated with a differential level of 
signaling following IFNγ treatment of VZV-infected T cells.  Specifically, the formation of 
phospho-Stat in T cells following IFNγ binding to its receptor was significantly diminished with 
ORF66 expression as compared to VZV infections lacking functional ORF66 (186).  It is not yet 
resolved as to how ORF66 blocks this activity, but it is notable that Roizman and colleagues 
have recently indicated that the HSV-1 US3 kinase may phosphorylate IFN-γRα to prevent its 
signaling (116). 
1.4.5.3 Apoptosis 
Arvin and colleagues also demonstrated that ORF66 protein kinase modulates the apoptosis of T 
cells that mediate dissemination of VZV from respiratory sites of infection to skin (106). VZV 
lacking ORF66 grew to levels 2 logs lower than parental virus in cultured human T cells but not 
in MeWo cells, and the expression of the kinase conferred a marginal growth advantage in skin 
xenografts .   T cells infected with a kinase-inactive G102A mutant showed increased levels of 
active caspase 3, the executioner protease in apoptosis, suggesting that loss of the ORF66 kinase 
correlated with VZV inability to check the development of apoptosis from VZV infection in this 
cell type (186).   These findings imply that ORF66 has an important function in extending the 
survival of infected T cells until they are able to home in on the skin (185).  Therefore, inhibition 
of apoptosis may be the contributing function or the defining function of ORF66 needed for 
VZV propagation in T cells.  It has also been reported that VZV modulates the PI3K/Akt 
pathway, involved in regulation of apoptosis.  Expression of ORF66 transiently or by VZV-
infected MeWo cells is involved in a  pro-survival signaling by activation of Akt, indicated by 
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the increase of Akt phosphorylation at serine 473, that decreased when 66 was not expressed 
(171). This may also partly explain the growth deficit of VZV in this cell type (133).  However 
results from studies of ORF66 kinase deficient infections in human corneal fibroblasts, which are 
very restrictive for such mutants, indicated no significantly increased levels of apoptosis. Recent 
work has revealed that the role of apoptosis in HSV-1 infection is more important in highly 
replicating or transformed cells than in primary cell lines (149).    
1.4.6 Alphaherpesvirus US3 kinase studies that guide the search for roles of ORF66 
Several roles of ORF66 may be speculated from identified roles of the HSV and PRV US3 
kinases, since there are clear structural similarities.  In addition to the kinase catalytic domain, all 
have a high proportion of acid residues in the amino terminal region, although this region is 
functionally ill-defined.  Here, we summarize the known features of the US3 kinases of other 
alphaherpesviruses.  
1.4.6.1 US3 Kinases and Inhibition of Apoptosis 
Viral perturbation of the host cell often triggers apoptosis, and herpesviruses have mechanisms to 
block programmed cell death and thus extend cell survival time to allow for viral replication (5).  
HSV-1 US3 kinase has been the most extensively examined in its role in blocking apoptosis, 
although the US3 kinases of others such as VZV, HSV-2, and PRV may have similar activities.  
US3 kinases block apoptosis by the virus as well as by a variety of ectopic treatments.  HSV-1 
US3 is one of four blockers of apoptosis (in addition to UL39, glycoproteins gD, gJ).   Kinase 
activity is required in HSV and PRV suggesting that cellular components are phosphorylated.  
The possible targets include the pro-apoptotic protein Bad, whose phosphorylation (and 
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inactivation) was found to be US3-dependent (22).  Recent studies indicate HSV-1 US3 kinase 
acts at a post-mitochondrial level, since US3, but not its inactive form US3 K220N, inhibited the 
cleavage and activation of procaspase 3, the zymogen form of caspase 3 - a major effector of the 
pro-apoptotic pathway.  This was also phosphorylated in vitro by US3(10).  
Two forms of HSV-1 US3 have been seen initating at different ATGs and these appear to 
differ in their ability to block apotosis. A US3 blocked apoptosis but US3.5 did not, even though 
both were able to localize in mitochondria (161) .  PRV also encodes two forms, a long (US3a) 
and short isoform (US3b) differing by an additional N terminal 54 residues from US3a that 
encodes a mitochondrial localization signal. However both block apoptosis, suggests that the 
mitochondrial signal and localization of the protein may only be partly responsible for the 
increase in its anti-apoptotic function (59).  There is evidence for the block in apoptosis to be 
downstream of cell signaling pathways activated by US3. HSV-1 US3 activates PKA, and PKA 
activation by forskolin inhibits apoptosis (9).  In sum, evidence points to the US3 kinases as one 
means to prevent programmed cell death, but several cellular targets may be involved.  
1.4.6.2 US3 Modulation of HDAC 
Inhibition of histone deacetylases is needed for efficient viral gene expression.  Although ICPO 
is thought to be the key player in blocking genomic silencing, HSV-1 US3 may contribute by 
post translationally modifying HDAC1 and HDAC2 (163, 165).  HSV-1 US3.5 shares this ability 
(161).  US3 and 3.5 enable viral or host gene expression from restrictive cells and enhance 
expression from permissive cells transduced with baculovirus carrying CMV immediate early 
promoter-driven genes (162).  While phosphorylation regulates HDAC 1 and 2 enzymatic 
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activity, it is not yet clear how US3 or ORF66 facilitates viral gene expression, but the suspicion 
is that HDAC1 and 2 are direct phosphorylation targets of US3 in infection .  
1.4.6.3 Nucleocapsid Egress 
Herpesvirus nucleocapsids assemble in the nucleus, and DNA packaged nucleocapsids pass 
through the inner (INM) and outer nuclear (ONM) membranes to the cytoplasm in an 
envelopment/de-envelopment fusion mechanism. Capsids then acquire most of the tegument and 
their final envelope as they bud through membranes of the trans-Golgi network (60).  In both 
HSV and PRV infection, deletion of the US3 kinase only moderately affects growth rates and 
infectious virus production in culture. However, EM analyses reveal that such mutants 
accumulate capsids in extended folds in between the INM and ONM, or perinuclear space (103, 
176).  The US3 kinase thus facilitates egress of the capsid from the intranuclear space. US3 
kinase mediated phosphorylation of several viral and cellular proteins have been implicated in 
this process, including UL34, a type 2 integral membrane protein that localizes to the INM, and 
UL31, both which are critical regulators of primary envelopment of nucleocapsids (88, 139, 169, 
179).  In HSV-1 infection, the UL34 forms a complex with UL31 and displays a smooth 
localization along the nuclear envelope, while in the absence of US3 kinase activity, the complex 
forms aberrant punctate accumulations at the nuclear membrane (175-176). UL34 was the first 
established target of the US3 kinase, but studies now indicate that UL34 phosphorylation at the C 
terminal end does not appear to be directly involved (89) in directing the normal localization of 
the UL34-UL31 complex.  The US3 kinase does phosphorylate UL31 in vitro (88) and 
prevention of phosphorylation at the serine rich N terminus of UL31 leads to virions 
accumulating in the perinuclear space.  Thus the US3 specific phosphorylation of UL31 may 
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facilitate virion nuclear egress (139).  The VZV homolog of UL34 and UL31 do not have 
obvious corresponding regions.  
Additional roles of the US3 kinase in nucleocapsid egress stem from recent studies 
indicating the kinase phosphorylates nuclear membrane forms of the major glycoprotein gB at 
the cytoplasmic tail. HSV with gB altered at the site of US3 mediated phosphoryation shows the 
same phenotype to the US3 kinase deletions, in that nucleocapsids accumulate in perinuclear 
invaginations that protrude into the nucleoplasma.  The US3 kinase may modulate gB-mediated 
fusion events at the ONM to allow de-envelopment during nuclear egress (221). With regards to 
VZV ORF66, VZV gB does have predictable IE62-like potential motifs for phosphorylation in 
the cytoplasmic tail which bear similarities to that targeted by US3, but it is not yet known if 
ORF66 phosphorylates gB. Schaap-nutt indicated no obvious accumulation of VZV 
nucleocapsids at the nuclear rim in T cells, but rather showed vastly decreased nucleocapsid 
formation (186).    
The US3 kinase also modulates host components of the nuclear envelope, including 
lamin A/C and emerin, an integral nuclear membrane protein which associates with lamin 
proteins (109, 138). The US3 kinase leads to the redistribution of these proteins in HSV-1 
infection, which normally lie just inside the nuclear membrane and act as a barrier for virions 
budding into the INM.  In the presence of US3 kinase, emerin becomes hyperphosphorylated, 
increasing its mobility during infection.  It was postulated that this causes dissociation of emerin 
and lamin A/C to facilitate the nuclear egress of nucleocapids . In the case of lamin A/C, it is 
theorized that US3 is involved in a careful balance in breaching the lamina network barrier to 
ease virion access to budding sites at the INM yet maintaining laminar structure (138). 
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1.4.6.4 Alteration of the host cytoskeleton 
Many viruses restructure the host cell cytoskeleton to promote viral inter and intracellular spread. 
The HSV-1, PRV and MDV US3 kinases have joined the group of increasing viral effector 
proteins reported to manipulate the host cell cytoskeleton (197).  PRV US3 has been shown to 
disassemble the actin cytoskeleton and induce novel formation of actin and microtubule-
containing cell projections in both the context of viral infection and in US3-transfected cells (56, 
208).  Viral particles found within these dynamic projections where shown to move directionally 
towards the tip of projections as infection progressed (56) enabling more efficient spread to 
adjacent cells. This may allow more efficient infection in the presence of virus neutralizing 
antibodies.  The US3-mediated actin disassembly also induced loss of cell-cell contacts and 
disassembly of focal adhesion which may be important to PRV spread (206).  Interestingly, US3 
was found to induce activation of group A p21-activated kinases through a threonine residue in 
the activation loop, and induce phosphorylation of PAK1 and PAK2 in vitro. These host proteins 
are players in Rho GTPase signaling pathways involved in actin disassembly and lamepodia or 
filopodia formation.  PAK1 and PAK2 were found to be required for infection-induced actin cell 
projections and disassembly, respectively (207).   
In HSV-2, US3 kinase induced cell rounding and dissolution of actin stress fibers in 
transfected cells and US3 expressing cell lines.  Dominant active forms of the RhoGTPases - Rac 
and Cdc42, co-transfected with US3 kinase reduced cell rounding, suggesting that US3 affects 
the Cdc42/Rac signaling pathway. Interestingly, the Rho family proteins regulate various aspects 
of actin dynamics and can activate PAKs (143).   Transient dissassembly of the actin 
cytoskeleton was also seen for MDV in infections and was dependent on expression of US3. 
Addition of cytochalasin D, which inhibits G actin repolymerization, blocked MDV plaque 
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formation. This taken together with the growth defects observed for US3-deficient MDV and the 
US3-dependent actin disassembly, support the idea that actin but not microtubule restructuring is 
important for virus intercellular spread (189). In contrast to PRV, MDV US3 kinase activity was 
not needed for actin remodeling in transfected cells (188), indicating US3-dependent actin 
disassembly may be dependent on its structure.  With regard to VZV, my work found that 
cellular stress fibers are reduced in wild type VZV- infected cells and are more prominent and 
abundant in VZV-infected cells if the kinase is disrupted. Thus it seems likely that a common 
target for ORF66 and the US3 kinases is the modulation of the actin-based cytoskeleton. This is 
of interest for future studies.   
1.4.6.5 Concluding Remarks 
VZV ORF66 clearly has important multifunctional roles in the infectious process which are 
highly cell type dependent. Thus it is likely that the critical functions of the kinase are inducing 
the phosphorylation of cellular targets or the induction of cellular signaling pathways that drive 
the altered phosphorylation states of cellular proteins.  It is clear that VZV has both novel 
functions as well as targets that are common to those targeted by other US3 kinases in other 
alphaherpesviruses.  What those common pathways and cellular targets are remain to be 
resolved.   
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Table 3.  In vivo and in vitro protein substrates of the ORF66/US3 kinases 
Specific US3 kinase and its protein target are noted.  Evidence of US3 induced phosphorylation in vivo or 
in vitro is denoted by a plus (+) sign or not done (ND).  Functions associated with phosphorylation of 
each protein are also listed.   
 
αherpesvirus ORF66/US3 
phosphorylated 
protein substrate 
In vivo /  In 
vitro 
target? 
Function 
VZV (52, 54, 99, 102) IE62 (ICP4) +/+ IE62 cytoplasmic 
accumulation / IE62 
tegument inclusion 
VZV, HSV, PRV  Matrin 3 +/ND ? 
VZV(210), HSV-1(165) HDAC 1 &2 +/ND Block HDAC 
transcriptional  repression 
HSV-1 (86, 221) gB +/+ Downregulate gB surface 
expression, promote virion 
nuclear egress 
 
HSV-1 (88, 139) UL31 +/+ promote virion nuclear 
egress 
HSV-1 (88, 169, 179) UL34 +/+ ? 
HSV-1 (138) Lamin A/C +/+ Disrupt nuclear lamina, 
promote virion nuclear 
egress 
HSV-1 (109) Emerin +/ND Disrupt nuclear lamina, 
promote virion nuclear 
egress 
HSV1,2 (41, 88) US9 +?/+  ? 
HSV-1 (88, 168, 196) ICP22 +?/+ ? 
HSV-2 (42) UL12 ND/+ ? 
HSV-2 (144) Cytokeratin 17 +?/+ Cell morphological changes 
HSV-1 (22, 88) Bad +/+ Block apoptosis 
HSV-1 (21, 88) Bid ND/ +/- Block apoptosis, 
Mediates protection from 
granzyme B cleavage of Bid 
HSV-1 (116) IFNRα +/ND Inhibit activation of IFN-γ 
genes 
HSV-1 (9) PKA +/ND PKA activation 
PRV (207) PAK1 and PAK2 +/+ Actin projection formation 
& stress fiber dissasembly 
HSV-1 (10) Procaspase 3 ND/+ Block activation of 
procaspase 3 and apoptosis 
HSV-1 (196) cdc25C phosphatase ND/+ Enhance interaction with 
ICP22, optimize viral gene 
expression 
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1.5 STATEMENT OF GOALS 
VZV ORF66 kinase is responsible for the direct phosphorylation of IE62 and induced 
phosphorylation of cellular proteins HDAC 1 & 2.   Additionally it is involved in the modulation 
of diverse cell signaling pathways such as causing surface MHC-I downregulation, inhibiting 
apoptosis and IFN-γ signaling pathways.    Morever, it is known that ORF66 is essential to viral 
growth in T cells. The US3 kinases have been implicated in the phosphorylation of multiple viral 
and cellular proteins in other αherpesviruses. In sum, the ORF66/US3 kinases are a group of 
multifunctional proteins important for establishing an optimal cellular environment for viral 
growth.  The mechanisms of how ORF66 modulates cell signaling pathways are unknown since 
specific targets of this kinase and the US3 kinases as a group are mostly unidentified.  The goals 
of this thesis work are to discover novel protein substrates for VZV ORF66 kinase to further 
define the specific roles of this kinase during the VZV life cycle.  These finding may also further 
highlight the potential of ORF66 kinase as a target for VZV antiviral therapy.  
 
Specific Aim 1: In chapter 2, we explore whether ORF66 expression is needed for VZV growth 
in primary stromal corneal fibroblasts.   Thus far, ORF66 has been reported to be non-essential 
for VZV growth except in T cells.  This study was based on our observations that VZV 
expressing ORF66kd did not replicate efficiently in corneal fibroblasts.  We hypothesize that 
either loss of VZV growth in this PCF is due to ORF66 kinase inability to function in 
phosphorylation of IE62 at the S686 site, or the inability to impede VZV-induced apoptosis.  For 
this purpose, we constructed a recombinant VZV with IE62 serine to alanine mutation at the 66 
targeted phosphorylation residue and also characterized this virus for IE62 localization and 
virion incorporation.  
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 Specific Aim 2: The basis for the studies in chapter 3, was the observation that the residue 
directly phosphorylated by ORF66 on IE62 is similar to that of PKA-substrate motif.  We 
hypothesize that we can utilize an antibody that recognizes proteins phosphorylated at serines or 
threonines within PKA-substrate-like motifs to find novel ORF66 substrate proteins.  Once a 
candidate protein was identified – matrin 3, we confirmed its phosphorylation induced by ORF66 
and tested if it is a conserved target for the alphaherpesvirus US3 family, as well as characterized 
the 66-targeted phosphorylation site and determined changes in subcellular localization of matrin 
3.  In these studies, we utilize VZV or adenovirus recombinant proteins expressing functional 
ORF66 kinase or mutated ORF66 that is kinase-inactive, in addition to HSV and PRV US3- 
expressing or US3 null viruses. 
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2.0  VARICELLA-ZOSTER VIRUS ORF66 PROTEIN KINASE IS REQUIRED FOR 
EFFICIENT VIRAL GROWTH IN PRIMARY HUMAN CORNEAL FIBROBLASTS 
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Note:  For this manuscript, I performed all immunofluorescence and image correction, as 
well as MRC-5 growth curves, NHS growth curve in Figure 2-6, growth curve enumeration by 
flow cytometry, and apoptosis experiments.  I also did all statistical analyses, and wrote the 
manuscript.   Recombinant VZV, virion purification and characterization, figure 2-3, 2-5, and 
PCF growth curve in figure 2-2 were done by M.B.Y.. 
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2.1 ABSTRACT 
Varicella-zoster virus (VZV) open reading frame (ORF) 66 encodes a serine/threonine protein 
kinase that is not required for VZV growth in most cell types, but is needed for efficient growth 
in T cells.  The ORF66 kinase affects nuclear import and virion packaging of IE62, the major 
regulatory protein, and is known to regulate apoptosis in T cells.  Here, we further examined the 
importance of ORF66 using VZV recombinants expressing green fluorescent protein (GFP)-
tagged functional and kinase-negative ORF66 proteins.  VZV with truncated or kinase-
inactivated ORF66 protein were marginally reduced for growth and progeny yields in MRC-5 
fibroblasts, but were severely growth and replication impaired in low passage primary human 
corneal stromal fibroblasts (PCF).  To determine if the growth impairment was due to ORF66 
kinase regulation of IE62 nuclear import, recombinant VZV were made that expressed IE62 with 
alanine residues at S686, the suspected target by which ORF66 kinase blocks IE62 nuclear 
import.  IE62 S686A expressed by the VZV recombinant remained nuclear throughout infection 
and was not packaged into virions. However, the mutant virus still replicated efficiently in PCF 
cells.  We also show that inactivation of the ORF66 kinase resulted in only marginally increased 
levels of apoptosis in PCF cells, which could not fully account for the cell-specific growth 
requirement of ORF66 kinase.  Thus, the unique short region VZV kinase has important cell 
type-specific functions which are separate from those affecting IE62 and apoptosis. 
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2.2 INTRODUCTION 
Varicella-zoster virus (VZV) is a highly communicable human alphaherpesvirus that causes 
chickenpox following a primary infection and herpes zoster (“shingles”) following reactivation 
from neuronal latency.  Current models (106-108) predict that VZV infects many cell types in 
the course of primary pathogenesis, including epithelial cells, fibroblasts, keratinocytes, T 
lymphocytes, dendritic cells, monocytes and sensory neurons (33, 137).  Furthermore, VZV 
reactivation from latency leads to viral replication in neuronal and non-neuronal cells in the 
sensory ganglion, and in skin tissues at multiple locations belonging to the affected dermatome.  
Reactivation may also lead to VZV replication in ocular tissues.  Reactivation involving the 
ophthalmic division (division V1) of the trigeminal nerve occurs in approximately 10-25% of 
zoster cases, a condition second only in frequency to thoracic zoster (155).  It causes herpes 
zoster ophthalmicus (HZO), a condition that leads to severe ocular diseases in both anterior and 
posterior compartments, which may ultimately threaten vision .  Two-thirds of HZO patients 
report serious ocular complications, most commonly involving the cornea(155).  VZV DNA, 
antigen and replication have been found in the corneal epithelium at the ocular cell surface, as 
well as in stromal keratocytes that sparsely populate the stroma to form an interconnected 
network in the clear extracellular matrix (141, 216).  VZV has also been found in the vitreous 
fluids and the retinal layers (155, 216).  As such, VZV genes affecting viral replication in ocular 
cell types have important implications for ocular disease.   
           VZV encodes two serine/threonine (S/T) specific protein kinases, from ORF66 
and ORF47, which have been shown to be dispensable for replication in many cultured cells used 
for VZV growth (73-74).  Both kinases, however, have important roles that are needed for viral 
growth in specific cell types (14, 80).  Disruption or inactivation of the ORF66 protein kinase 
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leads to minimal impairment of VZV growth in MeWo cells, but significant growth defects in T 
cells, both in culture (199) and in human thymus/liver xenografts in severe combined 
immunodeficiency (SCID-hu) mice (133, 185-186).  The functional roles directing the growth 
requirement of ORF66 in T cells are not yet clear.  ORF66 affects several host cell processes, 
including pathways that lead to the downregulation of surface class I major histocompatibility 
complex (MHC-I)-associated antigen presentation (1, 53).  In T cells, ORF66 modulates the 
interferon (IFN) γ-induced activation of the IFN signaling pathway (186), and inhibits virus-
induced apoptosis (57, 58).  Apoptosis is also inhibited by ORF66 orthologues (US3 kinases) in 
several alphaherpesviruses, including  herpes simplex virus type 1 (HSV-1), HSV-2, and 
pseudorabiesvirus (PRV) (9-10, 48).  Loss of ORF66 reduced VZV nucleocapsid production in T 
cells (186), but did not lead to the accumulation of virions in the nuclear membrane seen in HSV 
and PRV lacking US3.  HSV US3 is thought to be involved in the breakdown of the nuclear 
lamina to facilitate primary envelopment and egress of the nucleocapsid across the nuclear 
membrane (109, 138).  Several additional functions have been attributed to specific US3 kinases, 
but it is not known if ORF66 shares these functions.  These include modulation of the 
cytoskeletal actin structure (56), and in HSV-1, modification of histone deacetylase function 
(162).   
          The only well-characterized target of the ORF66 protein kinase is the IE62 
regulatory protein, orthologous to the well-studied HSV ICP4.  IE62 is encoded by a diploid 
gene (ORF62 and ORF71) and is a 1310 residue phosphoprotein with strong transcriptional 
transactivator functions.  It activates all VZV genes studied to date and can positively or 
negatively autoregulate its own promoter in transfection assays, depending on the cell type (157-
158) .  Functions of IE62 are predicted to be similar to HSV-1 ICP4, because IE62 can 
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complement HSV-1 ICP4 deletion mutants and partly replace ICP4 in the context of the HSV-1 
genome (51).  ICP4 facilitates the recruitment of cellular activating and basal transcriptional 
factors to viral promoters to enhance RNA polymerase II-mediated transcription (228).  In VZV 
infections, IE62 is at first nuclear, but transitions to the cytoplasm as infection progresses to a 
predominantly cytoplasmic distribution at late stage infection.  Unlike HSV-1 ICP4, IE62 is an 
abundant tegument protein incorporated at levels approximately 50% of the major capsid protein 
(100).  Virion packaging requires the ORF66 kinase, as kinase-negative mutant VZV fail to 
accumulate IE62 in virions (99-100).  In co-expression studies, ORF66 kinase phosphorylates 
IE62 directly in vitro at two sites, mapped to serine residues 686 (S686) and S722.  IE62 protein 
containing a S686A mutation does not accumulate in the cytoplasm in the presence of the 
ORF66 kinase, strongly suggesting that the ORF66 kinase phosphorylation of S686, immediately 
adjacent to the IE62 nuclear localization signal, drives IE62 exclusion from the nucleus (52, 99).  
Recent studies have suggested that the ORF66 kinase is not the only means by which IE62 can 
accumulate in the cytoplasm, since T cells infected with VZV lacking ORF66 kinase still show 
cytoplasmic forms of IE62 (185).  This suggests that a host cell component may be involved in 
the cytoplasmic accumulation of IE62 in infection.     
           Recently, we detailed the development of recombinant VZV which express 
enhanced green fluorescent protein (GFP) tagged to the amino terminus of either functional or 
truncated ORF66 protein (53).  Using these and a VZV expressing a kinase-inactivated ORF66 
protein, we show that VZV lacking ORF66 kinase activity fail to grow in PCF cells.  The ORF66 
growth requirement is, however, separate from its role in regulating IE62 nuclear import to 
enable virion packaging.  Furthermore, while cells infected with VZV expressing inactivated 
ORF66 show higher levels of apoptosis in PCF cells, this does not account for the failure of 
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ORF66 kinase- negative VZV to replicate in this cell type.   PCF cells represent the first non-
lymphocytic cell type in which the kinase has a critical role for VZV replication. 
2.3 MATERIALS & METHODS 
2.3.1 Cells.  
MRC-5 (human lung fibroblasts) (ATCC, Manassas, VA) and MeWo cells (human melanoma 
cell line; kindly provided by C. Grose, University of Iowa, Iowa City) were maintained and used 
to grow VZV as described previously (52).  Primary corneal stromal fibroblasts (PCF) were 
derived through the Tissue Culture and Morphology Core Module of the Department of 
Ophthalmology at the University of Pittsburgh.  All primary cells were isolated under protocols 
approved by the University of Pittsburgh Committee for Oversight on Research Involving the 
Dead (CORID).  Briefly, discarded donor rims of human corneas for transplantation were 
delivered under anonymous condition.  The scleral, endothelial and epithelial tissues were 
removed by mechanical debridement using forceps.  Washed corneal stroma was cut horizontally 
to expose internal stromal tissue to media.  Sections were then treated with 1 mg/ml collagenase 
for 30 s and then washed with 10% fetal bovine serum (FBS) in Dulbecco’s Modified Eagle 
Medium (DMEM) media before placement into plastic culture dishes overlaid with a glass 
coverslip.  Following incubation at 37oC under media for 2-3 days, cells on the coverslip and 
plastic support were trypsinized and passaged twice before being mixed with other donor 
fibroblasts and frozen in aliquots under liquid nitrogen.  PCF cells were used in experimental 
studies within 5-9 passages and were maintained in Dulbecco’s Modified Eagle Medium 
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Nutrient Mixture F-12 (Ham) (1:1) containing sodium bicarbonate and sodium pyruvate 
(Invitrogen) supplemented with 10% FBS and antibiotic/antimycotic mixture (100 U/ml 
Penicillin G, 100 μg/ml Streptomycin , and 0.25 μg/ml Fungizone; Gemini Bio-Products). 
2.3.2 VZV and derivation of rVZV 
VZV used here is based on the parent of Oka vaccine (pOka).  The construction and derivation of 
VZV.GFP-66 and VZV.GFP-66s from pOka-based cosmids have been detailed previously (53).  
These express amino-terminal GFP-tagged functional ORF66 protein or one that has been 
disrupted by insertion of stop codons at residue 84, respectively.  The same cloning procedure 
detailed in that study was used to derive VZV.GFP-66kd, which contains GFP-tagged ORF66 
protein with two highly conservative changes in the catalytic loop domain of the kinase (D206E, 
K208R) (98).  The derivation of a rescuant VZV was carried out by subcloning a unique SgrAI - 
AvrII fragment from the pSpe23 cosmid that was used to derive VZV.GFP-66kd into a modified 
pUC19 derivative containing sites for SgrAI and AvrII (53).  The AvrII-BamHI fragment within 
this construct that contains the ORF66 promoter and amino terminal portion of ORF66 with the 
inactivating mutations was replaced with the same corresponding DNA fragment containing 
functional GFP-tagged ORF66 (53).  The SgrAI-AvrII fragment was then reengineered back into 
the pSpe23 cosmid to generate pSpe23GFP66rsc, which was then used in conjunction with 
pFsp73, pSpe14 and pPme2 to derive rVZV designated VZV.GFP-66Rsc. 
 
Additional rVZV were derived from viral DNA cloned as a bacterial artificial 
chromosome (BAC) containing the entire pOka genome (204).  To generate S686A changes in 
ORF62 and ORF71, we conducted mutagenesis using the markerless two-step recombination 
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system, detailed previously (205).  All oligonucleotides were obtained from IDT, Inc. 
(Coralville, IA) and were SDS-PAGE purified by the manufacturer.  PCR was performed with 
Expand proofreading polymerase (Roche Diagnostics, Indianapolis, IN).  Two oligonucleotides 
used for mutagenesis were S686AF 5’-
GTGTGTCCACCGGATGATCGTTTACGAACTCCGCGCAAGCGCAAGGCTCAACCGGTC
GAGAGCAGAAGCCTCCTCGACAAAGGATGACGACGATAAGTAGGG-3’ and S686AR 
5’-
CGACGGGTGTCTCCCTAATCTTGTCGAGGAGGCTTCTGCTCTCGACCGGTTGAGCCT
TGCGCTTGCGCGGAGTTCGTAAACAACCAATTAACCAATTCTGATTAG-3’ (underlined 
residues mark the altered sequence discussed in the text).  The two oligonucleotides were used to 
PCR amplify the kanamycin resistance cassette (kanr) from the plasmid pEP-kanS2 (205) to add 
the IE62 flanking sequences required for homologous recombination and mutagenesis.  The gel 
purified PCR product was then electroporated into E. coli SW105 (a kind gift of N. Copeland, 
NCI Frederick MD) containing the pOka VZV BAC.  Recombination was induced by heating to 
42oC for 15 min, and growth of recombinants were selected by plating at 32oC on LB agar plates 
containing 15 μg/ml kanamycin (kan) and 25 μg/ml chloramphenicol (chm).  DNA of individual 
colonies was mapped for the correct insertion of the cassette (the first recombination occurred in 
ORF71) by restriction analyses using HindIII digestion.  Resolution of the construct to remove 
the kanr cassette was achieved by transformation of the plasmid pBAD-I-SceI into the SW105 
cells containing the modified VZV BAC, which was then growth-selected on LB-agar plates 
additionally containing 50µg/ml ampicillin.  I-SceI expression was induced by growth in liquid 
culture containing 1% arabinose, and a second round of recombination was induced by heating 
cultures to 42oC for 15 min.  Colonies growing at 32oC on LB agar containing chm, amp and 
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arabinose were checked for loss of the kanr cassette by replica plating individual colonies onto 
plates containing kanamycin.  E.coli containing the altered BAC were then subjected to a second 
round of mutagenesis with the same PCR fragment, selecting for homologous recombination into 
ORF62.  The BAC DNAs were transfected into MeWo cells using Lipofectamine 2000 
(Invitrogen Corp, Carlsbad, CA) and derived VZV plaques were visible after 3-5 days of 
incubation at 35oC.  VZV containing a single change in ORF71 was termed VZV.71.S686A, 
whereas rVZV with mutations in both IE62 genes was termed VZV.IE62(S686A)2.  The 
insertion of AgeI sites into both genes was confirmed by restriction analyses.  The presence of 
the changes in VZV was carried out through Southern blotting of AgeI digested infected cell 
genomic DNA (gDNA), purified from VZV-infected MeWo cells using Qiagen’s Blood and Cell 
Culture DNA Midi Kit (Valencia, CA) onto a positively charged nylon membrane (Nytran 
SuPerCharge, Schleicher & Schuell, Keene, NH).  The 1018 bp fragment isolated from an AgeI 
digest of pKCMV62 DNA was used as a probe following radiolabeling with dCTP-[α-32P] 
(Perkin Elmer, Waltham, MA) and random prime labeling kit (Roche Diagnostics Corp., 
Indianapolis, IN). 
2.3.3 Antibodies & Immunological Procedures 
Rabbit polyclonal antibodies to IE62 (99) and to VZV proteins ORF 4, 61, and 63 were detailed 
previously (97).  Previously detailed anti-peptide antibodies to ORFs 10 (97) and 29 (101) were 
also used in this work.  Antibodies to ORF 9 (26) were a kind gift of W.T. Ruyechan, SUNY at 
Buffalo NY and antibodies to ORF 47  were a kind gift of C. Grose (University of Iowa, Iowa 
City,  IA).  Mouse antibodies to β-actin (Sigma, St. Louis, MO) and to ORF40 major capsid 
protein (MCP) (Virusys Corp., Sykesville, MD) were purchased commercially.  All 
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immunofluorescent staining procedures were carried out as described previously (53), and 
antibodies were detected using goat anti-rabbit immunoglobulin G-antibody conjugated to Alexa 
Fluor 546 or goat anti-mouse immunoglobulin G-antibody conjugated to Alexa Fluor 488.  
Immunofluorescence was visualized using a Nikon Eclipse TE2000-E epifluorescence 
microscope equipped with a xenon lamp.   
2.3.4 Analaysis of viral growth 
VZV for growth rate studies was prepared from aliquoted and titrated stocks of virus in MeWo 
cells stored in liquid nitrogen.  Stocks were 80-95% infected at the time of preparation, to 
minimize addition of uninfected cells.  Viral growth rates were determined using similar 
procedures detailed elsewhere (53).  Briefly, confluent monolayers of cells were established, and 
infected with cell-associated VZV at an estimated 300 infectious centers (IC) per well.  Serial 
dilutions of the infecting virus were immediately titrated on MeWo cell monolayers to determine 
the exact titer of the inoculum.  At specific times, cells were trypsinized, diluted in fresh media 
and added to fresh MeWo monolayers.  At 4-5 days post-infection (p.i.) plaques were quantified 
using either autofluorescence of GFP, or were immunofluorescently stained for IE62. Statistical 
analysis to compare overall growth curves was done using Dunnett’s multiple comparison test 
using GraphPad Prism software v. 4.0.  For growth curve enumeration by flow cytometry, a 
similar setup was established, except that trypsinized cells were immediately fixed in 1% 
paraformaldehyde, washed in 1X PBS and counted using a FACSaria cytometer/cell sorter 
(Becton-Dickinson).  GFP gates were set using mock infected cell controls.   
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2.3.5 Virion purification and characterization 
Virion purification was performed as described previously (21).  Briefly, monolayers of MeWo 
cells infected with VZV were grown at 35°C until showing ~80% cytopathic effect.  Harvested 
cells were washed with ice-cold PBS containing a protease inhibitor cocktail (Complete EDTA-
free; Roche Diagnostics, Indianapolis, IN), and subjected to dounce homogenization to obtain 
cytoplasmic extract.  Virion particles were also collected from the cell-free media by high speed 
centrifugation and combined with cytoplasmic fractions.  Virions were purified by velocity 
gradient ultracentrifugation for 2 hours (hrs) at 17,000xg on 5-15% Ficoll gradients made in 
PBS.  The diffuse virion band migrating approximately 2/3rd down the tube was harvested, 
concentrated by centrifugation, and resuspended overnight at 4oC in PBS containing protease 
inhibitors.  Virions were then subjected to 10-50% sucrose gradients made in PBS, which were 
then fractionated using a piston gradient fractionator.  For protein analyses, proteins were 
precipitated from the fractions with 10% trichloroacetic acid, washed with ice-cold acetone and 
resuspended in 100 μl protein gel loading buffer for SDS-PAGE.  For immunoblotting, proteins 
were separated by SDS-PAGE, transferred to Immobilon-P membrane (Millipore, Billerica, MA) 
and probed with rabbit polyclonal antibodies to ORF10 to identify the peak virus fractions.  
These were pooled for further studies for VZV proteins.  Virion samples for protein stain were 
run on 4-15% Tris-HCl linear gradient polyacrylamide SDS gels (Bio-Rad Laboratories, 
Hercules, CA), and stained with SYPRO Ruby Protein Gel Stain (Invitrogen, Carlsbad, CA).  
Proteins were visualized using a Bio-Rad Fluor-S MultiImager. 
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2.3.6 Apoptosis Assay 
Confluent cells were seeded onto 6 well plates, and infected with VZV at a multiplicity of 
infection (MOI) of approximately 0.02 or mock infected.  At times indicated, cells were 
harvested and stained according to manufacturers’ instructions for APC Annexin V (BD 
Pharmingen).  Briefly, cells were washed twice in cold PBS, resuspended in the supplied binding 
buffer, and counted.  Approximately 1 X 105 cells were then stained with APC Annexin V and 7-
Amino-Actinomycin D (7-AAD).  Stained cells were analyzed by flow cytometry and GFP gates 
were set using mock infected cell controls.  Cells were characterized and analyzed using BD 
FACSDiva v4.1 software.  Experimental values are the fraction of GFP positive cells showing 
APC Annexin V positive stain as a percentage of the total GFP positive cells.  Values represent 
the mean of three identical experiments.  Statistical analysis was done by Student’s t-test using 
GraphPad Prism software v4.0. 
2.4 RESULTS 
2.4.1 ORF66 is required for efficient growth in PCF cells 
The VZV ORF66 protein kinase is categorized as a non-essential gene in culture, yet recent 
studies indicate it is needed for VZV growth in T cells .  To explore the growth properties of 
VZV with or without ORF66 kinase in other cell types, we employed two fluorescent VZV 
recombinants, which express a GFP-tagged and functional ORF66 protein or one that is 
disrupted at residue 84.  GFP has no apparent effect on VZV growth when compared to parent 
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pOka virus (53).  We also generated VZV which expressed the full length ORF66 protein in 
which the kinase was inactivated by two point mutations in the catalytic loop (VZV.GFP-66kd), 
as well as a rescuant of this change (VZV.GFP-66Rsc) in which the two point mutations were 
reversed.  These mutations abrogated the ability of ORF66 to induce accumulation of 
cytoplasmic IE62 or phosphorylate IE62 peptides in co-expression assays (99).   The rescuant 
was phenotypically indistinguishable from VZV.GFP-66 and parental Oka in all assays 
examined.   
IE62 produced by viruses expressing functional ORF66 protein in both MRC-5 cells (Fig. 
2-1A) and PCF cells (Fig. 2-1B) showed predominantly cytoplasmic forms in most GFP-positive 
cells (Fig. 2-1A. a,c,j,l & Fig. 2-1B. a,c,j,l).  In contrast, IE62 expressed by VZV.GFP-66kd and 
VZV.GFP-66s displayed a predominantly nuclear localization in both cell lines in GFP positive 
cells (Fig. 2-1A. d,f,g,i & Fig. 2-1B. d,f,g,i).  GFP-66s showed a diffuse cellular localization 
(Fig. 2-1A. h,i & Fig. 2-1B. h,i), but GFP-66kd protein exhibited a distinct predominantly 
nuclear localization in both cell lines (Fig. 2-1A. e,f & Fig. 2-1B. e,f) that was clearly different 
from functional kinase produced by VZV.GFP-66, suggesting that the kinase activity of ORF66 
affected its cellular localization.  Some cells displayed marked nuclear rim accumulations of 
GFP-66kd.  
In addition to differences in cellular distribution patterns, it was obvious that ORF66-
negative VZV formed tiny plaques on PCFs that involved far fewer cells.  In MRC-5 cells, 
plaque size of all four viruses increased in size during the duration of the study (up to 7 days 
post-infection), although plaques of VZV not expressing kinase were slightly smaller (data not 
shown).  In PCF cells, plaques of the VZV lacking the kinase formed very small centers of 
infection at day 1-2 that involved 10-20 cells, but these failed to increase further in size, 
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suggesting that infections were initially established but failed to progress.   We also found severe 
growth impairment of a previously described ORF66 kinase-deficient VZV made in the Vaccine 
Oka background .  To quantify this more accurately, we determined yields of progeny virus on 
both cell types for all four viruses.  In MRC-5 cells, VZV without the kinase were marginally 
impaired for virus growth as compared to VZV.GFP-66, yielding 0.4 to 0.7 log reduction at 96 
hours (hrs) post-infection (p.i.) (Fig 2-2A).  Maximal titers of VZV.GFP-66s and VZV.GFP-
66kd were lower (7.5 X 103 and 4.8 X103 IC, respectively) than that of VZV.GFP-66 (2.0 X104 
IC) and VZV.GFP-66Rsc (2.2 X104 IC), at 96 hrs p.i.  However, the overall growth curve 
differences compared to VZV.GFP-66 were not statistically significant (p>.05).  In contrast, a 
much greater impairment for growth of ORF66-negative viruses was observed in PCF cells.  
While VZV.GFP-66 and VZV.GFP-66Rsc reached maximum titers of 3.2 X 104 and 4.0 X 104 
IC respectively at 96 hrs p.i., VZV.GFP-66s and VZV.GFP-66kd maximal titers peaked at 48 hrs 
(1.1 X 103 and 4.3 X 102 IC, respectively) and declined thereafter (Fig. 2-2A).  Extension of the 
growth curves to seven days did not lead to any increases in viral titer (data not shown).  These 
results indicate that PCF cells do not permit efficient growth of VZV if the ORF66 kinase is not 
functional.   
The growth impairment in PCF cells was also detected when flow cytometry was used to 
quantify GFP-positive cells as an indicator of infection.  In MRC-5 cells infected with 
VZV.GFP-66, greater than 40% of cells showed GFP positive signals by day 9 p.i. (Fig.2-2B).  
ORF66 kinase-negative viruses showed a reduced rate of increase in the number of GFP-positive 
cells, with VZV.GFP-66kd showing marginally greater impairment.  However, in PCF cells, 
VZV with non-functional kinase showed only a very small increase in the number of GFP 
positive cells at day 1, which then subsequently diminished.  VZV.GFP-66 infection resulted in a 
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reduced rate of increase of GFP positive cells as compared to that seen in MRC-5 cells, but this 
reflects a slightly reduced growth rate in PCF cells (see Figure 2-2a) rather than a loss of GFP 
positive cells in flow cytometry.  We did not find there was untoward significant loss of cell 
structure due to mechanical damage in these studies.  Thus, these results reflect growth curve 
studies and further establish that PCF cells are unable to support VZV replication in the absence 
of functional ORF66 protein kinase.   
 
 
 
 
Figure 2-1.  IE62 cellular distribution and GFP expression in VZV-infected cells 
IE62 cellular distribution and GFP expression in VZV-infected cells.  MRC-5 cells (A) or 
PCF cells (B) were infected at an MOI of 0.0005 with MeWo cell-grown VZV.GFP-66 (panels 
a-c); VZV.GFP-66kd, expressing complete GFP-tagged kinase-inactivated ORF66 protein 
(panels d-f); VZV.GFP-66s, expressing GFP tagged to residues 1- 84 of ORF66 (panels g-i); or 
VZV.GFP-66Rsc (panels j-l).  Cells were fixed with 4% paraformaldehyde at 3 days p.i. and 
immunostained with rabbit anti-IE62, which was then detected with anti-rabbit Alexa Fluor 546 
(panels a,d,g,j).  ORF66 expression was determined using GFP autofluorescence (panels b,e,h,k).  
The merge panels (panels c,f,i,l) are overlays of GFP (green), IE62 (red) and nuclei stained with 
Hoescht dye (blue).  Fluorescence images were taken using a 40X objective.   
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Figure 2-2.  Progeny virus growth curves reveal a requirement for ORF66 for VZV growth in PCFs 
Progeny virus growth curves reveal a requirement for ORF66 for VZV growth in PCF cells.  (A) Growth 
curves were performed as detailed in Methods, and the titers of the progeny VZV in MRC-5 cells (top) 
and PCF cells (bottom) are shown.  Confluent monolayers were infected at an MOI of 0.001 with 
VZV.GFP-66 (▲), VZV.GFP-66kd (▼), VZV.GFP-66s (●), or VZV.GFP-66Rsc (□).  The inoculum 
(Inoc) of each virus was immediately determined upon the setup of the studies at time 0 h.  At 24, 48, 72 
and 96 h post-infection, infected cells were trypsinized and titrated onto subconfluent monolayers of 
MeWo cells.  Plaque formation and enumeration were assessed by fluorescent microscopy at 4-5 days 
post-infection.  X- axis values represent hours post-infection when cells were harvested and Y-axis values 
represent average total number of infectious centers at each time point.  Each data point was determined 
in quadruplicate, and results represent the mean +/- SE of these values.  (B) GFP-positive infected cell 
numbers fail to increase in PCF cells if the ORF66 protein is disrupted.  MRC-5 cells (top) or PCF cells 
(bottom) in confluent monolayers in 35 mm dishes were infected with VZV.GFP-66 (▲), VZV.GFP-
66kd (▼), VZV.GFP-66s (●) at an MOI of 0.001, or mock infected (■).   At the day after infection 
indicated (X-axis), cells were harvested and counted by flow cytometry, gating for GFP-positive cells.  
The ratio of GFP-positive cells to the total number of cells in the harvested monolayers is expressed as a 
percentage (Y-Axis).  Values represent the mean +/- SE of three parallel but independent values.      
 
 
 
 58 
2.4.2 Derivation of VZV expressing IE62 protein mutated at the critical ORF66 
phosphorylation site.   
The most well characterized target of the ORF66 kinase is IE62, the VZV major regulatory 
protein.  In transfection studies, IE62 expressed alone is largely nuclear, but when it is 
coexpressed with the ORF66 kinase, IE62 accumulates predominantly in the cytoplasm.  We 
have previously shown that the accumulation of cytoplasmic IE62 requires the ORF66 kinase 
activity, and that the kinase phosphorylates IE62 both in vivo and in vitro at two residues, S686 
and S722.  However, IE62 containing S686A changes (but not IE62 containing S722A 
mutation), were resistant to ORF66 induced cytoplasmic accumulation, and remained 
predominantly nuclear in cells expressing the ORF66 protein kinase .  While it was concluded 
that ORF66 kinase phosphorylated IE62 at residue S686 to induce its cytoplasmic accumulation, 
the interaction has not been addressed in the context of VZV infection.  It is clear that VZV-
infected cells not expressing the ORF66 kinase show only nuclear IE62 (Fig. 2-1A, B) and loss 
of the kinase abrogates virion packaging of the IE62 protein (52).  Thus it was possible that the 
requirement of the kinase in PCF cells reflected a loss of the cytoplasmic accumulation and 
virion packaging of IE62.  
 To test this possibility, we developed recombinant VZV in which the IE62 residue 
targeted by the kinase, S686, was altered to alanine (VZV.IE62(S686A)2).  Our previous studies 
predict that IE62 with this change would not be regulated by the ORF66 kinase during VZV 
infection.  The mutations were generated in a VZV pOka BAC, and were designed to 
simultaneously introduce a marker AgeI site with the S686A mutation (Fig. 2-3A).  In the 
parental BAC, AgeI digestion produced a 2-molar 1018 bp fragment, representing an internal 
fragment of ORF62 and ORF71 (Fig. 2-3B).  DNA of BACs engineered to contain the S686A 
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mutation in only the ORF71 gene showed a loss of one copy of the 1018 bp fragment, while 
DNA from BACs containing S686A mutations in both the ORF62 and ORF71 genes showed loss 
of both 1018 bp fragments (Fig. 2-3B).  The introduction of the mutation resulted in the 
generation of two smaller AgeI DNA fragments of 605 and 413 bp. While these could not be 
easily identified in ethidium bromide stained gels (Fig. 2-3B) due to small size and comigration 
with other DNA fragments, we confirmed their presence by Southern blot analyses.  Viruses 
derived from each BAC were used to generate infected cell DNA, and AgeI digests were 
examined by Southern blotting and probing with a radiolabeled 1018 bp AgeI DNA fragment 
(Fig. 2-3C).  As expected, a prominent 1018 bp fragment was detected in pOka, one copy was 
reduced to 605 and 413 bp fragments in VZV with the ORF71 mutation, and both copies were 
converted to the smaller fragments in DNA of  VZV.IE62(S686A)2.  VZV with single and 
double copies of the S686A mutations grew and formed plaques that were similar in size and 
appearance to that formed by BAC-derived pOka VZV in MeWo cells.  We then confirmed the 
presence of the S686A mutations by DNA sequencing.   
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 Figure 2-3.  DNA characterization of BAC DNA and of VZV-infected cell of the recombinants 
VZV.71.S686A and VZV.IE62(S686A)2 
DNA characterization of BAC DNA and of VZV-infected cell DNA of the recombinants 
rVZV.71.S686A and VZV.IE62(S686A)2.  (A) Schematic representation of the mutagenesis of IE62 
residue S686. The top portion represents IE62 and its nuclear localization signal (NLS), with the presence 
of the existing AgeI sites.  Part of the DNA sequence and encoded amino acids of the target region in the 
parental DNA and in mutant DNA are shown underneath.  The DNA sequence of the alterations induced 
by mutagenesis that introduce the novel AgeI site is underlined.  (B) 1.2% agarose gel showing DNA 
fragments generated by AgeI digestion of the VZV BAC DNAs derived from pOka and BACs containing 
the mutation in ORF71(S) or in both ORF62 and ORF71 (Dbl).  M is the DNA size marker (1Kb plus, 
Invitrogen). The abundant 5 Kbp DNA seen in the mutant BACs represents the pBAD-I-SceI plasmid 
used to select for loss of the kanr cassette.  The positions of the 1018 bp fragment in the pOka BAC and 
 61 
the resultant smaller digestion fragments in the mutants are arrowed.  (C) Southern blot of rVZV-infected 
MeWo cell genomic DNA, digested with AgeI and probed with a dCTP-[α-32P]-labeled 1018 bp fragment 
obtained from an AgeI digest of pKCMV62.  The autoradiograph shows DNA of VZV pOka, the 
VZV.71.S686A and VZV.IE62(S686A)2.  The approximate sizes of DNA markers are indicated to the 
left.     
 
 
2.4.3 VZV.IE62(S686A)2 IE62 remains nuclear in the presence of functional ORF66.   
The prediction was that IE62 expressed from VZV.IE62(S686A)2 would remain nuclear 
throughout viral infection, because IE62 could not be  phosphorylated by the ORF66 protein 
kinase at the site affecting its cellular distribution (52).  While VZV.GFP-66 formed abundant 
cytoplasmic forms of IE62 in MeWo cells, VZV.IE62(S686A)2  expressed IE62 that remained 
exclusively nuclear at all stages of infection, even in cells expressing the late ORF40 major 
capsid protein (Fig. 2-4A).  VZV.71.S686A produced IE62 that showed an intermediate 
phenotype (data not shown).  Extension of these studies to MRC-5 and PCF cells revealed that 
IE62 remained exclusively nuclear in both cell types, fully overlapping the Hoescht nuclear stain 
(Fig. 2-4B).  Thus, it is clear that residue S686 of IE62 is critical for ORF66 to regulate IE62 
nuclear import in the context of viral infection of several cell types.  
The predominantly nuclear localization of IE62 in VZV.IE62(S686A)2-infected cells is 
similar to that seen for ORF66 kinase-negative VZV.  To confirm the integrity of the ORF66 
protein kinase, we sequenced the ORF and its promoter and also evaluated the ORF66 gene in 
VZV.IE62(S686A)2 by PCR amplifying it, placing it into an expression vector and then 
examining it for the ability to induce cytoplasmic forms of IE62 in co-expression studies.  As the 
kinase retained the ability to regulate the cellular localization of IE62 (data not shown), we 
conclude that the exclusively nuclear phenotype of IE62 was due to a loss of the IE62 S686 site 
rather than a spurious kinase-inactivating mutation in the ORF66 protein.  
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 Figure 2-4.  IE62 localizes to the nucleus in VZV.IE62(S686A)2 - infected cells 
(A) Scanned images of VZV.GFP-66 and VZV.IE62(S686A)2-infected MeWo cell plaques, 
immunostained with rabbit anti-IE62 and mouse anti-major capsid protein (MCP), which was then 
detected with anti-rabbit Alexa Fluor 546 or anti-mouse Alexa Fluor 488, respectively .  The merge 
panels are overlays of IE62 (red) and MCP(green). (B) Immunofluorescence images of 
VZV.IE62(S686A)2-infected MRC-5 (top row) or PCF cells (bottom row) immunostained for IE62 (red). 
Nuclei detected using Hoescht stain (blue) are displayed in the merge images.  All cells were fixed at 3 
days p.i. with 4% paraformaldehyde and images were taken using a 40X objective.   
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2.4.4 Tegument proteins of VZV.IE62(S686A)2 
Previous studies demonstrated that genetic disruption of the ORF66 kinase in VZV resulted in 
the IE62 protein remaining completely nuclear throughout infection, and simultaneously 
abrogated the packaging of IE62 into virions, leading us to conclude that the cytoplasmic 
distribution of IE62 during infection was required for its virion packaging (98).  The 
predominantly nuclear IE62 seen in VZV.IE62(S686A)2-infected cells would also be predicted to 
abrogate IE62 packaging into VZV.IE62(S686A)2 virions.  To examine this possibility, we 
infected MeWo cells with VZV.IE62(S686A)2 or VZV.GFP-66 and used methods established 
previously to obtain purified virions from the cytoplasmic extracts (98). We consistently 
obtained lower levels (approximately 1/3rd to 1/5th) of VZV.IE62(S686A)2 virions compared to 
virions obtained from VZV.GFP-66 infected cells, based on total protein content of the Ficoll 
gradient-purified virion fraction, although virion bands migrated to the same relative position in 
the gradients.  Comparison of Ficoll gradient-purified virions to cell extracts of VZV.GFP-66 
(Fig. 2-5A), showed that virions contained a prominent polypeptide of 155 kDa, the major capsid 
protein, and had a virion protein profile that was similar to that previously reported.  We noted 
that two polypeptides of 175 kDa and 180 kDa seen only in infected cell extracts (arrowed in 
Fig. 2-5A) were likely the predominant forms of IE62 seen in infected cells in a past study.  
Comparison of 15% of the total Ficoll gradient virion preparations from VZV.GFP-66 with 30% 
of the total virion preparation from VZV.IE62(S686A)2 -infected cells revealed that both virions 
had similar protein profiles, with the exception that the 175 kDa polypeptide was not seen in 
VZV.IE62(S686A)2 virions.  This is the size of virion-packaged IE62 reported previously (98).   
To further assess virion protein content, virions were then purified on sucrose gradients, 
which were subsequently fractionated.  Fractions containing virions (identified by probing SDS-
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PAGE separated proteins in each fraction for ORF10 protein) were restricted to three fractions 
from the central region of each gradient.  The total protein stain for VZV.GFP-66 virions was 
highly similar to that seen from the Ficoll gradient, although the low levels of virions obtained 
for VZV.IE62(S686A)2  virions did not permit a total protein comparison..  It is possible that 
virions produced by VZV.IE62(S686A)2  may have reduced stability, although this has not been 
investigated further.  Based on the levels of the ORF10 major tegument protein, proteins of the 
sucrose gradient-purified virions were normalized, and probed for additional VZV proteins.  The 
absence of non-structural proteins encoded by ORF29 (the homologue of HSV ICP8, which is 
also non-structural) and ORF61 established that the preparations were not contaminated with 
infected cell material (Fig. 2-5B). Virions of VZV.IE62(S686A)2 showed no reactivity to IE62 
specific antibodies, although IE62 was present in VZV.GFP-66-infected whole cell extracts and 
virions. This supports the conclusion that the major immediate early regulatory protein is not 
packaged into VZV.IE62(S686A)2 virions, and that virion packaging of IE62 required IE62 
localization to the cytoplasm.  
The VZV tegument contains additional VZV regulatory proteins encoded by ORFs 4, 10, 
47, 62, and 63 .  The ORF9 protein, which has recently been shown to interact with IE62, is also 
a suspected structural protein, based on its orthologue, the major tegument protein VP22 in HSV-
1 .  We conjectured that the abrogation of cytoplasmic IE62 accumulation may also impair the 
tegument incorporation of some of these proteins, particularly the proteins encoded by ORFs 4, 
9, 47 and 63, which are known to physically interact with IE62.  Probing of blots of ORF10-
normalized virion proteins of VZV.GFP-66 and VZV.IE62(S686A)2 revealed that ORF4 and 
ORF47 proteins were present at similar levels for each virus (Fig. 2-5B).  The ORF9 protein was 
incorporated into virions as predicted, and multiple forms of the protein were seen in both 
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infected cell extracts and in virions.  Interestingly, we consistently observed from two studies 
that VZV.IE62(S686A)2 virions exhibited increased levels of ORF9 and ORF63 proteins. 
Interestingly, we did not detect actin as a component of VZV virions from either virus. From this 
work, we conclude that the mutation of S686A in both copies of IE62 abrogated the 
incorporation of IE62 into virions. While virion packaging of other tegument-associated 
regulatory proteins did not require virion IE62, some appeared to compensate for the absence of 
tegument IE62.   
 
 
Figure 2-5.  VZV.IE62(S686A)2 does not incorporate IE62 into the virion tegument 
(A) Sypro Ruby staining of purified VZV virion particles harvested from infected MeWo cells 
following separation on a 4-15% Tris-HCl linear gradient SDS gel.  A MeWo-infected cell extract is also 
shown (cell ext), with arrows indicating two suspected forms of IE62.  Virion particles were obtained 
from cells infected with VZV.GFP-66 (P) or VZV.IE62(S686A)2 (686).  Virions are shown following 
purification after the 5-15% Ficol gradient step (Ficol 1), and after the second fractionation on 10-50% 
sucrose gradients (Sucrose 2).  Arrows depict the 175 kDa protein in the VZV.GFP-66 virion fractions.  
B) Immunoblot analysis of cell extracts and sucrose gradient purified virions that were equalized based on 
the abundance of ORF10 protein, and then probed with rabbit antibodies to VZV proteins derived from 
ORFs 4, 9, 10, 29, 47, 61, 62, 63 and β-actin.  The HSV homologs of some VZV proteins are indicated in 
brackets. M indicates the marker lane. 
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 2.4.5 Growth comparisons of VZV.IE62(S686A)2 and rVZV lacking functional ORF66 in 
PCF cells   
The previous data established that VZV.IE62(S686A)2 showed a similar phenotype to VZV 
deficient in functional ORF66.   However, comparative reassessment of growth curves of 
VZV.IE62(S686A)2  revealed differences to VZV.GFP-66kd, and VZV.GFP-66s in PCF cells 
(Fig. 2-6).  Specifically, by 96 hrs p.i., VZV.IE62(S686A)2 grew to titers in PCF cells (2.2 X103 
IC) that were only marginally lower than those of VZV.GFP-66 (5.2 X103 IC).  In contrast, 
VZV.GFP-66s and VZV.GFP-66kd showed little increase in progeny virus titers subsequent to 
24 hrs p.i., and at 96 hrs p.i, titers were 3.4 X 101 and 7.3 X 101 IC, respectively.  The difference 
between titers of ORF66-negative viruses and VZV.GFP-66 were statistically significant 
(p<.01), mirroring the results shown in Fig.2-2A.  As VZV.IE62(S686A)2 clearly replicated in 
PCF cells, we conclude that the critical ORF66 function required for productive VZV growth in 
PCF cells is independent of its functions in regulating IE62 nuclear import through 
phosphorylation of the IE62 S686 site.  We presume that virions produced in PCF cells by 
VZV.IE62(S686A)2 and by ORF66 kinase-negative VZV do not incorporate IE62 in VZV 
virions, as IE62 would not localize to the site of tegumentation in the cytoplasm of these cells.    
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 Figure 2-6.  Progeny growth curves of VZV.IE62(S686A)2, VZV-66, and ORF66 mutants in PCFs 
Growth curves were performed as detailed in Fig. 2, using confluent PCF cell monolayers 
infected with VZV.GFP-66 (▲), VZV.GFP-66kd (▼), VZV.GFP-66s (●), or VZV.IE62(S686A)2 (◊) 
after infection at an MOI of 0.001.  To quantify plaques of VZV.IE62(S686A)2,  cells were fixed in 4% 
paraformaldehyde at 4-5 days p.i., permeabilized and immunostained with primary rabbit anti-62 
antibodies so that plaques could be enumerated using fluorescent microscopy.  Inoculant data values 
represent direct seeding onto MeWo cells on the same day PCF cells were infected.  X-axis values 
represent hrs p.i. when cells were harvested and Y-axis values represent infectious centers.  Each data 
point was done in quadruplicate and represent the mean +/- SE of these values.  Growth curves are 
representative of two independent experiments.  
 
2.4.6 Detection of apoptosis levels in recombinant VZV-infected corneal fibroblasts 
Several alphaherpesvirus US3 kinases orthologous to ORF66 have been shown to block 
apoptosis in response to both the stress of viral infection and to exogenous agents or treatments.  
Recent studies have indicated that ORF66 inhibits apoptosis in VZV-infected T cells (186), as a 
fraction of cells infected with VZV lacking ORF66 show higher levels of caspase-3 activation 
(185).  In the context of the corneal stroma, keratocytes are highly sensitive to apoptosis 
following injury (130, 217, 220).  To test the role of apoptosis in the PCF cell-specific growth 
requirement for ORF66, we assessed MRC-5 or PCF infected cells for the early apoptosis marker 
Annexin V and the viability stain 7-AAD.  Gating for GFP fluorescence enabled assessment of 
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VZV-infected cells in which the ORF66 promoter was active (Fig.2-7).  In MRC-5 cells infected 
with VZV.GFP-66, indicators of apoptosis were seen in mean levels of 6.5, 10.5, and 18.9 % of 
GFP-expressing cells at 24, 48, and 72 hrs p.i., respectively.  Cells infected with VZV.GFP66-kd 
displayed almost equivalent levels (9.2, 9.5 and 18.7%) and VZV.GFP-66s levels were slightly 
lower (6.4, 4.8, and 13.5 %, respectively).  Statistical evaluation revealed no significant 
difference in numbers of cells showing APC Annexin V signal between VZV.GFP-66 and the 66 
kinase mutants at any time.  In contrast, PCF cells infected with VZV.GFP-66kd showed 
significantly higher levels of apoptosis (17.5, 13.6, and 19.7 %) as compared to VZV.GFP-66 
(8.2, 8.5 and 11.1%) at the 24 and 48 hr time points, although the levels of apoptosis of cells 
infected with VZV.GFP-66s were not statistically significant at any time point (11.3, 10.5, and 
14.0% at 24, 48 and 72 hr p.i.).  Longer times of incubation (96 hrs) did not result in any further 
increase in levels of apoptosis.  Of importance, the total levels of cells undergoing apoptosis 
under all conditions were in the minority, as seen previously in VZV-infected T cells (185).  GFP 
negative cells present in VZV-infected cultures did not show variations in levels of Annexin V 
staining (data not shown).  These results indicate that corneal fibroblasts infected with VZV 
lacking ORF66 kinase activity do not have dramatically increased levels of apoptosis, although 
the slightly increased levels of apoptosis in VZV.GFP-66kd may be a contributing factor to its 
growth phenotype.  We conclude that apoptosis cannot fully account for the almost complete loss 
of viral growth in this cell type.   
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 Figure 2-7.  Apoptosis in PCF and MRC-5 cells infected with VZV and kinase negative mutants 
MRC-5 (top) and PCF cells (bottom) were infected at a MOI of 0.02 with VZV.GFP-66, VZV.GFP-66kd, 
VZV.GFP-66s, or mock infected.  At 24, 48, and 72 hrs p.i., cells were carefully harvested and stained 
with APC Annexin V, and the viability stain, 7-Amino-Actinomycin D (7-AAD).  Cells for analysis were 
gated on GFP-positive cells for infection. The X-axis shows the fraction of GFP-positive cells that stained 
APC Annexin V-positive as a percentage of total GFP-positive cells. Results represent a mean +/- SE of 
values from three separate but identical experiments.  Statistical analysis was done by Student’s t-test.  
Asterisks represent the level of statistical significance:   p<.05(*), or p<.001(**) compared to VZV.GFP-
66 values.                        
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2.5 DISCUSSION 
In this work, we report the first non-lymphocytic cell line in which the ORF66 protein 
kinase is required for efficient VZV replication.  We also show that ORF66 kinase-mediated 
phosphoryation of IE62 residue S686 is necessary and sufficient for IE62 cytoplasmic 
accumulation and virion packaging in the context of VZV infection.  However, this activity is 
not the PCF cell-specific requirement for the kinase.  Our data also indicate that the loss of the 
protein kinase does not result in a marked increase in VZV-induced apoptosis in the cell types 
studied, although it might contribute to growth impairment of VZV.GFP-66kd in PCF cells.  
Therefore, the ORF66 protein kinase has at least one additional critical role in VZV infection of 
this cell type. 
             This work contributes to the changing concept that ORF66 is required for VZV 
growth in certain cell types.  It can thus be grouped with additional VZV genes that, when 
deleted, result in VZV with cell type-specific or conditional growth patterns, including  
glycoprotein I (gI) (31),  ORF17 (183), ORF49 (180) and ORF63 (30).  In addition, it has 
become clear that many VZV genes deemed not essential for VZV growth in cultured cells are, 
nevertheless, required for VZV growth in human tissue in SCID–hu mice models of 
pathogenesis.  An example is gI, which is not required for VZV growth in MeWo cells, but is 
needed for growth in Vero cells and for efficient VZV replication in skin and T cells in the 
SCID-hu mouse model (131).  A second example is the non-essential ORF10 gene, orthologous 
to the VP16 of HSV-1 which is required for growth in human skin implants (24).  Third, deletion 
of the ORF47 kinase does not affect growth in culture, even though abnormal virions are formed.  
Such viruses show severe impairment of VZV growth in both T cells (132-133)) and skin (15) 
implants in SCID-hu mice.  Regarding ORF66, while its disruption was initially reported to have 
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no influence on growth of the VZV vaccine strain in cultured MeWo cells (74), its disruption in 
the pOka background marginally reduced replication in this cell type (185).  As such, it was not 
unexpected to find that our mutants disrupted for ORF66 kinase expression exhibited reduced 
cell-to-cell spread and infectious virus yields in MRC-5 cells (53).  The additional VZV detailed 
here expressing complete but kinase-inactive ORF66 protein also has some growth impairment 
in MRC-5 cells.   However, the lack of growth in human corneal fibroblasts of both ORF66 
kinase-negative VZV was not expected and highlights important cell type-specific functions for 
the kinase.  Our data suggest that ORF66 kinase-negative mutants are able to enter PCF cells, as 
we detected small foci of infection in which both IE62 and the ORF66 kinase were expressed.  
This suggests the block is at a later stage of the infectious cycle after early gene expression.  
Previously, it was shown that viruses disrupted for ORF66 expression or kinase activity by 
mutation of the ATP binding region (G102A) abrogated virus replication in T cells in the SCID-
hu thy/liv mouse model (185), and in cultured T cells.  It was further demonstrated that 
functional ORF66 was needed to modulate host cell signaling pathways in vitro in human 
tonsillar CD4+ T cells, which have been proposed to be involved in the transfer of infectious 
virus from circulation to sites on the skin in this mouse model of VZV pathogenesis (108).  We 
conclude that the important ORF66-encoded function involves the unique short kinase 
phosphorylating host or viral proteins in PCF cells.  Identification of an easily cultured non-
lymphocytic cell type in which the kinase is required opens up avenues to investigate these 
targets.   
Since the PCF specific function of ORF66 likely involves phosphorylation of a target, it 
was logical to investigate the only well-defined target, IE62.  Our work confirmed that S686 was 
the critical residue by which the kinase induces cytoplasmic IE62 in the context of VZV 
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infections and established its importance in the assembly and packaging of IE62 into virions.   
We also established that virion incorporation of proteins encoded by ORFs 4, 9, 10, 47, and 63 
do not require IE62 in the tegument for packaging.  The proteins from ORFs 4, 9, 47, and 63 
have been suggested to physically interact with IE62, but it seems unlikely that these interactions 
with IE62 are required for their virion incorporation.  The increased levels of ORF9 and ORF63 
in the virion in the absence of structural IE62 is reminiscent of several reports in which absence 
of one tegument protein is compensated by an increase in the incorporation of other tegument 
components (128) or even host proteins such as actin (129).  McKnight et al., in their 
investigation of the essential α-TIF tegument protein speculated that protein-protein interactions 
in the tegument allows a certain level of flexibility of packaging, and noted that larger virion-
fusion protein mutants were still packaged into virions (128).  
Our work has separated ORF66 phosphorylation of IE62 S686 from the PCF cell-specific 
function of the kinase.  VZV.IE62(S686A)2 expresses a functional kinase but showed the IE62 
phenotypes of ORF66-negative VZV, yet displayed only slightly diminished growth by 96 hrs. 
This also suggests that IE62 tegument inclusion is not required for viral growth in PCF cells.  A 
similar conclusion was proposed from studies in tonsillar T cells, such that the ORF66 function 
critical for VZV growth is independent of its effects on IE62.  It was reported that in T cells, 
IE62 locates to the cytoplasm in a VZV ORF66 stop mutant or ORF66 kinase-inactive mutants 
(185).  This suggests that IE62 sub-cellular localization is controlled by an ORF66-independent 
mechanism in tonsillar T cells, possibly a cellular kinase that regulates IE62 nuclear import.  It is 
not known if IE62 incorporates into virions from T cells infected with ORF66-deficient VZV. 
We also show that the disruption of the kinase does not result in greatly increased levels 
of apoptosis in PCF cells that would account for the loss of VZV replication.  Modulation of 
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apoptotic pathways seems to be conserved for many alphaherpesvirus US3 kinases, although the 
mechanisms have not been fully elucidated.  It has been suggested that the kinase enables 
maintenance of survival of the infected cell long enough to allow virion production and spread 
(5).  Keratocytes are known to be highly susceptible to apoptosis in the corneal stroma, 
particularly following a corneal wound or infection (220).  Our data show that stromal fibroblasts 
derived from corneas show only significantly more apoptosis at 24 and 48 hr following infection 
with VZV expressing the kinase-dead protein. The fraction of cells showing apoptosis are similar 
to that seen in T cells (185).  However, unlike that study, we found that the levels of apoptosis in 
VZV expressing ORF66 stop mutants were not significantly different from those in cells infected 
by VZV with functional kinase.  The significantly higher apoptosis in VZV.GFP-66kd-infected 
PCF cells may reflect binding of the kinase-dead protein to a pro-survival factor that is normally 
phosphorylated, leading to dominant negative effects.  Interestingly, in HSV-1, anti-apoptotic 
activity stems from the amino terminus of US3 in transfected cells induced for programmed cell 
death (161, 165).  Thus, while ORF66 kinase activity may have a role in inhibition of apoptosis 
in PCF, it is unlikely to be the ORF66 function responsible for the severe growth deficiency of 
VZV lacking functional ORF66 in PCF cells.   
The critical target(s) of the kinase in this cell type remain to be defined, and our current 
studies are aimed at determining if the VZV kinase shares the same functions attributed to other 
alphaherpesvirus US3 kinases.  The US3 kinases of HSV-1, Marek’s disease virus (MDV), and 
PRV have been implied to modulate the nuclear membrane to facilitate de-envelopment of 
nucleocapsids into the cytoplasm, since absence of US3 kinases causes irregular nucleocapsid 
accumulations in the perinuclear space. It has been suggested that phosphorylation of lamin A/C 
and emerin hyperphosphorylation aid in nuclear lamina breakdown that is required for proper 
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virion nuclear egress.  Our recent studies (Eisfeld and Kinchington, unpublished studies) indicate 
that nuclear rim concentrates of GFP-66kd co-localize with nucleocapsid proteins.  Work by 
Schaap-Nutt et al. suggests that complete virion formation is not affected in T cells infected with 
VZV encoding ORF66 stop mutants, and there is no similar nucleocapsid accumulation in the 
perinuclear regions (186). Rather, they reported lower levels of nucleocapsids in infected cells.  
It is possible that in PCF cells the kinase may have a more important role in virion egress than in 
T cells, and studies are ongoing using the GFP tag to cell sort and concentrate the initially 
infected PCF cells for electron microscopy studies of nucleocapsid maturation at the nuclear 
membrane.  
It is possible that the ORF66 kinase augments activity of a cellular protein kinase which 
has different levels of activation or expression in different cell types.  The US3 kinase of HSV-1 
overlaps the targets of protein kinase A, which may be reduced in PCF cells (9).  ORF66 also 
modulates the induction of the IFN pathway, as the level of Stat1 phosphorylation in a small 
fraction of tonsillar T cells is higher in response to IFN-γ when the kinase is not expressed (186).  
In SCID-hu mouse skin xenografts, VZV lesions are surrounded by a defined region of 
uninfected epidermal cells positive for Stat1 phosphorylation (triggered in the IFN signaling 
pathway), yet actual VZV-containing lesions downregulate IFN-α.  Although ORF66 only has a 
modest effect on VZV titers in skin xenografts infected with pOka VZV66 stop mutants (186), it 
is thought that inhibition of IFN signal transduction may promote the survival of infected 
tonsillar T cells.  Thus, it is possible that PCF cells express higher levels of IFN and that this 
may exert an antiviral effect.  Human corneal epithelial cells have been found to increase 
transcriptional expression of various cytokines including IFN-β in response to HSV-1 infection 
in vitro (113).  Interestingly, addition of recombinant human IFN-α2a can inhibit VZV 
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replication in human corneal stromal fibroblasts cultures (166). Investigation of the role of 
interferon pathway modulation by ORF66 in PCF is an area under study.           
In conclusion, VZV deficient in functional ORF66 protein kinase expression is severely 
growth-impaired in human corneal stromal fibroblasts, but this is not due to the kinase mediated 
phosphorylation of IE62 residue S686, that drives cytoplasmic accumulation and virion 
packaging of IE62. While our data suggests that there is a role for ORF66 in inhibition of viral 
induced apoptosis in PCF cells, this effect seems unlikely to be solely responsible for the 
complete growth deficiency.  This work establishes that ORF66 may be critical for productive 
VZV growth in some non-lymphocytic cell types and additional primary cell cultures are now 
being explored.   
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3.1 ABSTRACT 
Alphaherpesviruses express a protein kinase termed US3 in herpes simplex virus type 1 (HSV-1) 
and ORF66 in varicella zoster virus (VZV), that affects multiple viral and host cell processes, 
although targets of the kinases remain poorly studied. The HSV-1 US3 substrate motif overlap to 
that of cellular protein kinase A (PKA) prompted use of an antibody specific for phosphorylated 
PKA substrates to address possible US3/ORF66 targets. While HSV-1, VZV and 
pseudorabiesvirus induced very different profiles of substrates, most species were US3/ORF66 
kinase dependent. The predominant VZV 125KDa species was identified was Matrin 3, one of 
the major nuclear matrix proteins.  Matrin 3 was phosphorylated by coexpression with the VZV 
ORF66 kinase alone but not by point mutant innactivated kinase. It was also phosphorylated by 
HSV-1 and PRV in a US3 dependent manner.  The phosphorylation occurred primarily at residue 
T150, which was not a major residue targeted by PKA, and as T150 phosphorylation was not 
blocked by inhibitors of PKA nor induced by forskolin activation of PKA, we conclude that 
herpesvirus-induced matrin 3 phosphorytlation at this site is PKA-independent. However, 
purified VZV ORF66 kinase did not phosphorylate matrin 3 in vitro, suggesting additional 
intermediate cellular kinase(s) were involved.  In VZV-infected cells matrin 3 showed subtle 
nuclear differences in localization in the absence of the ORF66 kinase, while a pronounced 
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cytoplasmic location in late stage cells infected with US3 negative HSV-1 and PRV suggests 
matrin 3 phosphorylation is required for its nuclear localization late in infection.  This work thus 
defines a new conserved substrate protein of this kinase group.              
 
 
 
 
 
 
 
3.2 INTRODUCTION 
All mammalian and avian herpesviruses studied to date include one to several proteins that are 
predicted to be protein kinases, based on the presence of conserved signature domains found in 
all cellular kinases. Two such protein kinases are found in the genomes of the 
alphaherpesviruses- that termed UL13 in herpes simplex virus types 1 and 2 (HSV-1, HSV-2) 
has recognizable homologs in all known mamalian herpesviruses, while the second, termed US3 
in HSV and ORF66 in VZV and its close relative Simian Varicella Virus, are only in members of 
the alphaherpesvirus subfamily.  Studies of the VZV ORF66 and US3 kinases of HSV-1 and 
pseudorabies virus (PRV) have revealed them as all basophilic serine/threonine (S/T) kinases, in 
which the preceeding residues of the target serine or threonine are composed of multiple arginine 
and/or lysine residues.  
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Multiple functions have been associated with various members of the alphaherepsvirus 
US3 kinases.  In VZV, PRV, HSV-1 and HSV-2, the kinase appears to be not essential for viral 
growth in most cell types. However kinase deficient viruses are unable to replicate in certain cell 
types and invariably show significant attenuation in animal models of disease. Functions 
attributed include establishing an environment conducive to viral replication by modulation of 
the nuclear membrane facilitating virion nuclear egress (86, 109, 138-139, 221), inhibition of 
apoptosis (10, 21-22, 88), restructuring cytoskeletal networks to aid in intercellular spread (56, 
143, 165, 189, 207),  chromatin regulation through modification of histone deacetylases 1 and 2 
(HDAC 1 and 2) (165), and downregulation of interferon gamma (IFN-γ) signaling (116). The 
HSV-1 and PRV US3 kinase show multiple forms: US3 in HSV-1 includes a predominant 481 
a.a. full length US3 kinase and a second form that can initiate at an alternate ATG to encode for 
the US3.5 kinase lacking the amino-terminal 76 a.a. of US3.  PRV US3 also encodes for two 
forms of its US3 kinase, differing by an additional amino-terminal 54a.a. in its long form.  For 
HSV and PRV, these forms have demonstrated to have different kinase function capabilities (20, 
161).   The 393 residue VZV ORF66 kinase is only seen as one form in VZV infected cells.   
 VZV lacking ORF66 or its kinase activity shows modest growth impairment in several 
tissue culture cell types, and severe impairment of VZV growth in T cells (133, 185-186, 199) 
and in primary corneal stromal fibroblasts (54), leading it to become increasingly recognized for 
its importance for viral replication.  ORF66 is also expressed during the VZV neuronal latent 
state in human sensory ganglia that is established after the primary infection, varicella, or 
chickenpox (35).  ORF66 kinase has one known direct phosphorylated viral target, which is the 
VZV major regulatory transcriptional activator and immediate early 62 (IE62) protein (52).  IE62 
phosphorylation by ORF66 leads to nuclear exclusion of IE62 and its redirection to the trans-
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Golgi network for incorporation into the assembling VZV tegument (52, 54, 98-99).   Its 
detection in neurons may explain the apparent cytoplasmic location of neuronal IE62 seen during 
latency (35).   More recently, VZV has been shown to have a role in transcriptional regulation 
through an ability to induce the hyperphosphorylation of HDAC1 & 2 (210).  This feature, 
initially recognized for HSV-1 US3, is theorized to be viral attempts to resist transcriptional 
silencing of viral DNA by the infected host, since chemical inhibition of HDAC activity relieves 
the growth defects seen for ORF66 deficient VZV.  VZV ORF66 contributes to immune evasion 
tactics by modulating apoptosis and IFN-γ pathways in infected human tonsil T cells (186), and 
displays a mechanism to inhibit viral antigen presentation by reducing class I major 
histocompatibility complex surface expression (1, 53) in VZV-infected cells.   
 Collectively, the US3 kinases and ORF66 kinase are basophilic S/T kinases.  The 
HSV and PRV US3 kinase motif, determined by optimal peptide substrates, is characterized by 
(R)nX-(S/T)-Y-Y where n >2, Ser/Thr is the phosphorylated site, and X can be absent or 
preferably Arg, Ala, Val, Pro, or Ser and Y cannot be an absent amino acid, Pro, or an acidic 
residue (167) (110-111).  The known ORF66 kinase sites on IE62 suggest it also target serines or 
threonines carboxy-terminal to multiple basic residues ( RKRKS686QPV and KRRVS722EPV).  
Furthermore, such motifs are similar to the target motifs of cAMP-dependent protein kinase 
(PKA), defined by RRX(S/T).  Bennetti et al. used this overlap to show that multiple proteins 
were similarly targeted by US3 and PKA, and that US3 may induce PKA activity in HSV-1 
infected cells (9).  PKA is found ubiquitously in eukaryotic organisms and has pleitropic effects 
and many substrates, directing phosphorylation of metabolic enzymes, ion channels, regulatory 
& structural proteins, and transcription factors (193).  In its inactive form, PKA is a tetrameric 
holoenzyme composed of catalytic subunits (C) bound to a regulatory subunit dimer.  
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Cooperative binding of cAMP to the regulatory subunits releases the active C subunits that in 
turn can phosphorylate specific S/T residues on substrate proteins (195).  Benneti et al. suggests 
that US3 activates PKA and can parallel its anti-apoptotic function through phosphorylation of 
common protein substrates.  One study in VZV reports evidence for increased expression of the 
catalytic subunit of PKA early in VZV infection, as well as phosphorylation of some PKA 
substrates (49).   
 Despite accumulating evidence that ORF66 kinase is critical for growth in a 
certain cell types and has a role in mitigating host cell defense mechanisms, much is unknown 
about further viral and host cell targets.  Here, we described a novel host cell phosphorylation 
target for this kinase family, the nuclear matrix protein matrin 3 (MATR3).  The nuclear matrix 
is a fibrogranular network within the nuclear interior characterized as a proteinaceous subnuclear 
non-histone fraction resistant to high salt, detergent and nuclease treatment of the interphase cell 
(147).  Proteins forming the nuclear matrix are participant in many nuclear functions, including 
DNA replication & transcription, since they serve as a structural framework for these activities & 
their binding to key protein factors (3, 11, 83).  Approximately 12 major proteins make up this 
internal matrix, composed of Lamins A, B, and C, the nucleolar protein B-23, residual 
components of nuclear ribonuclear proteins, and 8 nuclear matrins (Matrin 3, 4, D, E, F, G, 12, & 
13) (147).  Here we report the nuclear matrix protein, matrin 3 as an unprecedented protein target 
of the alphaherpesvirus US3 kinase family. 
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3.3 MATERIALS & METHODS 
3.3.1 Cell culture 
MRC-5 (human diploid lung fibroblasts), human embryonic kidney (Hek) 293 , Hek 293T 
(ATCC, Manassas, VA) and MeWo cells (human melanoma cell line; a gift from C. Grose, 
University of Iowa, Iowa City) were maintained as described previously (52).  SF9 cells 
(Invitrogen Corp.) were grown at 28ºC in Grace’s Insect Medium (Gibco) supplemented with 
10% fetal bovine serum (FBS) & gentamicin (50μg/ml) (Gibco) & antibiotics as detailed by the 
supplier. 
3.3.2 Viruses 
(i) VZV.  VZV used here are based on the parent of the Oka vaccine strain and were amplified in 
MeWo cells as detailed previously (98).  Recombinant VZV.GFP-66, VZV.GFP-66kd (kinase 
dead), VZV.GFP-66s (truncated ORF66 protein), and rescuant VZV were constructed from 
pOka-based cosmids as described previously (53-54).  VZV.GFP-66kd contains two 
conservative mutations (D206E, K208R) within the catalytic loop domain to inactivate kinase 
activity (99).  VZV.GFP-66s was constructed with a stop codon at 84 a.a. of the 393 a.a. ORF66 
kinase, to form a truncated protein that is also kinase inactive. 
(ii) HSV-1. The HSV-1 RE strain has been detailed by us previously. Recombinant wild-type 
(containing US3 or 3.5 with an N-terminal GFP tag) and US3 deleted HSV-1 were generated as 
follows. Plasmids were developed following PCR amplifying the HSV-1 RE genomic template 
using the GC-RICH PCR Proofreading System (Roche, Indianapolis, IN) under hot start 
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conditions and primers US3F 5' - 
GGGAATTCATGGCCTGTCGTAAGTTTTGTCGCGTTTAC - 3' or US3.5F 5' - 
GGGAATTCATGTACGGAAACCAGGACTAC - 3', each in conjunction with US3R 5' - 
GGAAGATCTTCATTTCTGTTGAAACAGCGGCAA - 3'.  The PCR products for US3 and 
US3.5 were digested with BglII and EcoRI and ligated to BamHI/EcoRI digested pEGFP-C so as 
to be downstream and in frame of EGFP. These plasmids express the EGFP tagged versions of 
each kinase from the human cytomegalovirus immediate early (hCMV IE) promoter (pEGFP-
US3 and pEGFP-US3.5, respectively).  To derive HSV-1 US3null, the US3.5 construct was 
collapsed with Xho I, which removed the N terminal part of the US3 coding sequence encoding 
residues 1 to 169 and placed the remaining sequence out of frame with respect to EGFP and 
without an initating ATG. Any aberrant protein that might be unpredictably expressed would not 
retain sufficient domain to be kinase functional.  For derivation of recombinant viruses, all three 
plasmids were treated to replace the CMV IE promoter with DNA containing the US3 promoter 
immediately upstream of the US3 ATG, which was PCR amplified using primers US3PF 5' - 
GCGCCCTAGGGCTAGCTCGCCGCACCGTGAGTGCCA - 3' and US3PR 5' - 
GCCATTAATATTAATGCCGCGAACGGCGATCAGAGGGTCAGT - 3'.  The PCR product 
was digested with Ase I and Nhe I and ligated to constructs which had been digested with Ase I 
and Nhe I to remove the CMV IE promoter. Viruses were derived by cotransfecting sspI-
linearized constructs with RE DNA and were identified and plaque purified based on gain of 
EGFP fluorescence as detailed previously (172).  Insertion of GFP and the integrity or deletion 
of US3 coding sequences were confirmed by Southern blot analysis of viral DNA.  
(iii) PRV. Wild-type PRV (Becker strain) was described previously.   PRV-US3 null virus 
(PRV645) was constructed by co-transfecting purified PRV DNA (Kaplan strain, kindly 
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provided by Dr. T. C. Mettenleiter, Federal Centre for Virus Diseases of Animals, Insel Riems, 
Germany) and SpeI linearized plasmid, pML7  into PK15 cells. Virus produced after co-
transfection was plated on PK15 cells, and plaques expressing EGFP were identified. Virus was 
isolated from EGFP-expressing plaques and subjected to three rounds of purification. Southern 
blot analysis was performed on PRV645 genomic DNAs to verify that the appropriate 
recombination events had occurred. US3 protein expression was examined in PRV645 and wild-
type PRV Kaplan strain (PRV-WT) infected cell lysates by western blot to confirm the absence 
or presence of US3 expression, respectively. Virus titer was determined on vero cells as detailed 
previously.  
(iv) Baculoviruses.  Baculoviruses expressing glutathione  S-transferase (GST) tagged ORF66 
(GST.66) or GST.66kd  were derived using the BaculoGold system (BD pharmingen, San Diego, 
Calif.) Full length HA tagged ORF66 or ORF66kd were excised using BstZ 17I and PstI sites 
from pGK2-HA66 or pGK2-HA66kd which contain an HCMV IE promoter and IE1 
polyadenylation site, as well as encode a HA epitope (YPYDVPDYA) (52). HA66kd is a kinase 
inactive mutant containing two highly conservative changes in the catalytic loop domain of the 
kinase (D206E, K208R) (99). These were inserted into pAcGHLT-A using SmaI and PstI sites.  
This vector contains a 6xHis tag and a glutathione S-transferase (GST) tag upstream of the 
multiple cloning site.  Resulting positive clone plasmid DNA were cotransfected with baculogold 
DNA in Cellfectin reagent (Invitrogen) and Grace’s insect media (serum/antibiotic free) 
(Invitrogen) into SF9 cells.  After 5 days, primary supernatant was collected (1º virus). GST66 or 
GST66kd expressing viruses were then amplified in SF9 cells. A control baculovirus expressing 
GST was also utilized. Cells infected with later stocks of these viruses were checked for proper 
protein expression by immunoblot anaylsis using HA or GST-specific antibodies.  
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(v) Adenoviruses. Replication-incompetent adenoviruses expressing GFP-HA-66 (Ad.GFP-66) 
or GFP-HA-66kd (Ad.GFP-66kd) containing tetracycline or doxycycline – responsive cassettes 
were constructed using the Adeno X Tet-Off system (Clonetech) described previously (53).  
These were used in conjunction with an Adeno.Tet-off (Ad.Toff) regulatory virus expressing a 
tetracycline-controlled transactivator as previously detailed (53) .   
 
3.3.3 Protein identification by MALDI TOF 
Confluent Hek293 cells were infected with Ad.GFP-66 at an MOI of 0.05, and then amplified by 
transferring infected cells to two 50% confluent 175-cm2 flasks. Cells were harvested when 
showing signs of cytopathic effect at 50%.  Cells were lysed for at least 30 min’ with three 10 
second sonication pulses on ice using a solubilization buffer (20mM Tris-HCl pH 7.0, 0.5M KCl, 
1mM EDTA, 1% NP40 with protease inhibitor cocktail (Complete, Roche Diagnostics) and 
phosphatase inhibitors (20mM NaF, 1mM Na4P2O7 ·10 H2O, 1mM Na3VO4).  Soluble fractions 
were collected and added at 4oC to Protein G agarose beads (Sigma, Saint Louis, MO)  bound to 
rabbit α-phospho-PKA substrate antibody (1:10 for IP) for immunoprecipitation.  The beads 
were then washed with a modified RIPA buffer (20mM TrisHCl pH 7.4, 1% NP40, 150mM 
NaCl, 1mM EDTA) with a final wash in low salt buffer (20mM TrisHCL pH7.4 100mM KCl) 
and lastly resuspended in SDS-sample buffer and boiled.  Samples were then seperated by 6% 
sodium-dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).  The gel was then 
stained with Bio-Safe Coomassie G-250 stain (BioRad, CA).  The region approximately between 
the 100 and 150kDA marker was cut out of the gel and sent for LC tandem MS/MS at the 
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University of Pittsburgh Proteomics Core Facility. Returned candidate proteins were 
subsequently identified through the use of specific antibodies.   
 
3.3.4 Plasmid construction 
Plasmids expressing maltose binding protein (MBP) and the MBP-IE62 peptide fusion of IE62 
residues 571 to 733 were described previously (52).  To generate an MBP fused to the full length 
matrin 3, a commercial plasmid of the matrin 3 gene was purchased from InVitrogen. The gene 
was placed in frame with MBP protein using the vector pMalC2 and a PCR amplifications of 2 
PCR products forming full length Matrin 3 using the proofreading polymerase combination sold 
as Expand (Roche).   MBP-Matrin 3 protein was purified using amylose affinity 
chromatography, as recommended by the manufacturer. 
An HA tagged version of Matrin 3 with or without single residue point mutations was 
prepared using Splicing by overlap (SOE) PCR with the proofreading polymerase Expand.   All 
Matrin 3 constructs were developed using the terminal PCR oligonucleotides Matrin3Start (5’-
gcgcaattgtcgaccacc atgtccaagtcattccagc-3’) and Matrin 3 end (5’- gcgggatccttaactagt 
ttccttcttctgtctgcgttcttctgccaat-3’ ) so that the resulting constructs were cut with MfeI and BamHI 
(sites shown in bold) and then cloned into the EcoRI and BamHI sites in the vector PGK2-HA 
detailed previously (53)  so as to be in frame with an N terminal HA tag.  Candidate residues 
were mutated using SOE of left and right sides of Matrin 3 gene with the terminal primers and 
the following pairs, followed by reamplification of the entire matrin 3 gene with the terminal 
primers and a 1:1 mix of left and right ends as substrates.  Primers to mutate T150A  and insert a 
novel silent AscI site for identification were  T150Fasc  (5’-
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cttaaaaggaggcgcgcggaagaaggccctacc-3’) and T150Rasc (5’-ggtagggccttcttccgcgcgcctccttttaag-
3’): those to mutate S188A also inserted a novel silent  NsiI site  S188Fnsi (5’-
cactttagaagagatgcatttgatgatcgtggt-3’) and S188Rnsi (5’-accacgatcatcaaatgcatctcttctaaagtg-3’): 
mutation of S592A, S596A and S598A simultaneously and insert a silent BsiWI site were 
nucS123fbsiw (5’-ctgaaaaaagataaagcccgaaaaagagcgtac gctccagatggcaaagaa and nucS1Rbsiw (5’-
ttctttgccatctggagcgtacgctctttttcgggctttatcttttttcag-3’):  and primers to mutate S596A and S598A 
and insert a novel BsiW I site were nucS23Fbsiw (5’-gataaatcccga 
aaaagagcgtacgctccagatggcaaagaa -3’) and nucS23Rbsiw 5’-
ttctttgccatctggagcgtacgctctttttcgggatttatc-3’). Pimers to mutate S596A and insert a BsiWI site 
were nucS2FbsiW (5’-gataaatcccgaaaaagacgctactctccagatggcaaagaa-3’) and nucS2RbsiW (5’-
ttctttgccatctggagagtacgctctttttcgggatttatc-3’). All constructs were identified for expression in 
transfected cells followed by immunoblotting with HA specific antibodies. 
3.3.5 Drug treatments 
Forskolin (Fisher BioReagents,  Fair Lawn, New Jersey) and the PKA inhibitor (PKI) 14-22 
amide (EMD Biosciences, San Diego, CA)were purchased commercially .  Forskolin and PKI 
1422 amide were reconstituted in DMSO and minimum essential media (MEM), respectively.  
PKI 1422 amide treatment was started 2 hours prior to infection & continued until time of cell 
harvest.  Forskolin treatment was started at the time of infection & continued until the time of 
cell harvest as indicated in the figure and text.   
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3.3.6 Transfections & Infections 
For transfections for optimal expression, Hek 293T were seeded onto poly-lysine-coated 6-well 
culture dishes.  Cells were transfected with DNA using Fugene HD (Roche, Indianapolis, IN) 
and as recommended by the manufacturer.  For transfection – infection experiments, MeWo cells 
were transfected with DNA using Fugene HD, and then infected the following day with either 
HSV-1 using MOI of 5,   or overlaid with VZV infected cells at a 10:1 ratio uninfected to 
infected.   Adenovirus infections were performed in MRC-5 cells that were incubated under low 
serum conditions (Minimum Essential Media, 1% FBS, plus antibiotics) for 1 day prior to 
infection.  Infections where done at an MOI of 5 for Ad.GFP66, Ad.GFP66kd, or Ad.Vector and 
Ad.Toff at an MOI of 2.5 under low serum conditions.  Infections for immunoblot analysis were 
performed by binding of virus at room temperature, change of media, and subsequent transfer to 
37°C, for the times indicated in the figures. For HSV and PRV immunofluorescence (IF) 
analyses, the binding step was done at 4°C using chilled cells and 4°C media, with subsequent 
wash, addition of warm media and transfer to 37°C, then fixed with 4% paraformaldehyde at 18 
hrs p.i. (HSV) or 11 hrs p.i. (PRV).  For VZV IF analyses, cells were infected with VZV at an 
approximate ratio of 1 infected to 25 uninfected cells, and then immediately transferred to 37°C. 
Cells were fixed with 4% paraformaldehye at 36hrs p.i..  All VZV infections were performed 
using titrated stocks of virus in MeWo cells stored in liquid nitrogen. 
3.3.7 Antibodies & Immunological Procedures 
Rabbit polyclonal antibodies to VZV proteins IE62 and ORF4 were detailed previously (97, 99). 
Antibodies to VZV ORF 9 (26) were a kind gift of W.T. Ruyechan, SUNY at buffalo, NY.  The 
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mouse monoclonal antibody that recognizes the 9 amino acid epitope (YPYDVPDYA) from the 
influenza protein hemaglutinin (HA) has been described previously (52) and used at 1:600 for 
immunoblot analyses or approximately 4μl per immunoprecipitation. Mouse monoclonal 
antibodies to α-tubulin (Sigma-Aldrich, St. Louis, MO)  and α-Ku-86 (Santa Cruz 
Biotechnology, Inc, Santa Cruz, CA), were purchased commercially & used at 1:8000 and 1:500, 
respectively for immunoblot analysis. Monoclonal antibody pools that recognize HSV-1gB were 
a kind gift from William F. Goins, University of Pitsburgh) and was used at 1:6000 for 
immunoblot. Mouse α-ICP4 (Virusys, Taneytown, MD) was used at 1:1000 for IF.  PRV goat α-
UL34 (a kind gift from Dr. Bruce Banfield) was used  at 1:1000 for immunoblot and 1:500 for 
IF.  Rabbit monoclonal α-phospho-PKA-substrate antibody was purchased commercially (Cell 
Signaling Technology, Danvers, MA).  This p-PKA-sub antibody was used at a dilution of 1:800 
for immunoblot analysis and 1:50 for IP.  Rabbit α-matrin 3 antibody (Bethyl Laboratories, Inc, 
Montgomery, TX) was purchased commercially and used at 1:3000 for IF and 1:8000 for 
immunoblot.  Goat α-glutathione S-transferase (GST) (GE Healthcare,Piscataway, NJ) was 
purchased commercially, and used at 1:20,000 for immunoblot analysis.  Rabbit α-MBP (New 
England Biolabs, Inc, Beverly, MA) was purchased commercially, & used at 1:15000 dilution 
for immunoblots.  Secondary antibodies used in immunoblot analysis used were goat α-mouse, 
goat α-rabbit, and donkey α-goat conjugated to horseradish peroxidase (ICN-Cappel, Aurora, 
OH) were purchased commercially and used between 1: 20,000 -1:40,000. 
All immunofluorescent staining procedures were carried out as described previously (53).  
Briefly, MRC-5 cells were grown on glass coverslips or on 2-well slides.  At the indicated time 
point, cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton-X, and 
antibody incubations done in heat-inactivated goat serum or donkey serum.   For VZV and HSV 
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IF staining, antibodies were detected using goat α--rabbit immunoglobulin G antibody 
conjugated to Alexa Fluor 546 or goat α-mouse immunoglobulin G antibody conjugated to Alexa 
Fluor 647.  For PRV IF staining, donkey α-rabbit immunoglobulin G antibody conjugated to 
Alexa Fluor 555 or donkey α-goat conjugated to Alexa Fluor 647 (Invitrogen Corp).  
Immunofluorescence was visualized using an Olympus Fluoview FV1000 confocal microscope 
equipped with a 60X oil objective.  Images are of one slice of Z-stacks acquired in 0.48μm steps. 
3.3.8 Immunoblot analysis & Immunoprecipitation 
For analysis of protein expression, infected or transfected cells, whole cell lysates, soluble 
fractions or protein bound to IgG beads were treated with SDS- sample buffer and separated by 
sodium dodecyl sulfate – polyacrylamide gel electrophoresis (SDS-PAGE)  and transferred to 
PVDF membranes (Immobilon- P membrane , Millipore, Billerica, MA)  as  previously 
described (52).  When soluble fractions were needed, lysates were treated with protease 
inhibitors (Complete protease inhibitor cocktail (Complete EDTA-free; Roche Diagnostics, 
Indianapolis, IN) and phosphatase inhibitors (20mM NaF, 1mM Na4P2O7 ·10 H2O, 1mM 
Na3VO4).  Where indicated Immobilon-P membranes were stripped by using 0.2 M NaOH for 5 
minutes and rinsed with distilled H2O, then reblotted.  Following exposure to film, digital images 
were acquired using an Epson Perfection 4990 photo scanner with Silver Fast Ai and Adobe 
Photoshop CS imaging software.   
 For immunoprecipitations, equivalent numbers of cells per condition were washed 
with ice-cold 1X phosphate-buffered saline (PBS) and lysed using a solubilization buffer (20mM 
Tris-HCl pH 7.0, 0.5M KCl, 1mM EDTA, 1% NP40) plus protease and phosphatase inhbitors for 
30 minutes on ice.  During the lysing period, cells were sonicated on ice 3 times in 30 second 
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pulses.  Soluble fraction was collected by centrifugation at 16.1 RCF for 35 min, then incubated 
with antibody-bound protein G beads for 3-4 hours.  Protein G agarose beads bound to antibodies 
were prepared by washing with 1XPBS and incubated with mouse or rabbit antibodies for 3 hrs. 
Following incubation of Protein G beads to soluble fractions, beads bound to antigen where now 
extensively washed in solubilization buffer with a final wash in 1X PBS, and lastly resuspended 
in SDS-sample buffer and boiled. When specified in figure legend, blocking peptide (Bethyl 
Laboratories, Inc, Montgomery, TX) against matrin 3 antibody was used.  Here, antibody bound 
beads were prepared, washed, then were incubated with excess blocking peptide (5-fold more 
peptide than antibody) for 45 min’.  This preparation was then incubated with soluble fractions, 
with subsequent steps as described above.   
3.3.9 GST fusion protein purification & In vitro kinase assay 
GST proteins were purified from SF9 infected cells by first solubilizing infected SF9 cells in 
radioimmunoprecipitation (RIPA) buffer (20mM Tris-HCL pH8.5, 50mM KCl, 1mM EDTA, 
1mM DTT, 1% NP-40, and 0.5% deoxycholate).  These were sonicated on ice in the presence of 
protease and phosphatase inhibitors.  Soluble fractions were then collected and combined with 
glutathione beads (Glutathione Uniflow Resin) (BD Biosciences) for 3 hrs or overnight.  GST 
beads were then collected and washed extensively in 2M KCl (pH7.5), followed by RIPA buffer, 
and finally kinase buffer (pH7.5) for a total wash time of 1hr. GST fusion proteins were then 
eluted overnight at 4ºC with glutathione elution buffer containing 0.1% Triton X-100 and protein 
levels were measured by Bradford assays.  MBP proteins were constructed and purified as 
detailed previously (52) except inductions were carried out in E. coli BL21 cells at 30C for 3 hrs.   
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   In vitro kinase assay.   Approximately 2 μg of GST or GST fusion protein were 
incubated with 2μg of MBP or MBP fusion proteins in 70ul kinase assay buffer (20mM Hepes-
KOH (ph7.5), 50mM KCl, 10mM MgCl2, and 5ug/ml Heparin) and 5μCi of [γ-32P] ATP (6000 
Ci/mmol) for 25 min’ at 35ºC. Kinase assays were normalized so that they were performed in 
equal reaction volumes.  Reactions were stopped by addition of SDS-PAGE sample buffer.  
Proteins were then separated on 7% SDS-PAGE gel and then transferred to an Immobilon-P 
membrane.  Phosphorylated bands were then detected by autoradiography directly from 
Immobilon-P membranes.  Following exposure, membranes were then subject to immunoblot 
using Rabbit α-MBP or Goat α-GST antibodies to ensure equivalent protein levels.  For PKA 
kinase assasys, PKA catalytic subunit (New England Biolabs, Inc, Beverly, MA) was purchased 
commercially and in vitro kinase assays were performed as recommended by manufacturer.  
Briefly, approximately 2 μg of PKA and MBP fusion proteins were incubated using PKA 
reaction buffer or ORF66 kinase assay buffer for 30 min’ at 30°C.  Reactions were then stopped 
with SDS-sample buffer.  Where indicated, protein G beads bound to HA-tagged matrin 3 
proteins were subject to a PKA in vitro kinase assays.   
3.4 RESULTS 
3.4.1 PKA-substrate profiles show drastic differences between VZV, HSV, &PRV 
The ORF66 phosphorylation motifs found in IE62 are similar to the consensus motifs for HSV 
US3 and, by extrapolation from the work of Benetti and Roizman, were suspected to also overlap 
the substrates of PKA. We thus speculated that a phosphospecific (p) PKA-substrate antibody 
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would identify candidate protein substrates of ORF66 kinase.  The p-PKA-substrate profile of 
whole cell extracts (WCE) of MeWo cells infected with VZV expressing functional ORF66 
(VZV.GFP-66) or a point mutated kinase-dead (kd) ORF66 (VZV.GFP-66kd) revealed a modest 
number of protein species (approximately 9) in ORF 66-expressing VZV infected cells that were 
absent in VZV ORF66kd-expressing cells.  Intriguingly, the predominant species was a 125 kDa 
species (Fig. 3-1a).  The predominant 125 kDa species was also observed in several cell types 
infected with VZV, including MRC-5s, human foreskin fibroblasts and primary human corneal 
fibroblasts, and was also seen in cells infected with VZV lacking the expression of the ORF47 
protein kinase (data not shown).   Comparison to wild type HSV-1 and HSV-1 expressing only 
the the US3.5 form in the same cell type revealed many more species that were absent from HSV 
not expressing either form of the US3 kinase (ΔUS3), and several species that were present in 
HSV infected cells that were kinase independent. It has been reported that US3 and US3.5 drive 
PKA activation (9).   Furthermore, the same cell type infected with PRV and PRV not expressing 
its US3 kinase (ΔUS3) revealed a very different profile of species that was US3 dependent.  
Species in the 125kDa region were less obvious yet distinguishable over other areas (Fig 3-1a.).  
To demonstrate equal infections, WCE were also probed for VZV ORF9 (a tegument protein), 
HSV-1 gB (an envelope glycoprotein) and PRV UL34 (membrane associated phosphoprotein) 
(Fig 3-1b.).  We conclude that the p-PKA-substrate profiles differed extensively for these three 
alphaherpesviruses and may indicate that each kinase has very different influences on the host 
cell targets.   
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Figure 3-1.  Conserved ORF66/US3-dependent phosphorylation of a 125kDa protein by 
alphaherpesviruses displaying different PKA-substrate profiles 
MeWo cells were infected at an MOI of 0.1 with VZV.GFP-66 (66), or VZV.GFP-66kd expressing 
kinase-inactivated ORF66 protein (66kd) or mock infected.  Cells were infected at an MOI of 1 with 
HSV-1 (US3), HSV-EGFP-US3.5 expressing truncated US3 which lacks the N teriminal 76 a.a. of the 
kinase (US3.5), HSV-EGFP-XhoΔUS3 that does not express US3 (ΔUS3), PRV (US3), or PRV.ΔUS3 
that does not express US3 (ΔUS3).  WCE were harvested 20hrs p.i. and separated by 7% SDS-PAGE gel 
and immunoblot analysis of proteins is shown. Membranes were probed with (A) rabbit α-p-PKA-
substrate antibody, then stripped and reprobed for loading controls (LC) mouse α-tubulin (VZV & PRV) 
and α-Ku-86 (HSV-1) antibody. (B) Immunoblot analysis of viral proteins to show equal infections 
(rabbit α-VZV ORF9, mouse α-HSV gB, or goat α-PRV UL34 antibodies).  Protein size markers in kDa 
are specified to the left. 
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3.4.2 The 125 kDa protein represents a host cell target 
We have previously detailed the use of replication defective adenoviruses expressing EGFP and 
HA tagged forms of the ORF66 protein kinase (53).  To determine if the 125 kDa species seen in 
VZV-infected cells was a cellular protein, Hek293 cells were infected with replication-deficient 
adenoviruses expressing ORF66 (Ad.66) or ORF66kd (Ad.66kd), together with a regulatory 
virus, Ad.Toff, and in the absence or presence of doxycycline to turn off expression of ORF66 
and 66kd.  WCE extracts analyzed by western blot & probed with a p-PKA substrate antibody 
show the appearance of a 125 kDa species when ORF66 was expressed. Its absence in all 
controls, including when ORF66 gene expression was turned off with doxycycline, or in 
conditions of kinase inactive forms (Fig 3-2.) establishes the 125 kDa species as a host cell 
protein.  In this study, Hek293 cells show a consitutively expressed 135 kDa species that was not 
ORF66 dependent.  Antibody to HA showed expression of the HA tagged 66 and 66kd proteins.   
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 Figure 3-2.  The 125 kDA 66-specific PKA-substrate is a host cell protein 
MRC-5 were coinfected with replication-deficient adenoviruses Ad.Toff which expresses a tetracycline-
controlled transactivator at an MOI of 2.5 and one of the following : Ad.GFP-66 expressing functional 
ORF66 (Ad.66), Ad.GFP-66kd expressing kinase-inactive ORF66 (Ad.66kd), or Ad.Vector at an MOI of 
5 or mock infected.  Doxcycline was added (+) to turn off ORF66/66kd gene expression.  Cells were 
harvested 1 day p.i.  and immunoblot analysis was done of WCE.  Membranes were probed with rabbit α-
p-PKA-substrates, then stripped and reprobed with mouse α-HA to analyze for ORF66/66kd expression. 
Mouse α-tubulin was used to evaluate equal amount of total protein levels.  Protein size markers in kDa 
are specified to the left. 
 
 
3.4.3 Matrin 3 is a conserved phosphorylation target for the alphaherpesvirus 
ORF66/US3 kinases. 
To identify the 66-induced p-PKA-substrate 125 kDa protein(s), the 125 kDa species in 
adenovirus infected ORF66 expressing HeK293 cells was scaled up and immunoprecipitated 
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with p-PKA substrate antibody.  SDS-PAGE gel fragments stained with colloidal coomassie blue 
without fixation for the 100kDa to 140kDa species were sent for LC MS/MS analysis.  A 
returned target candidate was the nuclear matrix protein, matrin 3.   
The identification of matrin 3 as the 125 kDa species differentially phosphorylated by 
VZV ORF66 was then confirmed using commercial matrin 3 specific antibodies. Anti-Matrin 3 
immunoprecipitated extracts of Hek 293 cells transduced with Ad.66 or Ad.66kd at an MOI of 
0.3, followed by western blot using the p-PKA-sub specific antibody (Fig 3-3a) revealed that 
immunoprecipitated matrin 3 was differentially recognized by p-PKA-substrate proteins in an 
ORF66 kinase-dependent manner.   In a similar experiment in which anti PKA-sub reactive 
proteins were immunoprecipitated & probed for matrin 3, results were similar in that the ORF 
66-induced 125 kDa p-PKA-sub protein was recognized by the matrin 3 specific antibodies.   We 
then confirmed that matrin 3 was differentially phosphorylated in a 66-dependent manner in 
VZV infection.  MeWo cells infected with VZV.GFP-66 or kinase-inactive mutants (VZV.GFP-
66kd and VZV.GFP-66s) were analyzed in a similar manner, in which extracts were 
immunoprecipitated for either matrin 3 (Fig. 3-3B, top panel) or PKA-sub proteins (Fig. 3-3B 
middle panel) and probed for PKA-sub reactive proteins or matrin 3, respectively.   These 
approaches revealed that functional ORF66 expression in the context of VZV infection induced 
phosphorylation of multiple forms of matrin 3 during VZV infection, although matrin 3 was 
present in the IP fraction for all VZV infections (Fig. 3-3B lower panel).  These studies also 
indicated that VZV infection did not radically alter global levels of matrin 3 as a result of 
infection, since similar amounts of matrin 3 were seen by western blot and from 
immunprecipitates.   
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A final approach to establish matrin 3 was the detected 125kDa protein and not a 
similarly sized protein contaminating the IP fraction used a matrin 3 blocking peptide. The 
blocking peptide contains the epitope that is recognized by the matrin 3 antibody, thus blocks the 
antibody-antigen interaction.  An IP was done on VZV-infected cells using matrin 3 or p-PKA 
substrate antibody in the presence or absence of a blocking peptide added to the soluble fractions 
containing functional ORF66 kinase.  The peptide efficiently blocked α-matrin 3 from binding 
matrin 3 (Fig. 3-3c left) and this prevented immunoblot detection of a 125kDa PKA-sub 
antibody in the presence of ORF66 kinase (Fig. 3-3c right); hence, matrin 3 is the ORF66-
dependent 125kDa p-PKA substrate protein and not a contaminating phosphorylated protein.   
These approaches were then extended to examine US3 kinase-dependent matrin 3 
phosphorylation in cells infected with HSV-1 and PRV.  Immunoprecipitates of matrin 3 that 
were subsequently probed for p-PKA- sub antibody revealed that matrin 3 was phosphorylated in 
cells infected with HSV expressing US3 or US3.5, and in PRV infected cells expressing US3, 
but were not phosphorylated or only marginally phosphorylated in cells infected with each virus 
lacking its respective US3  kinase (ΔUS3). Fig 3-4a (left top panel) cells probed with PKA-
substrate showed that the 125 kDa protein was strongly detected when functional HSV US3 or 
US3.5 was present, but diminished in ΔUS3 virus infected cells. Global matrin 3 levels did not 
change during HSV or PRV infection (Fig. 3-4a left middle panel).  Similar findings resulted in 
PRV- infected cells, where phosphorylation in the 125 kDa region occurred in cells infected with 
PRV expressing functional US3 (Fig. 3-4b left panels). PRV ΔUS3 reproducibly showed a small 
level of matrin 3 phosphorylation (Fig. 3-4b right top panel).  We conclude from these data that 
matrin 3 is a conserved phosphorylation target for the VZV, HSV and PRV US3 kinases.   
 
 99 
 Figure 3-3.  VZV ORF66 kinase activity induces specific matrin 3 phosphorylation 
(A) Hek 293 cells were infected with Ad.GFP-66 or Ad.GFP-66kd at an MOI of 0.3 or mock infected.  
Soluble fractions (sol) & immunoprecipitation (IP) products were separated on a 7% gel and analyzed by 
immunoblot (WB). IPs were performed using rabbit α-matrin, followed by probing of membranes with 
rabbit α-PKA-substrate antibody (top panel), or IPs were performed using rabbit α-PKA-substrate 
followed by probing of membranes with rabbit α-matrin 3 antibody (bottom panel).  (B) MRC-5 cells 
were infected with VZV.GFP-66 (66), VZV.GFP-66kd (66kd), or VZV.GFP-66s expressing a.a. 1 to 84a  
of ORF66 (66s) at an MOI of 0.01 or mock infected, then harvested 2 days p.i. & separated on a 7% SDS-
PAGE gel, then transferred to a PVDF membrane. Immunoprecipitations followed by immunoblot 
analysis (top & middle panel) were performed as described above.   The top membrane was then stripped 
and reprobed for Matrin 3 to analyze levels of matrin 3 in IP fractions (bottom panel). Protein size 
markers in kDa are specified to the left.  (C)  MRC-5 were infected with VZV expressing 66 or 66kd at an 
MOI of 0.01 or mock infected and harvested at 2 days p.i..  Cleared lysates where then 
immunoprecipitated using rabbit α-matrin 3 antibody in addition to matrin 3 blocking peptide (BP) where 
indicated. Proteins were separated on a 6% SDS-PAGE gel and membranes were then probed with rabbit 
α-matrin 3 antibody (left panel) to test for efficiency of IPs and the blocking peptide, or to analyze for 
phosphorylation of matrin 3 with rabbit α-PKA-substrate antibody (right panel).   
 
 
 100 
 Figure 3-4.  Matrin 3 is a conserved phosphorylation target for the US3 kinases during infection 
MRC-5 cells were infected with (A) HSV-1 (US3), HSV-EGFP-US3.5 (US3.5) or HSV-EGFP-XhoΔUS3 
(ΔUS3) at an MOI of 0.1 or (B) PRV (US3) or PRV.ΔUS3 (ΔUS3) at an MOI of 1 or mock infected, then 
harvested 1 day p.i..  Cleared lysates were immunoprecipitated using rabbit α-matrin 3 antibody.  Whole 
cell extracts (Cell Ext.) or immunoprecipitation (IP) products were separated by 7% (HSV) or 6% (PRV) 
SDS-PAGE gel and analyzed by immunoblot.  Membranes were probed with rabbit α-PKA-substrate 
antibody, and then stripped and reprobed using rabbit α-matrin 3 antibody as indicated on the 
autoradiograph above.  Cell extracts were also analyzed for viral protein expression using mouse α-HSV 
gB (A) or goat α-PRV UL34 antibodies (B).  Protein size markers in kDa are specified to the right.   
 
3.4.4 Identification of matrin 3 target residues for the ORF66/US3 kinases 
Screening of matrin 3 for the phosphorylation target residue(s) of matrin 3 was based on the 
manual identification of serine and threonine residues immediately preceded by multiple basic 
residues.    To identify the key residues targeted by ORF66 for phosphorylation, a series of HA 
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tagged matrin 3 mutants was generated in which the full length matrin 3 was expressed from the 
CMV IE promoter (HA-Matr3) with key S/T residues changed to alanine.  S/T residues chosen 
reflected sites that fit the PKA-substrate motif or those that showed similarity to the US3 
phosphorylation motif or IE62-target-like motifs. 293T cells were transfected with each HA 
tagged construct either alone or cotransfected with CMV IE driven EGFP-66, harvested the next 
day, followed by immunoprecipitation of soluble fractions using HA monoclonal antibodies.  
Immunoprecipitates were then analyzed by western blot and probed with p-PKA-sub or HA 
antibody.  All constructs expressed in cells without the ORF66 kinase showed no detectable 
phosphorylation, as detected using the p-PKA sub antibody (Fig 3-5a), but when coexpressed 
with functional ORF66 kinase, all showed strong phosphorylation of matrin 3 with the exception 
of the HA-Matr3 - T150A mutant (T150A).  This construct was expressed at the same levels, but 
showed only trace levels of phosphorylation (Fig. 3-5a).  These results strongly indicate that the 
T150 residue is the major ORF66 dependent phosphorylation site on matrin 3.  Matrin 3 with the 
T150A mutation showed identical cellular localization to wild type and all other mutants, with a 
strong nuclear  localization, suggesting the differences in phosphorylation were not due to 
aberrant cellular localization due to misfolding or aggregation (data not shown). As such we 
conclude that T150A changes remove the predominant residue targeted for phosphorylation.    
 The T150 mutation was subsequently examined for phosphorylation in the context of 
wild type VZV and HSV infections.  MeWo cells were tranfected with HA vector, HA-Matr3-
T150A, or HA-Matr3, and the next day infected with VZV or HSV-1. 24 h post infection, the 
HA tagged Matrin 3 protein was assessed for specific ORF66 directed phosphorylation as just 
detailed.  The T150A mutant was found to display greatly diminished levels of phosphorylation 
compared to HA-Matr3 in both VZV and HSV-1 infections (Fig. 3-5b).  Thus these results are 
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consistent with an ORF66/US3  directed phosphorylation of matrin 3 at residue T150 by both 
VZV and HSV-1. 
 
Figure 3-5.   Matrin 3 a.a. T150 is the major phosphorylation site for VZV ORF66 and HSV-1 US3 
kinase 
(A) Immunoblot analysis of Hek 293T cells transfected with plasmids expressing HA alone, HA tagged to 
full length matrin 3 (HA-Matr3), or one of the following five HA tagged matrin 3serine/threonine to 
alanine mutants: S188A, T150A, S592/596/598A, S596/598A or S596A (top panels).  Alternatively, cells 
were cotransfected with one of the HA tagged proteins and EGFP.66 (bottom panels).  The next day cells 
were harvested and cleared lysates where immunoprecipitated using mouse α-HA antibody, followed by 
separation of IP products on a 6% SDS-PAGE gel and transfer to PVDF membranes.  Membranes were 
probed with rabbit α-PKA-substrate antibody to analyze matrin 3 phosphorylation or with mouse HA 
antibody to analyze equivalent HA immunoprecipitation.  Protein size markers in kDa are specified to the 
left. (B) Immunoblot analysis of a MeWo cell transfection-infection.  Cells were transfected with 
plasmids expressing HA alone, or HA matrin 3 containing a T150A mutation (T150A), or HA tagged to 
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full length matrin 3 (HA-Matr3), and the following day infected with VZV (top panels) at an MOI of 0.3 
or HSV-1 (bottom panels) at an MOI of 5.  Cells were harvested 1 day p.i. and clear lysates were then 
immunoprecipitated using mouse α-HA antibody.  IP products were separated by 6% SDS-PAGE gel and 
analyzed by immunoblot using rabbit α-PKA-substrate or mouse α-HA antibodies.   
 
3.4.5 ORF66-induced matrin 3 phosphorylation is through a non-PKA dependent 
pathway 
As outlined in the introduction, the HSV-1 US3 kinase has been shown to induce the activation 
of PKA (9). The possibility existed that matrin 3 phosphorylation was the result of a similar 
ORF66 mediated activation of PKA. To address this question, cells were infected with Ad.GFP-
66 or Ad.GFP-66kd in the absence or presence of increasing doses of a PKA-inhibitor (PKI), 14-
22 amide.  Cells were pretreated with PKI 2 hours prior to infection, and treatment continued till 
the time of harvest. An immunoblot of cell extracts probed for p-PKA-substrates showed that 
most detectable PKA substrate bands were essentially unchanged with the presence of 30-50uM 
of PKI, but at 60uM PKI, the p-PKA-sub antibody still detected the 125kDa species and a 
47KDa species without recognition of most other PKA-substrate bands species (Fig. 3-6a).  
Probing for HA shows that ORF66 or ORF66kd were similarly expressed in infected cells. These 
results indicate the inhibition of PKA signaling did not prevent phosphorylation of the 125 kDa 
PKA-substrate band/matrin 3. 
  Further studies utilized the well established PKA activator forskolin, which acts 
by activating adenylate cyclase, leading to increases in intracellular cAMP and activation of 
PKA.  Assessment of extracts of cells infected with VZV.GFP-66 or VZV.GFP-66kd in the 
presence of forskolin or DMSO control added at the time of infection show that the p-PKA-sub 
antibody recognized several novel protein species following forskolin treatment, with 37 and 60 
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kDa proteins being the most apparent. However the 66 kinase – dependent 125 kDa species 
identified as matrin 3 was virtually unchanged in the absence or presence of forskolin (Fig.3-6b).  
To ensure that matrin 3 phosphorylation was unaffected by forskolin treatment as detected by the 
p-PKA-substrate antibody, matrin 3 immunoprecipitates were  analyzed and found to show no 
increase in detection of phosphorylated matrin 3 with forksolin treatment (Fig. 3-6b lower 
panels).  Taken together with the inhibitor studies, these results suggest PKA did not play a 
significant role in the 66-directed matrin 3 phosphorylation. 
It is known that matrin 3 can be targeted by PKA in neurons (64). We subsequently 
addressed whether the matrin 3 T150 residue affected PKA directed phosphorylation of matrin 3.  
The premise was that if PKA was not involved in the 66-dependent PKA phosphorylation, then a 
mutation at T150 should not affect PKA direct phosphorylation of matrin 3.  To investigate this, 
an in vitro kinase assay was performed using purified PKA protein kinase and 
immunoprecipitated HA tagged matrin 3 proteins obtained from transfected cells.  Mutants 
chosen for this assay were those that fit the PKA-substrate target motif RRXS/T.  Tagged matrin 
3 proteins were precipitated using HA-antibodies and these showed extensive phosphorylation in 
vitro when incubated with approximately 2 μg of PKA catalytic subunit alpha (Fig. 3-6c). HA-
Matr3, S596A, and T150A mutants all demonstrate similar levels of phosphorylation by PKA. 
Interestingly, matrin 3 with S188A mutations showed diminished phosphorylation compared to 
HA-Matr3.  This data supports the conclusion that ORF66 dependent phosphorylation of matrin 
3 is not mediated through PKA, and suggests that the S188 site on matrin 3 accounts for a 
significant amount of the PKA-specific phosphorylation of matrin 3 in vitro.  
To test if ORF66 kinase could directly phosphorylate matrin 3, we employed an in vitro 
kinase assay.  Here, ORF66 or ORF66kd are fused to GST and matrin 3 is fused to MBP.  GST 
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proteins were produced in SF9 using recombinant baculoviruses and MBP proteins expressed in 
E. coli BL21, and proteins were subsequently affinity purified.  Equal amounts of GST, GST.66 
or GST.66kd were incubated alone or with either MBP, MBPmatr3, or a positive control- 
MBP62p under optimal kinase assay conditions.  After 25 minutes, reaction mixtures stopped 
using SDS sample buffer and were separated by SDS-PAGE gel, then transferred to an 
Immobilon-P membrane.  These were then exposed to film and subsequently probed for GST or 
MBP proteins.  The autoradiograph shows a band at 75kDa for GST.66 (Fig. 3-7, lane 2, 6, 10, 
14), that was much diminished in GST.66kd (Fig 3-7lane 3, 7, 11, 15). This was expected as 
ORF66 has previously been reported to autophosphorylate (52). As shown previously (52), 
MBP62p is extensively phosphorylated by GST66 (Fig. 3-7, lane 10) and this phosphorylation is 
much diminished when the protein was combined with GST66kd (Fig. 3-7, lane 11). No 
phosphorylation is detected for GST or MBP proteins alone (Fig. 3-7, lane 1, 4, 5, 8, 9, 12, 13).  
MBPmatr3 migrated as two bands, one at approximately 170 kDa & 125kDa, neither of which 
were appreciably phosphorylated by any of the GST fusion proteins (Fig. 3-7, lanes 12-15 ). 
These results indicate that matrin 3 is not an in vitro ORF66 target under the conditions optimal 
for MBP62p phosphorylation.  Because MBPmatr3 is bacterially expressed, we wanted to ensure 
that the protein was in a folded form that allowed phosphorylation. Thus, MBPmatr 3 was 
incubated with PKA which is known to phosphorylate matrin 3 (64).  Results showed that both 
MBPmatr3 bands were phosphorylated by PKA, hence indicating that MBPmatr3 was in a 
properly folded form to serve as target of PKA in both PKA reaction buffer (Fig. 3-7, lane 17) as 
well as optimal 66 kinase buffer (Fig. 3-7, lane 18).  Together, this data suggests that 66-
dependent phosphorylation of matrin 3 is not a direct ORF66 target and phosphorylation occurs 
through a non-PKA signaling pathway.   
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Figure 3-6.  The 125kDa PKA-substrate protein is phosphorylated through a non-PKA pathway 
 (A) MRC-5 cells were pre-treated with a PKA-substrate inhibitor, 14-22 amide (PKI), 2 hours prior to 
infection.  Cells were then infected with Ad.Toff at an MOI of 2.5 and Ad.GFP-66 (66) or Ad.GFP-66kd 
(66kd) at an MOI of 5 with or without PKI, or mock infected.  Dose of PKI at increasing μM levels are 
indicated at the top of the figure.   An immunoblot was done of whole cell extracts.  The membrane was 
first probed with mouse α-HA antibody, stripped, then reprobed with rabbit α-PKA-substrate antibody.  
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The arrow denotes the 125kDA PKA-sub/matrin 3 protein.  The star denotes an undefined protein whose 
phosphorylation is PKI resistant.  (B) MRC-5 cells were infected with VZV.GFP-66 (66) or VZV.GFP-
66kd (66kd) at an MOI of 0.1 or mock infected.  When indicated, cells were treated with 10μM forskolin 
or DMSO at the time of infection.  Cells were harvested 1 day p.i., analyzed by immunoblot, and probed 
with rabbit α-PKA-sub antibody.  Viral protein expression was analyzed using rabbit VZV ORF4 
antibody.  Cleared lysates were immunoprecipitated for matrin 3 and subsequently analyzed by 
immunoblot using rabbit PKA-substrate, stripped, and reprobed with rabbit matrin 3 antibody.  (C) In 
vitro kinase assay of immunoprecipitated HA alone or HA tagged matrin 3 (HA-Matr3) or HA tagged 
matrin 3 mutants S188A, T150A, and S596A incubated with PKA where specified (lower panels). HA 
proteins were derived from transfected Hek293T cells, that were purified from immunoprecipitations 
using mouse α-HA antibody.  Following the kinase assay, proteins were separated on a SDS-PAGE gel, 
and transferred to a PVDF membrane, exposed to film as shown in the above autoradiograph.  These 
membranes were then analyzed for HA fusion protein expression by probing with mouse α-HA antibody.  
Protein size markers in kDa are specified to the left. 
 
 
Figure 3-7.  ORF66 does not target matrin 3 under the conditions required for IE62 
Purified MBP proteins and GST kinase were incubated in optimal kinase buffer, separated by 7% SDS-
PAGE gel, transferred to PVDF membranes and exposed to film for autoradiography. Lanes 1-4 contain 
GST, GST.66, or GST66kd, or MBP incubated alone respectively. Lanes 5-7 contain MBP incubated with 
GST, GST.66, or GST.66kd respectively. Lane 8 contains MBP62p alone, and lanes 9-11 contain 
MBP62p incubated with GST, GST.66, or GST.66kd, respectively. Lane 12 contains MBPmatr3 alone, 
and lanes 13-15 contain MBPmatr3 incubated with GST, GST.66, GST.66kd, respectively.  Lane 16 also 
contains MBPmatr3 alone, and lanes 17-18 contain equivalent levels of PKA incubated with MBPmatr3 
in PKA reaction buffer (lane 17) or optimal 66 kinase buffer (lane18).  Protein levels were then analyzed 
by immunoblot using rabbit MBP and goat GST antibodies (lanes 1-15).  Protein size markers in kDa are 
specified to the left of autoradiographs. 
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3.4.6 Matrin 3 localization in VZV-infected cells 
Protein kinases often induce subcellular localization changes following phosphorylation of their 
target substrates in order to modulate function.  This is certainly exemplified by ORF66 kinase 
phosphorylation of IE62, where phosphorylation induces radical changes in subcellular 
localization.  In this case, IE62 is excluded from the nucleus and localized in the cytoplasm 
which is a requirement for IE62 tegument incorporation (52, 54, 98).  We then asked whether 
ORF66-specific phosphorylation of matrin 3 lead to changes in the protein’s intracelluar 
localization.  MRC-5 cells were infected with VZV.GFP-66Rsc, VZV.GFP-66kd, or mock 
infected.  In mock-infected cells matrin 3 exhibited dominantly nuclear localization, with 
exclusion from what appeared to be nucleoli (Fig. 3-8a (panels i and iv) and 3-8d (panel i)).  This 
is in accordance with previously described subcellular localizations for matrin 3 in other cell 
types.  In infected cells expressing ORF66, matrin 3 was largely retained in the nucleus with a 
slightly more diffuse intranuclear localization (Fig. 3-8d (panel ii)), even late in infection as 
depicted in the shown synctia (Fig. 3-8 b (panels i and iv)).  In cells expressing the kinase-
inactive ORF66kd, matrin 3 was still retained in the nucleus but many cells displayed multiple 
areas within the nucleus that were devoid of matrin 3 (Fig. 3-8c (panels i and iv) and Fig. 3-8d 
panel iii), yet were filled with IE62 and followed early replication compartment patterns.  
Additionally, few cells also exhibited matrin localizing in 2-10 nuclear punctae.    As reported 
previously, IE62 was cytoplasmic - nuclear excluded in ORF66-expressing cells (Fig. 3-8b panel 
iii & iv) and exclusively nuclear in ORF66kd-expressing cells (Fig. 3-8c panel iii & iv).  
Furthermore, GFP.66 showed both cytoplamic and nuclear localization (Fig. 3-8b panel ii and 
iv), compared to the more predominant nuclear localization of GFP.66kd (Fig. 3-8c panel ii and 
iv).  Overall, our immunofluorescence analysis indicates that matrin 3 localizes to the nucleus 
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late into VZV infection, and presents subtle differences in its intranuclear localization when 
kinase activity is abrogated.   
 
 
 
 
Figure 3-8. VZV infection leads to subtle differences in matrin 3 cellular localization 
 Immunofluorescence analysis of MRC-5 cells (A) mock infected or infected with (B) VZV.GFP-66Rsc 
or (C) VZV.GFP-66kd at an MOI of 0.003.  Cells were fixed with 4% paraformaldehyde 3 days p.i. and 
immunostained with rabbit anti-matrin 3 antibody (A-C (panel i) detected with α-rabbit Alexa Fluor 546, 
D) or mouse anti-IE62 (A-C (panel iii) detected  with α-mouse Alexa Fluor 647.  ORF66 expression was 
determined by GFP autofluorescence (A-C (panel ii).  The merge image (A-C (panel iv)) are overlays of 
matrin 3 (gray), GFP (green), IE62 (red), and nuclei stained with Hoechst dye (blue). (D) Single cell 
representative images depicting matrin 3 localization.  Infection conditions are indicated in the image.  
Fluorescence images were taken using a 60X objective.  
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3.4.7 Matrin 3 efficient nuclear retention is dependent on US3 kinase expression 
Our previous data had indicated that ORF66/US3 – dependent matrin 3 phosphorylation was 
conserved for the alphaherpesvirus, and shared a common phosphorylation site. We extended our 
immunofluorescence analysis to HSV-1 and PRV, to investigate whether US3 kinase activity had 
any influence on matrin 3 cellular localization.  MRC-5 cells were synchronously infected with 
HSV-1, HSV-1 expressing GFP.US3.5 (HSV.US3.5), HSV that did not express US3 
(HSV.ΔUS3), PRV, PRV that did not express US3 (PRV.ΔUS3) or mock infected.   At 18hrs 
p.i., cells expressing HSV US3 (Fig. 3-9 B) or US3.5 (Fig. 3-9C) displayed matrin 3 
predominantly in the nucleus (Fig. 3-9B,C panels i & iv), although many instances of nuclear 
condensation were visible for US3.5-expressing cells.  Localization did not differ substantially 
from mock-infected cells (Fig. 3-9A) except matrin 3 exhibited a more diffuse nuclear 
localization, in addition to what appears to be loss of most detectable nucleoli. Redistribution of 
nucleolar proteins have been reported previously in HSV infected cells (19). However, when 
HSV US3 was not expressed, cytoplasmic accumulation of matrin 3 were consistently observed 
in addition to nuclear localization (Fig. 3-9D panel i & iv).  To visualize HSV infection, an ICP4 
IF stain was included in our analysis. HSV-1 ICP4 was observed in all cells, and exhibited a 
mainly nuclear localization in all infected cells (Fig. 3-9B-Dpanel iii), with some cytoplasmic 
accumulations in HSV.ΔUS3 infected cells (Yee, MB unpublished results).   GFP.US3.5 located 
in the cytoplasm and nucleus of infected cells (Fig. 3-9B panel ii), and GFP alone was expressed 
from the US3 native promoters in HSV.ΔUS3 (Fig. 3-9C panel ii).  In PRV infected cells 11 hrs 
p.i., matrin 3 again displayed a mostly nuclear localization late in infection (Fig. 3-9E panel i & 
iv) although some cytoplasmic forms where noted.  Interestingly, in the absence of PRV US3 
expression, matrin 3 exhibited nuclear exclusion in multiple cells, with accumulation now in the 
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cytoplasm of infected cells (Fig. 3-9F panel i & iv).  All cells were infected as displayed by 
UL34 stain (Fig.3-9 E &F panel iii), and GFP expression was evident from the PRV US3 native 
promoter in PRV.ΔUS3- infected cells (Fig. 3-9F panel ii).  Our results reveal that both HSV and 
PRV US3 modulate matrin 3 cellular localization, and US3 expression is necessary for efficient 
matrin 3 nuclear localization. 
 
 
Figure 3-9.  HSV-1 and PRV US3 kinase expression leads to matrin 3 nuclear retention or shuttling 
to the nucleus during infection 
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Immunofluorescence analysis of MRC-5 cells (A) mock infected or infected with (B) HSV-1, (C) 
HSV.US3.5, (D) HSV.ΔUS3 (E) PRV, or (F) PRV.ΔUS3 at an MOI of 5.  Cells were fixed with 4% 
paraformaldehyde 18hrs p.i.(HSV) or 11hrs p.i (PRV), then immunostained with rabbit α-matrin 3 
antibody (A-F (panel i)) detected with α-rabbit Alexa Fluor 546 (HSV) or  α-rabbit Alexa Fluor 555 
(PRV), mouse α-HSV ICP4 (A-D (panel iii)) detected with α-mouse Alexa Fluor 647, or goat anti-PRV 
UL34 (E & F (panel iii)) detected with α-goat Alexa Fluor 647.  GFP-US3.5 expression or US3 promoter 
activity in HSV.ΔUS3 and PRV.ΔUS3-infected cells was determined using GFP autofluorescence (A-F 
(panel ii)).  The merge image (A-F (panel iv)) are overlays of matrin 3 (gray), GFP (green), ICP4 
(magneta) or PRV UL34 (magneta), and nuclei stained with Hoecht dye (blue).  Fluorescence images 
were taken using a 60X objective. 
 
3.5 DISCUSSION 
Increasingly, the multifunctional roles for ORF66 kinase are realized, as well as the kinases’ cell-
type dependent importance for proper VZV growth and replication in the hosts.  This is in 
alignment with the multifunctional nature of the alphaherpesvirus US3 kinases.  ORF66 kinase 
activity is key in regulating IE62 cellular localization & tegument inclusion, and modulates 
multiple cellular activities involved in immune evasion strategies, as well as induces 
phosphorylation of proteins involved in silencing viral gene expression.  Additionally, ORF66 is 
critical for VZV growth in specific cell types.  Nevertheless, many specific protein targets are yet 
to be determined.  In this work, we reveal that matrin 3 is an indirect phosphorylation target of 
ORF66, and is a conserved target of the ORF66 orthologues, HSV-1 and PRV US3 kinases.  Our 
data also suggests that a function of this phosphorylation is to maintain matrin 3 nuclear 
localization.  This is the first report, to our knowledge, of matrin 3 protein modification by any 
virus.   
Matrin 3 is a 847 a.a. 125 kDa slightly acidic protein with a predicted weight of 95kDa 
(7).  The N-terminus contains a large number of free hydroxyl groups (26 of the first 100 
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residues) as characteristic of lamin proteins, in addition to an acidic C-terminus found in many 
nuclear proteins, and  two tandem RNA recognition motifs (7).  Specific functions for matrin 
proteins are mostly unknown, yet there are reports proposing intriguing roles for matrin 3 in host 
cell processes.  Recent studies have implicated it as a component of functional nuclear 
microenvironments of chromatin replication & transcription (123).  Moreover, matrin 3 has been 
found to interact with hnRNP-L, an RNA splicing regulator, & SAFB, involved in RNA 
processing & chromatin organization (229). Matrin 3 can bind DNA at scaffold/matrix 
attachment regions (S/MAR) sites which influence chromatin structure by associating with 
matrix-binding proteins that anchor chromatin into loop domains.  Interestingly, matrin 3 is also 
part of a three protein complex including p54nrb and PSF that prevent the nuclear export of 
nuclear dsRNAs that are hyperedited by members of the ADAR (adenosine deaminase that act 
on RNA) enzyme family (45, 231).  In rat neurons, activation of the glutamate receptor, NMDA 
by PKA induces matrin 3 phosphorylation.  This phosphorylation in turn leads to matrin 3 
degradation and subsequent neuronal death (64).   Lastly, matrin 3 has been linked to the genetic 
disorders such as one type of autosomal-dominat distal myopathy, VCPDM, and found in 
decreased levels in fetal Down’s syndrome brains (13, 192). 
 The goal of our analysis was to uncover novel phosphorylation targets of ORF66 
kinase and get a clearer understanding of the roles of ORF66 in VZV infection.  The 
phosphorylation motif for ORF66 is unknown, yet the target sites in IE62 are well-described.  
Based on the similarity between these sites and that of the cellular kinase PKA phosphorylation 
motif, we took advantage of a phosphospecific PKA-substrate antibody to find novel ORF66 
protein targets.   Interestingly, we found that these alphaherpesviruses varied widely in number 
and molecular weights sizes of bands that were induced with infection (Figure 3-1).  These 
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proteins may be direct ORF66 or US3 targets, direct PKA targets, or downstream 
phosphorylation targets of activated PKA signaling pathways. HSV-1 displayed the strongest 
induction of phosphorylation of PKA-substrate proteins, agreeing with previous findings that 
US3 induced the phosphorylation of proteins fitting PKA substrate specificity, in addition to 
their model which predicts that HSV-1 infection activates PKA and may share protein substrates 
(9).   VZV is reported to increase expression of the PKA catalytic subunit as well as induce 
detection of PKA-substrate bands.  Although, some of the phosphorylated sizes were of similar 
molecular weight, it is unknown whether the same proteins are detected as these proteins have 
not been identified (49).  Notably, in our study a novel ORF66-dependent 125 kDa PKA-
substrate was the dominant protein present. Importantly, although profiles between the 
alphaherpesviruses differed, there was conservation of ORF66/US3-dependent phosphorylation 
of the 125 kDa protein/matrin 3 (Figure 3-1, 3-3, & 3-4).  This leads to the prediction that 
because phosphorylation of this specific protein is conserved, it may be important for 
alphaherpesvirus replication.  Also in figure 3-1, HSV.ΔUS3-infected cells, a faster migrating 
band for gB protein was observed and likely represents an unphosphorylated gB fraction (86, 
221).  gB migrates at a similar molecular weight as matrin 3, and this may account for some 
phosphorylation seen in HSV-1.ΔUS3 in the 125kDa region of cell extracts on longer exposures 
of autoradiographs (Figure 3-4a). Some gB phosphorylation in cells infected with HSV-1 
expressing inactive US3 has been reported previously using PKA-substrate antibody (86).   
 We also observed that expression of ORF66 using adenovirus vectors, strongly 
induced phosphorylation of the 125 kDa protein, indicating that this band represented a cellular 
protein (Figure 3-2).  Other host proteins bands were detected with expression of ORF66, albeit 
less strongly than the 125kDa protein but are of interest for future identification.  Our mass 
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spectrometry analysis identified the protein as matrin 3.  Interestingly, the results for this region 
of the gel did not identify additional proteins in this region except for keratin contaminants 
which are common for LC/MS/MS methods.  Identification of matrin 3 and the observation that 
for all 3 viruses this nuclear matrix protein is phosphorylated in an ORF66/US3 – dependent 
fashion provides much evidence that matrin 3 is the 125kDa-PKA-substrate protein.  While 
matrin 3 has not been linked as a modified protein of any virus, interaction of virus with matrix 
proteins have been described for HIV, SV40, PRV, HCMV and HPV (8, 66, 142, 182, 187, 201),  
and notably for HSV-1 (16-17, 23, 138, 223, 226).  For most of our analysis at least two forms 
were detected in whole cell extracts and 2 or more in IP fractions.  Importantly, both matrin 3 
and p-PKA substrate antibodies detect a stronger faster migrating band, and a slower migrating 
125kDa band in cell extracts.   Because IP forms are detected by the p-PKA substrate antibody, 
we believe that these likely represent different phosphorylated forms.  The fact that IP fractions 
are enriched for matrin 3, combined with the use of specific PKA-substrate antibody, we predict 
leads to additional forms of this protein revelead in this fraction.  Differentially phosphorylated 
matrin 3 isoforms have been documented in rat cells, with a 130kDa and 123kDa matrin 3 
localizing to the nucleus and extracellular compartments, respectively (75).  Differing matrin 3 
forms with slightly different isoelectric points have been isolated from neurons (64).  Whether a 
specific function is attributed to these forms or whether they represtent phosphoryation status in 
the process of turnover or degradation fragments is unclear. Two transcricpts have been recorded 
for matrin 3, differing at the 5’UTR but encoded the same protein (NCBI).  Nevertheless, 
alternate protein modifications should still be considered.   
 One of the objectives for analyzing 66-dependent phosphorylation of matrin 3 
serine/threonine to alanine mutants was to explore potential functions of this specific matrin 3 
 116 
targeting.  Matrin 3 contains two recognition RNA recognition motifs, matrin-type zinc fingers, 
and potential nuclear localization signal (a.a. 710-718). We chose candidate ORF66 sites with 2 
or more basic residues adjacent and N-terminal to a serine or threonine.  Interestingly, S592, 596 
and 598 were within the human homologue region of the identified chicken matrin 3 bipartite 
nuclear localization signal (77).  Our data shows that the T150 mutation to alanine drastically 
dimished phosphorylation detected for the HA-tagged matrin 3 mutant (Figure 3-5.).  However, 
there was still some phosphorylation detected for this mutant indicating the possibility for 
additional matrin 3 residues that are phosphorylated in a 66-dependent manner.  It is intriguing 
that different alphaherpesviruses would share a common target and phosphorylation site on that 
target protein; this may be due to the nature of similar phosphorylation target motifs for the US3 
kinase.  This would predict that this phosphorylation would have similar outcomes on matrin 3 
function.  
Activation of PKA-substrates during viral infection has been reported for HCV (55), and 
activated PKA pathways have been exploited by many viruses including adenoviruses, HIV 
(114, 203), HCMV (90), and HSV (222) to enhance infection.  However our data suggest that 
PKA does not directly phosphorylate matrin 3 at the T150 major phosphorylation site (Figure 3-
6), although matrin has been shown here and in previous studies to be a PKA target.  Inhibition 
of PKA with a highly specific inhibitor, 14-22 amide, did not prevent detection of the 
phosphorylated 125kDa protein, although other PKA-substrates proteins were no longer 
detected.  Activation of PKA using forskolin also did not increase matrin 3 phosphorylation and 
minimally increased its phosphorylation in ORF66kd-expressing infected cells (Figure 3-6.).  
Moreover, in vitro phosphorylation of HA-Matr-T150A mutant by PKA did not differ from the 
non-mutated form of matrin 3, yet there was reduced phosphorylation for HA-Matr-S188A.  
 117 
These results indicate that PKA does phosphorylate matrin 3 at the S188 site in vitro and 
potentially other sites, but does not target the T150 site which is the 66-dependent matrin 3 
phosphorylation site. Thus these data suggests that PKA or PKA signaling pathways have a 
minor role in the 66-dependent phosphorylation of matrin 3.  We did note a prospective 60kDa 
likely viral protein that was phosphorylated in response to forskolin treatment in ORF66kd 
expressing cells.  This indicates that there is a protein which is phosphorylated in response to 
activation of PKA pathways that is dependent on VZV infection.  We then explored whether 
matrin 3 was directly phosphorylated by ORF66 in vitro.  Surprisingly, ORF66 did not 
phosphorylate MBPmatr3 under the same in vitro kinase assay conditions for which ORF66 
phosphorylates MPP62p (Figure 3-7), while PKA did phosphorylate matrin 3 under these same 
conditions.  PKA phosphorylation of matrin 3 may reflect targeting of other S/T sites other than 
those sites phosphorylated (T150) in response to ORF66 expression.  This data does suggest that 
ORF66 does not directly phosphorylate matrin 3.  However, this does not exclude the possibility 
that matrin 3 may be phosphorylated by ORF66 under different kinase assay conditions, or 
require an additional nuclear protein; this will be the subject of further investigation.   
ORF66 kinase has demonstrated the ability to regultate VZV IE62 localization and this 
determines IE62 inclusion in the virion tegument.  HSV US3 kinase activity is known to cause 
the redistribution of a nuclear matrix protein, lamin A/C, involved in breaching the laminar 
network needed for proper nucleocapsid envelopment yet still maintaining laminar structure 
(138).  In our immunofluorescence study, matrin 3 remained nuclear in VZV infection with a 
more diffuse localization of the protein compared to the mock-infected cells.  In contrast, many 
cells in VZV.GFP-66kd expressing cells displayed regions devoid of matrin 3 of which were 
filled with IE62 protein (Figure 3-8).  This is reminiscent of the findings for lamin A/C that 
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normally forms a reticular pattern in infected cells, yet in the absence of US3 kinase activity 
leads to larger intranuclear regions devoid of lamin A/C (138).  Thus, similarly to what happens 
to lamin A/C distribution, ORF66 may also be responsible for maintaining a balance between 
disruption of a major component of the nuclear matrix yet retaining matrin 3 at replication 
compartments, where viral replication and transcription occurs.  This implies that ORF66 kinase 
activity may be necessary for matrin 3 interaction with components of early replication 
compartments, such as IE62.  HSV infection also causes reorganization of another nuclear matrix 
protein, nuclear mitotic apparatus (NuMA) protein and is excluded from replication 
compartments, with redistribution dependent on viral DNA synthesis (226).  In HSV-1 and PRV 
immunofluorescence analysis, matrin 3 showed a diffusely nuclear localization in infected cells, 
as well as in HSV.EGFP-US3.5 expressing cells.  In contrast, subtle yet reproducible 
cytoplasmic accumulation of matrin 3 was visible in cells that did not express US3 kinase in 
HSV-1.  These differences were likely not due to apoptotic cells, as HSV-1 US3.5 like US3-null 
viruses do not possess the US3 function in inhibiting apoptosis (162), yet matrin 3 was still 
predominantly nuclear.  Cytoplasmic accumulation were even greater in PRV-infected cells that 
lacked US3 with some cells displaying nuclear exclusion of matrin 3 (Figure 3-9), and for both 
viruses the difference between US3 and US3-non-expressing infected cells was most 
distinguishable late in infection.  Together these findings point to a role for the US3s in the 
active retention of matrin 3 in the nucleus or increased shuttling of matrin 3 to the nucleus.  
Regulation of matrin 3 cellular localization by phosphorylation has been reported previously 
where the use of a general kinase inhibitor staurosporine leads to matrin 3 accumulation in the 
cytoplasm (77).  It is possible that phosphorylation by US3 may be key for matrin 3 interaction 
with cellular proteins that are retained in the cytoplasm.  In the absence of US3, matrin 3 may be 
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lost to the cytoplasm due to the nuclear component reorganization that occurs in HSV infection . 
Secondly, matrin 3 may be interacting with a viral protein that is also a US3 target which 
localizes to the cytoplasm late in infection in the absence of US3 expression.  The nuclear 
exclusion seen in PRV.ΔUS3 may be explained by this latter scenario or an active export of 
matrin 3 to the cytoplasm.  We also observed that in infection with VZV, HSV-1 & PRV, global 
matrin 3 levels remained unchanged as visualized by western blot. This suggests that matrin 3 is 
a very stable protein and supports the idea that matrin 3 is a necessary protein for 
alphaherpesvirus infection.  This will be an interesting question to be addressed for future siRNA 
studies.    
Our studies thus far have indicated that matrin 3 is specifically phosphorylated in an 
ORF66/US3 kinase-dependent manner, and the kinases’ function in either modulating 
intranuclear localization or nuclear-cytoplasmic shuttling.  This leads us to question the potential 
functions of matrin 3 in alphaherpesviral infection, and how the ORF66/US3 specific matrin 3 
phosphorylation contributes to this function.  However, matrin 3 cellular functions are not clearly 
defined but recent evidence points to a multifunctional nature for this protein.  Nuclear matrix 
has long been reported to be the site of organization for numerous nuclear processes such as 
DNA replication, DNA loop attachment, transcription and RNA processing (3, 11-12, 83).  
Matrin 3 specifically locates in close proximity to nascent DNA replication and transcription 
zones within the nucleus.  Thus, as matrin 3 is a major nuclear matrix protein, is may serve as a 
platform for these essential genomic functions.  Furthermore, we can conceive that matrin 3 is 
also needed to be present at sites of viral replication and transcription.  Recently, a comparable 
role has been proposed for lamin a/c as serving as a scaffold for HSV genomes and nuclear 
factors that reduce heterochromatin assembly on viral promoters (194).   Matrin may also serve 
 120 
as part the nuclear matrix that is involved as part of the site of capsid assembly due to findings 
that capsid proteins localized to nuclear matrix fractions (16, 23).  If ORF66 is involved in capsid 
assembly, then this may explain the reduced intranuclear assembly of nucleocapsids in T cells 
from SCID-hu T cell xenografts infected with VZV lacking ORF66.  Matrin 3 is also involved as 
part of a complex that retains hyperedited nuclear dsRNAs in the nucleus and to prevent their 
export to the cytoplasm for translation.  dsRNAs have been identified for HSV (84).  The 
ORF66/US3 kinases may potentially be involved in regulating interaction of matrin 3 with the 
p54nrb-PSF complex and modulate the balance between nuclear accumulation and release of 
viral dsRNA to the cytoplasm.   Lastly, matrin 3 degradation in neurons leading to neuron death 
may be in response to the hyperphosphorylatin of matrin 3 detected using PKA-substrate 
antibody.  This leads to the speculation of whether ORF66 phosphorylates matrin 3 leading to its 
degradation during VZV reactivation in neurons, and in turn causing the neuronal death or 
damage that is sometimes associated with herpes zoster (153).   
 In summary, this study describes a novel cellular target for ORF66 kinase, the 
essential nuclear matrix protein –matrin 3, that is specifically phosphorylated in a 66-dependent 
manner through a non-PKA pathway.  This is a conserved target for two other alphaherpesvirus 
US3 kinases from HSV-1 and PRV.  This phosphorylation functions in modulation of matrin 3 
intranuclear localization, or in the case of HSV and PRV, in efficiently maintaining matrin 3 
nuclear localization.   This is the first report of a viral manipulation of this nuclear matrix 
protein.   
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4.0  FUTURE DIRECTIONS & GENERAL SUMMARY 
Overall, the results presented here offer new insights for roles in ORF66 in VZV biology as well 
as revealing a novel host protein target with potentially important implications for ORF66 
manipulation of cellular biology.  Previously, ORF66 was regarded as a non-essential protein for 
VZV replication, yet it was obvious that this kinase must be important for VZV pathogenesis as 
it specifically targeted the VZV major transcriptional activator, IE62, and its direct 
phosphorylation determined IE62 virion incorporation.  In recent years, VZV ORF66 has 
demonstrated that it is indeed a multifunctional protein in that its kinase activities are aimed at 
both viral and cellular proteins.  These diverse roles include downregulation of surface MHC-1 
in fibroblasts, modulation of interferon and apoptosis pathways, and targeting of HDAC 1 and 2.  
Furthermore ORF66 is important for growth in human T cells, which are believed to be key for 
VZV pathogenesis as they can transfer virions to sites in the skin in SCID-hu mouse models.   
Corneal Fibroblasts 
The work presented here describes the first non-lymphocytic cell line, primary corneal 
fibroblasts (54), for which ORF66 kinase activity is important for VZV growth.  Although our 
studies found that the basis for impaired growth was not an inability to phosphorylate IE62 at the 
major S686 site nor increased apoptosis, this study establish a new cell culture model for 
exploration of cell-type dependent functions of ORF66.   For future studies, the IFN-α/β 
pathways have yet to be explored.  It is thought that inhibition of IFN signal transduction may 
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promote the survival of infected tonsillar T cells.  Thus, it is possible that PCF cells express 
higher levels of IFN, exerting an antiviral effect when ORF66 is inactive or not expressed.  
Human corneal epithelial cells have been found to increase transcriptional expression of various 
cytokines including IFN-β in response to HSV-1 infection in vitro.  Interestingly, addition of 
recombinant human IFN-α2a can inhibit VZV replication in human corneal stromal fibroblasts 
cultures. Thus, investigating whether there are differences in cytokine transcription induction in 
PCF cells compared to another VZV permissive cell line could point out possible ORF66 
substrates.  
 In infected PCF cells, small VZV foci were produced when ORF66 was not expressed or 
inactivated. This suggests that there may be a block in late gene expression, therefore analyzing 
at what point the delay is occuring may highlight potential viral proteins that are important VZV 
targets for efficient PCF infection.  Morevover, PCF expressing 66kd may have deficiencies in 
proper virion maturation or trafficking during nuclear egress.  gB is a leaky late protein that is 
involved in nuclear egress of virion  in HSV-infected cells and is phosphorylated by US3 kinase 
in addition to likely cellular kinases at the same site .  Interestingly VZV gB contains a potential 
candidate ORF66 phosphorylation motif at RSRRS495VP and potentially another at the C 
terminus.   
Ultimately, the lack of growth for 66-inactive VZV in PCF is cell-type dependent and the 
likelihood is that there is a cellular protein that aids in ORF66 kinase functions that is absent or 
altered in PCF cells, or alternatively an efficient VZV antagonist that is present or altered in this 
cell type.  Hence, a focus should be placed in outlining what signaling pathways and specific 
cellular proteins are targeted in VZV- infected versus VZV expressing 66kd in PCFs as 
compared to more permissive cell lines.   
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 Viral cell Targets 
 While ORF66 has been implicated in diverse cell processes, only one direct target 
is known for this kinase, IE62.  Thus a major endeavour of my studies was to find novel ORF66 
cellular or viral protein targets.  As a result, a set of candidate viral proteins were chosen that fit 
a phosphorylation motif based on IE62 direct targeting for further investigation using in vitro 
kinase assays (Figure 4-1) .  Using aforementioned MBP fused to viral proteins and GST-66 and 
GST-66kd, results showed that both VZV ORF4 and ORF9 were direct ORF66 targets in vitro 
(Figure 4-2).  Interestingly both of these proteins are viral tegument proteins and both contain a 
proline at the +2 position following the putative phosphorylated serine/threonine  -  both 
characteristics shared with the IE62 protein.  ORF 4 is an IE phosphoprotein and major 
transactivator, post-transcriptional regulator of gene expression, and partner in mRNA export.  
IE4 is divided into four regions, one which is an arginine rich region subdivided into 3 units –Ra, 
Rb, & Rc.  This argine rich region is important for transactivation properties & protein-protein 
interactions.  Intriguingly, the putative phosphorylation site is located within the Rb region 
which binds strongly to RNA in vitro (151), and is adjacent to IE4 nuclear localization signal.  
Therefore, it is important that further studies pinpoint the site of IE4 phosphorylation by ORF66 
to begin to understand possible functions of this phosphorylation.   ORF9 is a tegument protein 
and displays limited homology to its homologue HSV VP22.  This protein is not well 
characterized but has been reported to bind IE62 in complex with tubulin, possibly as a means of 
recruitment for virion incorporation (26). Interestingly, my studies with HA tagged ORF9 
indicate that ORF9 displays multiple different localizations.  This same observation has been 
reported for VP22 (126).  Namely for ORF9 - cytoplasmic accumulations, perinuclear speckling, 
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rod-shaped filaments were noted.  When cells were co-transfected with EGFP66, ORF9 
predominantly displayed a cytoplasmic localization (data not shown). This suggests that ORF66 
can modulate ORF9 subcellular localization. In VZV infection, ORF9 displayed cytoplasmic, 
nuclear, and at times rod shaped filaments as well as what appeared to be mitotic chromatin 
binding, yet it was unclear if there were localization differences in kinase-inactive cells.  In 
VP22, these rod-shaped bundles reflect VP22 binding to microtubules causing their stabilization 
and in turn bundling.  Thus, this implicates ORF66 in altering ORF9 intracellular localization, 
interactions with microtubules and any downstream effects resulting from that disruption.  
Challenges were encountered in in vivo phospholabeling of transfected cells, since ORF4 and 
ORF9 are phosphoproteins in addition to the observation that ORF66 seems to increase amounts 
of these proteins, therefore alternate methods should be considered.  However, investigation of 
these interactions may reveal undescribed viral protein targets for the alphaherpesvirus US3 
kinases as well as further understandings of the role of the ORF66 kinase in VZV infection.   
 
 
 125 
 Figure 4-1. List of candidate VZV ORF66 targets 
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 Figure 4-2.  VZV ORF66 targets ORF 4 & ORF9 in vitro 
Autoradiograph showing results of an in vitro kinase assay.  Maltose binding protein (MBP) ORF9 and 
ORF4 fusion proteins were incubated alone or in equal amounts with GST, GST66, or GST66kd under 
optimal ORF66 kinase assay condtions described in section 3.3.9. 
 
 
Actin. 
Viruses interact with cytoskeletal elements at almost every step of the infectious cycle.  
The cytoskeleton itself is a diffusion barrier that must be overcome for viruses to transport itself 
within the cell (197).  Actin is a globular structural protein that polymerizes into helical actin 
filaments forming a network within the cell.  This dynamic structure provides mechanical 
support, determines cell shape, and is involved in cell mobility and formation of cell-cell 
junctions. Viruses often depolymerize actin to alter the diffusion properties of the cytoplasm and 
facitilitate viral egress or induce actin polymerization to propel viruses to adjacent cells (197). 
Actin has also been implicated in nuclear activities such as transcription, chromatin remodeling 
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and modeling of the nucleoskeleton (170).  Interstingly, HSV, MDV and PRV US3 kinases all 
manipulate cellular signaling pathways in restructuring actin networks to form projections or 
network disassembly (See Section 1.4.6.4).  In PRV, the US3 kinases actually target PAK1 and 
PAK2 cellular kinases which in turn have roles in the Rho GTPase signaling pathways involved 
in actin dissaembly and lamellopodia and filopodia formation.  This concurs with a common 
theme as exemplified by US3 relationship with PKA, ORF66 phosphorylation of HDACs, and 
matrin 3; ORF66/US3 functions in direct phosphorylation of certain targets, but also seems to 
engage key host proteins for a common downstream effect especially when modulating cellular 
processes.  Results showed that VZV-infected cells disorganized normally stratified filamentous 
actin (F-actin) filaments 24 hrs p.i., yet when ORF66 was kinase-inactivated actin cytoskeletal 
networks remained mainly intact (Figure 4-3).  ORF66 expressed in the absence of other VZV 
proteins using Ad.GFP-66 or Ad.GFP-66kd, induced cell rounding and cellular extensions when 
ORF66 was functional and loss of stratified F-actin, yet ORF66kd expressing cells did not 
significantly alter overall cell morphology and F-actin filamentous where readily detected (data 
not shown).  These findings strongly suggest that ORF66 does alter cell signaling pathways 
responsible for the dissolution of actin filaments.  Initial studies should be directed at first 
delineating whether these effects are not solely because of differences in degree of infection 
between VZV and 66-inactive VZV, or in the case of adenoviruses a phenomenon due to 
apoptosis or protein overexpression, in addition to a concentration on what components of Rho 
GTPase pathways are modulated by 66 kinase activity.  Single-cell live cell imaging experiments 
using VZV with fluorescently tagged capsid proteins in a 66 or 66kd background, together with 
delivered commercially available fluorescent phallodin or transiently expressed actin-GFP may 
shed light on whether actin projections are produced in VZV with potential roles for intercellular 
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spread.  Because, VZV seems to place heavy restrictions on production of cell free virions, it is is 
highly probable that the virus would utilize the cytoskeletal network for intercellular spread and 
hijacking this cellular component is amongst the shared functions of the ORF66/US3 kinase 
family.   
 
 
 
 
Figure 4-3.  VZV ORF66 kinase activity induces actin rearrangement in infected cells 
MRC-5 cells were infected with VZV.GFP-66 or VZV.GFP-66kd.  Cells were fixed 24hrs p.i and fixed 
with 4% paraformaldehyde and stained with Alexa Fluor-546 phalloidin to visualize for F-actin (red).  
ORF66/66kd is visualized by GFP fluorescence (green). 
 
 
 
 
PKA-substrates & Matrin 3 
 Our investigation for ORF66 phosphorylation targets using a phosphospecific PKA-
substrate as a tool to identify potential candidates fitting an IE62-like motif, lead  to 
identification of Matrin 3.  VZV ORF66 expression did not lead to the phosphorylation of 
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multiple PKA-substrate proteins as noted for HSV and PRV, yet ORF66 kinase expression did 
lead to detection of protein bands of approximately 40kDa, 55kDa, and diffuse set of bands of 
65-75kDa.  Identification of these proteins by LC/MS in the context of VZV infection and 
adenovirus infection may highlight interesting new ORF66 viral or host targets.  One possibility 
is that these proteins are all part of a signaling pathway that is activated by ORF66, or 
components of different pathways with PKA as a common upstream activator, although our 
forskolin studies would indicate that the latter is not the case.  Using this antibody in IF studies, 
p-PKA-substrates were strongly noted in the nucleus in VZV.GFP-66-infected cells as opposed 
to mostly cytoplasmic accumulation in VZV.GFP-66kd.  Although this may represent the matrin 
3 target, it may also indicate that ORF66 is targeting other nuclear PKA-substrate proteins 
(Figure 4-4).  Use of this antibody in IF maybe useful in future studies to further investigate 
ORF66 targets. 
 A separate observation made during this investigation was that purified GST tagged 
ORF66 was detected as a PKA-substrate in western blots, but not kinase-inactive ORF66 (Figure 
4-5).  This suggests that ORF66 is a PKA-substrate or that the antibody may be detecting ORF66 
autophosphorylation .   Similarly, this antibody was used to reveal the HSV -1 US3 
autophosphorylation motif, and this self regulation was needed for some of US3’s physiological 
functions (87, 181).  Thus, this tool may also serve to find phosphorylation sites on ORF66 
which may impart regulation of the multiple functions of this kinase.  Interestingly, the antibody 
also detected a PKA-substrate band within the gel region for which MBP62p is usually detected 
when MBP62p or MBP62pDM and GST66 were incubated together.  This suggests that the 
antibody detected a phosphorylated residue on MBP62p other than the ORF66 phosphorylation 
sties – S686 and S722.  
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Figure 4-4.  VZV ORF66 kinase activity induces greater phosphorylation of nuclear PKA-substrate 
proteins. 
MRC-5 cells were infected with VZV.GFP-66 or VZV.GfP-66kd and fixed 2days p.i. with 4% 
paraformaldehyde.  Cells were then immunostained with rabbit anti-p-PKA-substrate antibody 
and visualized using Alexa Fluor 546 anti-rabbit and fluorescence microscopy.  ORF66 or 
ORF66kd expression is visualized by GFP fluorescence (green) and nuclei are stained with 
Hoechst dye (blue) 
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Figure 4-5.  GST66 is detected by PKA-substrate antibody. 
Purified GST, GST66 or GST66kd were subjected to an in vitro kinase assay alone or incubated 
with MBP62p or MBP62pDM (62p double mutant-S686A, S722A).  SDS-PAGE separated 
proteins were transferred to PVDF membranes and probed with rabbit- α-PKA-substrate and 
visualized by autoradiography for antibody detected proteins.  The star denotes MBP62 or 62-
DM peptide.   
 
 
Lastly, this work has uncovered the nuclear matrix protein, matrin 3, as a novel ORF66 
cellular protein phosphorylation target.  This is a first report of any virus targeting this 
component of the nuclear matrix, and reveals a common target for the alphaherpesvirus US3 
kinases.  The latter point is highly indicative that targeting of this protein is important at a point 
in the alphaherpesvirus life cycle. Moreover, this work strongly suggests that this induced matrin 
3 phosphorylation is involved in regulation of matrin 3 subnuclear localization in VZV-infected 
cells, or matrin 3 nuclear retainment late into infection in HSV-1 and PRV-infected cells.  
Although ORF66 and US3 kinase functions are not essential for viral replication in most cell 
culture, our studies with corneal fibroblasts, and studies in SCID-hu xenografts amongst others 
(56, 81, 181, 186), demonstrate that ORF66/US3 functions indeed are important for optimal viral 
growth when models closer to a natural host are used.  Hence, future studies should be directed 
at understanding the role of matrin 3 in VZV infection, potentially by using matrin 3 siRNA.   
While data demonstrated that the matrin 3 T150 a.a. was the major ORF66/US3 specific 
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phosphorylation site, there was a small fraction of phosphorylation detected in HA-Matrin-
T150A by the PKA-substrate antibody.  This indicates that there is still potential for ORF66 at 
another site(s) on matrin 3 that are not detected by the PKA-substrate antibody due to sensitivity 
or because the site does not fit the PKA-substrate consensus site.   Finding matrin 3 in vivo 
phosphorylation sites in the context of VZV infection versus infection lacking 66 kinase may 
unveil differential phosphorylation that may have been missed by our current analysis.  
Additionally, this phosphorylation may serve to increase solubility of the protein, as matrin 3 is a 
major nuclear matrix protein and this would likely aid in capsid egress from the nucleus.  Lamin 
A/C is phosphorylated at multiple sites by US3 expression in vitro which aids in its partial 
solubilization, though there is only one consensus site on the protein (138).  Matrin 3 has also 
been implicated in a nuclear complex containing p54nrb and PSF that prevent the nuclear export 
of nuclear hyperedited dsRNAs (45).   An interesting question to be pursued is to test whether 
ORF66 has any functional consequences on the formation of this complex or on the retention of 
these hyperedited RNAs.  If hyperedited dsRNAs occur in VZV infection either made accidently 
or by design, ORF66 regulation of this process may serve as a means to prevent defective viral 
RNAs from being translated or to override a natural cellular response.   These studies open up 
many interesting avenues of investigation for the role of ORF66 in VZV infection.  Matrin 3 
targeting by ORF66 may represent a large gradient of matrin 3 involvement in VZV 
pathogenesis, from involvement of a nuclear scaffold needed for VZV replication to potentially 
clinical consequences such as neuron death in chronic zoster. Overall, our studies contribute to 
the notion that ORF66 is critical for efficient VZV replication in a cell type dependent manner 
and unveils a novel ORF66 cellular protein phosphorylation target that is conserved for the 
alphaherpesvirus families, suggesting an added role of the kinase as a mediator of VZV DNA 
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replication and transcriptional activities.  Discovery of novel viral and host cell targets, as well as 
understanding the intricacies of each of these phosphorylation events and their functional effects 
will shed light on the complex and remarkably diverse roles of ORF66 in VZV infection & 
pathogenesis.   
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